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Abstract 
MicroRNAs (miRNAs) guide Argonaute (AGO) proteins to silence complementary 
mRNA targets. In bilaterians, AGO interact with GW182/TNRC6 proteins, which 
recruit CCR4-NOT deadenylases via short tryptophan-containing motifs (W-
motifs), thereby promoting the translational repression and decay of target 
mRNAs. To gain deeper insights into miRNA silencing mechanisms, I determined 
the W-motif-specific interactome of human TNRC6C proteins using quantitative 
proteomics. I identified 23 proteins that were at least two-fold enriched with wild 
type TNRC6C as compared to mutants where W-motifs were disrupted. Besides 
known functional interactors, such as subunits of the CCR4-NOT complex, I 
identified components of clathrin-coated vesicles (CCVs), metabolic enzymes, 
mitochondrial proteins, RNA helicases, kinases, and phosphatases with potential 
roles in miRNA-mediated repression. I showed that AGO and TNRC6 localize on 
CCVs via interactions between W-motifs and CCV adaptor protein 2A (AP2A). 
Depletion of AP2A intensified miRNA-mediated repression of RLuc-hmga2 
reporters, but it did not increase CCR4-NOT binding to W-motifs. Conversely, 
knockdown of CCR4-NOT increased W-motif-mediated interactions between 
TNRC6C and AP2A. Hence, binding to either CCR4-NOT or AP2A may be 
governed by specific modifications of TNRC6 proteins, and CCVs may mediate the 
storage or recycling of TNRC6 and AGO proteins.  
The second part of this study addresses the conservation of the 
mechanisms of miRNA silencing in the cnidarian Nematostella vectensis, 
separated by 600 million years from other Metazoa. Using cultured human cells, I 
showed that Nematostella GW182 (nvGW182) recruits the CCR4-NOT 
deadenylation complex via its W-motifs, thereby inhibiting translation and 
promoting mRNA decay. As in bilaterians, nvGW182 is recruited to the miRNA 
repression complex by AGO proteins, indicating this mechanism of miRNA-
mediated silencing was already active in the last common ancestor of Cnidaria 
and Bilateria. 
 
Keywords: miRNA silencing, Argonaute proteins, TNRC6/GW182 proteins, W-
motifs, clathrin-coated vesicles (CCVs), evolution, Cnidaria, Nematostella GW182 
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Zusammenfassung 
MicroRNAs (miRNAs) regulieren die Genexpression, indem sie Proteine der 
Argonaute Familie (AGO) zu komplementären Sequenzen in mRNAs rekrutieren. 
In Bilateria interagiert AGO mit GW182/TNRC6 Proteinen, die wiederum CCR4-
NOT Deadenylasen rekrutieren und so die Inhibition der Translation und den 
mRNA-Abbau fördern. Die Interaktion zwischen TNRC6 und CCR4-NOT ist 
abhängig von kurzen, Tryptophan-reichen Motiven (W-Motiven). Um mehr über die 
Mechanismen der miRNA-abhängigen Genrepression zu erfahren, habe ich W-
Motiv-abhängige Interaktionspartner humaner TNRC6C Proteine identifiziert. 
Hierzu habe ich, mithilfe von quantitativer Massenspektrometrie, das Interaktom 
von wildtyp TNRC6C Proteinen mit dem von TNRC6C Proteinen, deren W-Motive 
mutiert wurden, verglichen. Neben bekannten Interaktionspartnern wie 
Untereinheiten des CCR4-NOT Komplexes, habe ich Komponenten von Clathrin-
Vesikeln (CCVs), Stoffwechsel assoziierte Enzyme, mitochondriale Proteine, RNA 
Helikasen, Kinasen und Phosphatasen mit potentiellen Funktionen in miRNA-
assoziierter Repression identifiziert. Darüber hinaus konnte ich zeigen, dass AGO 
und TNRC6C sich auf CCV befinden und dass die W-Motiv-abhängige Interaktion 
mit dem CCV-Adapter-Protein 2a (AP2A) hierfür verantwortlich ist. Eine Depletion 
von AP2A/ Die Reduzierung der zellulären AP2A Menge verstärkt die miRNA-
abhängige Repression eines untersuchten Reportergens, hat aber keinen Einfluss 
auf die Bindung von CCR4-NOT an W-Motiven. Die Reduzierung von CCR4-NOT 
dagegen verstärkt die Bindung zwischen TNRC6 und AP2A. Es ist vorstellbar, 
dass post-translationale Modifikationen die Bindung von TNRC6 an CCR4-NOT 
oder AP2A beeinflussen und möglicherweise spielen CCVs eine Rolle beim 
recyceln von TNRC6 und AGO Proteinen oder fungieren als Reservoir/ Speicher. 
Der zweite Teil dieser Studie befasst sich mit der Konservierung von 
miRNA vermitteltem Gen-Silencing in Cnidaria (Nematostella vectensis), welche 
sich vor 600 Millionen Jahren von der Ahnenreihe der Metazoa abspalteten. Hier 
zeige ich in humanan Zellen, dass Nematostella GW182 (nvGW182) Teile des 
CCR4-NOT Komplexes über W-Motive rekrutiert und dadurch die Translation 
inhibiert und den mRNA Abbau fördert. Wie auch in Bilateria wird nvGW182 durch 
AGO rekrutiert, was darauf schließen lässt, dass der miRNA 
Inhibitionsmechanismus bereits in den letzten gemainsamen Vorfahren von 
Cnidaria und Bilateria aktiv war. 
 
Schlüsselwörter: miRNA Inhibitionsmechanismus, Argonaute Proteine, 
TNRC6/GW182 Proteine, W-motiven, Clathrin-Vesikeln (CCVs), Evolution, 
Cnidaria, Nematostella GW182 
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 1 
1. Introduction 
The goal of biology is to understand how life works. Back in 1869 Friedrich 
Miescher isolated DNA1. Years later, in 1944 Avery, MacLeod and McCarty 
demonstrated that DNA is the molecule that carries the genetic information2, 
pointing to DNA as the molecule of life. Within 20 years Watson, Crick and 
Rosalind Franklin solved the DNA structure3 and the genetic code was 
deciphered4,5. To then dissect how cells with the same DNA content can 
differentiate and develop into complex organisms, mechanisms of gene 
expression regulation had to be studied. To explain that, “the central dogma of 
biology” was proposed, stating that DNA passes its information onto RNA that acts 
as a temporary messenger carrying the information to synthesize proteins6. In this 
view, DNA is the crucial storage of information and proteins are the functional 
protagonists acting as gene regulators, while RNA is an overlooked intermediary. 
However, in 1982 one exception was identified: rybozymes, RNA molecules that 
act as catalysts7,8. This discovery contributed in refreshing the ‘RNA World 
Hypothesis’ stating that earlier forms of life might have been mediated by self-
replicating RNA molecules later replaced by more stable DNA molecules9. Later 
on, once the human genome was sequenced and assembled it was observed that 
nearly 99% of the genome is non-protein-coding and about 90% of it is transcribed 
into non-coding RNAs10-12. The news generated a debate on how functionally 
relevant the non-coding genome is, with opposing views regarding it as a 
byproduct of small population size or as an important trait of organisms 
complexity13-16. It is still unclear what percentage of the non-coding genome is 
actually functional. Current estimates suggest ~8%17-20, however additional 
experimental evidence is needed to answer this question. Nevertheless, the past 
two-three decades have signed an ‘RNA revolution’ with multiple novel classes of 
non-coding RNAs and their roles as gene expression regulators being 
identified12,21-23. It became evident that epigenetic regulation is not only mediated 
by histone modifier and DNA methylases, but also by a subset of RNA 
molecules13,16,24 and RNA modifiers (reviewed in25). Classes of non-coding RNAs 
include small RNAs (sRNAs), long non-coding RNAs (lncRNAs) and circular RNAs 
(circRNAs) amongst others (reviewed in17,18,20). Interestingly, some non-coding 
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RNAs harbor small ORFs (sORFs), potentially encoding peptides21-23,26-30. 
Although a few sORF-encoded peptides have been assigned a function31-35, the 
generality of their roles is still to be investigated.  
Small RNAs are the most extensively studied group of non-coding RNAs, 
comprising three classes: siRNAs, miRNAs, and piRNAs. 
1.1 Classes of small RNAs 
In the past twenty-three years novel classes of short non-coding RNAs, generally 
called small RNAs (sRNAs) have been described36-39. As the name suggests, they 
are all characterized by a small size, ranging between 20-30 nucleotides and are 
not translated into proteins36-39. sRNAs are derived from longer RNA precursors; 
which are then processed to mature sRNAs that associate with a member of the 
Argonaute (AGO) protein family. sRNAs guide AGO proteins to their RNA targets 
via Watson-Crick base pairing where they then exert their regulatory functions36,39. 
The striking common feature of all classes of sRNAs is that nucleotide base-
pairing is used as a strategy for highly specific target recognition36,39. They differ in 
respect to their biogenesis and in some aspects of their modes of action, despite 
all being governed by similar principles. RNA interference (RNAi)24,40,41, which 
refers to the regulatory processes mediated by small RNAs, was a breakthrough 
discovery and its main contributors, Fire and Mello24, were awarded with the 2006 
Nobel Prize. Generally, all classes of small RNAs function in repressing transcripts 
and/or potentially harmful genetic elements18,42,43. Lastly, it is important to mention 
that except for the budding yeast, Saccharomyces cerevisiae, and a few other 
species, all eukaryotic organisms analyzed so far express sRNAs and the RNAi 
machinery44. In prokaryotes (bacteria and archaea) sRNAs are on average longer 
than their eukaryotic counterparts (~50-500 nucleotides)45. Yet, they also act via 
base-pairing to regulate the expression of their targets45.  Additionally, prokaryotes 
express an RNAi-like machinery, which is functionally similar to the eukaryotic one 
despite its components are not homologous to their eukaryotic counterparts44. 
Notably, also the genomes of certain viral families encode for small RNAs 
(miRNAs)46.  
To date, the best-characterized classes of eukaryotic small RNAs are small 
interfering RNAs (siRNAs), microRNAs (miRNAs) and Piwi-associated RNAs 
(piRNAs). As for any human-built classification it is important to bear in mind that 
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the borders between the different classes are not clearly defined and several 
exceptions to the rules have been discovered. 
1.1.1 siRNAs 
Small interfering RNAs are 20–25 nucleotides long RNA molecules. They are 
usually processed from long double-stranded RNAs (dsRNA) formed by two 
complementary RNAs. The origin of these longer precursors can be endogenous 
(endo siRNAs), forming when two complementary DNA strands are transcribed. 
This can occur for instance in case of antisense transcription, transcription of 
transposable elements or from hairpin RNAs26-30,47-51. Alternatively, the source of 
dsRNA can be exogenous (exo siRNAs), such as from a viral infection, since 
many viruses, while replicating their genomes, produce both sense and antisense 
transcripts40,41,52. The longer precursors are then cleaved by a ribonuclease III 
enzyme (RNase III) known as Dicer into shorter dsRNA fragments (~20-25 base 
pairs). These shorter dsRNA products have a two nucleotides overhang on 3’ ends 
and phosphate groups on 5’ ends42,43,53. The duplex is then loaded into a member 
of the AGO protein family where the siRNA strand with the least 
thermodynamically stable 5’-end is retained, while the other strand is released18,47-
51,54-56. The loaded strand is commonly referred to as the guide strand, while the 
strand that is not loaded is called passenger strand. Once the guide strand is 
loaded, it forms an effector complex known as RNA induced silencing complex 
(RISC)52,57. The siRNA guide then acts to recruit RISC to perfectly complementary 
stretches of mRNA sequences, where it then induces gene silencing. Silencing is 
achieved through mRNA cleavage catalyzed by the endonucleolytic activity of 
AGOs.  AGOs cleave in the middle of the siRNA-mRNA duplex, between the 10th 
and 11th residues. The two halves of the mRNA are subsequently degraded via 
3’5’ and 5’3’ decay pathways (reviewed in58). siRNAs do not only function as 
post-transcriptional gene regulators in the cytoplasm, but can also serve as 
transcriptional regulators or genome structure modulators in the nucleus (reviewed 
in53,59-63). Additional details about siRNA biogenesis and functions can be found in 
these reviews18,54-56. 
siRNAs are mostly important to keep the activity of transposons under 
control and to face viral infections. Nevertheless siRNAs can also regulate protein-
coding genes and have therefore been exploited as powerful tools to control gene 
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expressions not only for research purposes, but also for applications in the clinic 
and biotechnology industry.  
1.1.2 piRNAs 
P-element-induced wimpy testis (PIWI)-interacting RNAs (piRNAs) are 25-30 
nucleotides long RNA molecules expressed across the animal kingdom, from 
sponges to humans, but depleted from plants and fungi57,64.  All piRNAs have a 
modified 2’-O-methyl 3’-end suggested to increase their stability59-63. They were 
first discovered in D. melanogaster as short sequences complementary to 
intergenic repetitive elements, such as retrotransposons, specifically expressed in 
animal germ cells59,64-69.  Most of the repetitive regions complementary to piRNAs 
were found in discrete genomic regions, later defined as piRNA clusters64,70-74.  In 
contrast to siRNAs, piRNAs are generated from long single stranded precursors 
arising from the transcription of these repetitive regions in a Dicer-independent 
manner59,75,76. To exert their function, piRNAs associate with a member of the Piwi 
subclade of Argonaute proteins, which is mainly germline-specific59,64,67-69,77.  The 
effector complex, piRISC, is then guided by piRNAs to silence the expression and 
transposition of mobile genetic elements both in the cytoplasm and in the nucleus. 
Indeed, piRNAs and Piwi proteins are essential for functional gametogenesis and 
reproduction57,70-74,78,79. To date, they are the largest class of small non-coding 
RNAs75,76,80. Importantly, piRNAs can mediate trans-generational silencing thereby 
protecting newly synthesized genomes from mobile elements77,81. More recent 
analysis extended the presence of Piwi-piRNAs to somatic cells82-84 and pointed at 
a novel role of piRNAs in repression of partially complementary mRNA targets, 
similarly to miRNAs85,86. 
1.1.3 miRNAs 
MicroRNAs are 21-23 nucleotide long single-stranded RNAs expressed in animals, 
plants, unicellular algae and by some viral genomes80,87. Current release of 
miRBase (miRBase v21)88 annotates 1881 human miRNA precursors and 2588 
human mature miRNAs. Their number varies across species, for instance for D. 
melanogaster 256 precursors and 466 mature miRNAs are currently annotated, for 
C. elegans 250 and 434 and for a non-bilaterian animal, such as N. vectensis, 141 
and 142. Transcription of miRNA-encoding genes produces long single-stranded 
RNAs that fold back into hairpins and are then processed by two RNAse III 
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enzymes, Drosha and Dicer, to form mature miRNAs (reviewed in89). Mature 
miRNAs are loaded into AGO proteins and guide them to partially complementary 
mRNA targets, which are then silenced by the miRISC via translational repression 
and mRNA degradation (reviewed in90,91).  
miRNAs were first discovered in 1993 in Caenorhabditis elegans in the 
laboratories of  Ruvkun and Ambros92,93. A few years later another C. elegans 
miRNA, named let-7, was characterized87. Interestingly its sequence and function 
was conserved from flies to human94,95. Since then thousands of miRNAs have 
been discovered across species80,96-102 as a class of small RNAs ubiquitously 
expressed in somatic tissues103,104. Most miRNA binding sites are located in the 3’-
UTR of protein-coding transcripts95,105. Animal miRNAs are only partially 
complementary to their targets. Typically, they have a uracil (U) at their 5’-
end99,106, a region between nucleotides 2-7, called ‘seed’, that has perfect 
complementarity to mRNA targets, and the most 3’-region that has only partial 
complementarity to targets103,107,108. This feature allows single miRNAs to target 
multiple genes. Considering that more than 60% of human genes contain miRNA 
binding sites105,109-111, miRNAs have the ability to regulate nearly every biological 
process. Therefore, miRNAs are often deregulated in pathologies. As a matter of 
fact, molecules targeting miRNAs (anti-miRs) or synthetic miRNAs (miR mimics) 
are being developed for therapeutics (reviewed in106,112,113). Functionally important 
molecules are usually conserved across evolution. However, miRNA sequences 
as a whole show poor conservation across species. For a few conserved miRNAs, 
their target sequences complementary to seed regions are also significantly 
conserved across species, underlying the importance of miRNA-mediated gene 
regulation107,108,114.  
1.2 miRNA biogenesis and modes of action 
miRNA genes are mostly transcribed by RNA polymerase II into hundreds to 
thousands nucleotide long primary transcripts (pri-miRNAs) that fold into hairpin-
containing structure where the miRNA sequences reside109-111,115. Processing into 
mature miRNAs differs in animals and plants. This chapter will focus on animal 
miRNA biogenesis (Figure 1).  
In mammals miRNA-encoding genes are mainly located within intergenic 
regions and introns of protein-coding genes, although some can also be found 
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within exons. miRNA loci are organized in individual transcription units or, as often 
is the case, they are clustered together and transcribed as single polycistronic 
transcripts112,113,116. Although some reside within protein-coding genes, their 
promoters can differ114,117-120 and miRNA genes can have several transcription 
start sites (TSS)115,121-123. Once RNA polymerase II has transcribed them, pri-
miRNAs are capped at their 5’-end and polyadenylated at their 3’-end. They are 
usually kilobases long and fold in an imperfectly matched stem-loop structure with 
free ends. In the canonical pathway a nuclear complex called microprocessor 
digests the free ends of the pri-miRNA to form a ~65 nucleotides long hairpin 
named pre-miRNA with a typical 2 nucleotides overhang at the 3’-end and a 
phosphate group at the 5’-end116,124-128. The microprocessor is composed of an 
RNase III enzyme called Drosha and its cofactor DGCR8 (Pasha in D. 
melanogaster and C. elegans) that bind dsRNAs. The importance of the 
microprocessor complex is emphasized by the fact that Drosha depletion is 
embryonic lethal and lack of DGCR8 leads to DiGeorge syndrome117-120,129-131. 
Pre-miRNAs are exported to the cytoplasm by Exportin 5 with the help of 
RanGTP121-123,132,133. In the cytoplasm, the RNase III enzyme Dicer further 
processes the pre-miRNA near the terminal loop to form a ~22bp long dsRNA124-
128,134-137. Similarly to Drosha, depletion of Dicer in mouse is embryonic lethal and 
causes proliferation and differentiation defects in mouse embryonic stem cells49-
51,129-131. The RNA duplex is then loaded into Argonaute family protein, forming a 
premature effector complex called pre-miRNA-induced silencing complex (pre-
miRISC).  Two heat-shock proteins, HSC70 and HSP90, use ATP to induce a 
conformational change in AGOs that allows loading of the duplex132,133,138-142. 
Sorting of RNA duplexes in specific AGO proteins is a consequence of (I) which 
Dicer processes the precursor, (II) the structure of the RNA duplex, (III) the 
terminal nucleotide, and (IV) its thermodynamic properties (reviewed in143). In D. 
melanogaster and C. elegans RNA duplexes with central mismatches, as most 
miRNAs have, are preferentially loaded into AGO1140-142 and ALG-1 or ALG-
2144,145, respectively. Conversely, perfectly matched duplexes are generally sorted 
to AGO2140-142 in flies and RDE-1 in worms144,145. By contrast in mammals 
perfectly and imperfectly matched duplexes are similarly sorted between AGO1-
4135,146,147. Once the duplex is loaded, one of the two strands, named passenger 
strand, is then rapidly degraded. Usually the strand that is retained, guide strand, 
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is the one with the least thermodynamically stable 5’-end and with a uracil as first 
nucleotide138-142,148.  
A minority of miRNAs can also be generated via non-canonical biogenesis 
pathways that are either microprocessor independent or Dicer independent. In the 
so-called mirtron pathway, pre-miRNAs are generated by splicing and de-
branching or trimming of a lariat, bypassing the requirement for Drosha-DGCR8149-
153. Further processing is similar to the canonical pathway. The microprocessor 
can be bypassed also in the case of short hairpins RNAs generated directly by 
transcription120,154 or by tRNAs148,155-157, snoRNAs152,158 and small nuclear viral 
RNAs95,154,159,160. For example, miR-451, a conserved miRNA in vertebrates, is 
processed in a very short hairpin by the microprocessor (~18bp), exported and 
directly loaded onto AGO2, which cleaves it into a 30 nt RNA, that is then trimmed 
to produce a mature miRNA95,99,155-157,161,162. Lastly, pre-miRNA with only 1 nt 3’-
overhang have to be elongated by an additional nt through monourydilation to be 
efficiently processed by Dicer158,163-166. 
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Figure 1. Canonical and non-canonical pathways of miRNA biogenesis In the 
canonical miRNA biogenesis pathway miRNA genes are mainly transcribed by RNA-Pol II 
into primary RNA transcripts (pri-miRNAs), nuclear processing of the pri-miRNA is 
performed by the microprocessor Drosha-DGCR8, and results in a ~65 nt pre-miRNA 
exported to the cytoplasm by exportin 5 (EXP5). In the cytoplasm the RNaseIII Dicer 
further processes the pre-miRNA producing double stranded short RNAs that can be 
loaded onto AGO proteins. In Drosha and DGCR8-independent pathways, transcription 
generates directly pre-miRNAs, which will be then exported to the cytoplasm by EXP1. 
Alternatively, mirtron loci produce pre-miRNAs through splicing and debranching. Some 
mirtrons require additional trimming of the RNA tails before Dicer processing. Cleavage of 
snoRNAs and tRNAs (or tRNA-like RNAs) can also directly originate pre-miRNAs. In the 
TUTase-dependent biogenesis pathway, the microprocessor produces pre-miRNAs with 
shorter 3’-overhang that require monouridylation for efficient Dicer processing. In a Dicer-
independent pathway, short pre-miRNAs are produced by Drosha, exported and directly 
loaded on AGO2, which cleaves the stem of the pre-miRNA that is further trimmed by the 
3ʹ-5ʹ exonuclease PARN. Question marks indicate experimental evidence supporting that 
step is missing. MHV, murine γ -herpesvirus; mmu, Mus musculus; Pol II, RNA 
polymerase II. Figure from Nature review; Minju Ha and V. Narry Kim, 201489. 
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When the mature miRNA is loaded into AGO, it will from a mature miRISC 
complex and it will guide it to mRNA targets via complementary base pairing. In 
most cases, miRNA share only partial complementarity with their mRNA targets 
leading to translational repression and target degradation. Typically, the seed 
region, nucleotides 2-7 of the miRNA, perfectly matches to its targets, while the 3’-
end of the miRNA is imperfectly matched95,147,159,160,167,168. Having a uracile as first 
nucleotide and perfect match also at position 8 increases the activity of the 
miRNA95,99,161,162,169-173. Though, there are reported cases of functional miRNAs 
with imperfect seed matching to targets95,163-166,174. In some instances, miRNAs 
have extensive perfect complementarity with their targets. If this is the case they 
lead to silencing via AGO2-mediated cleavage of target mRNAs, similarly to 
siRNAs105,147,162,167,168,175,176. 
miRNAs mainly target the 3’-UTR of protein-coding genes, but they can 
also bind the 5’-UTR and the coding region162,169-173,177-179. Certain features of the 
3’-UTR influence the overall effect exerted by miRNAs. For instance, target sites 
positioned at least 15 nt away from the stop codon, AU-rich sequences near target 
sites, targets far from the center of long 3’-UTR and multiple miRNA binding sites 
across the 3’-UTR increase the effect of miRNA-binding95,174. Functionality of 5’-
UTR and CDS miRNA sites is not entirely clear. Sites in coding regions were 
reported to be functional only in case of ribosome stalling, for example, due to a 
stretch of rare codons180. More recently, they have been proposed to function in 
translation inhibition and to augment the repression effect of sites in the 3’-UTR181. 
miRNA sites within the 5’-UTR are more criptic, they are suggested to repress 
mRNA targets by preventing ribosomal association due to occupancy of 
miRISC182.  
Overall, miRNAs affect expression levels of hundreds of genes105,162,175,176 
mostly by moderately (average ~ 30%) downregulating target expression, thereby 
fine-tuning tissue specific gene expression of nearly all cell types162,177-179,183,184. 
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1.3 Biological functions of miRNAs 
miRNAs are a wide class of gene regulators. In fact 1-2% of genes in worms, flies 
and mammals encode for miRNAs95,185-190. Their mechanism of targeting by 
complementary base pairing represents an exquisite strategy to selectively 
regulate the majority of genes and therefore potentially all biological 
processes105,191,192. Most metazoan miRNAs recruit the RISC to target RNAs via 
imperfect base-pairing with sites typically within the 3’-UTR of their targets, 
thereby inducing translational repression and RNA destabilization, with the latter 
mechanism contributing the most to miRNA silencing162,176,183,184.  Regardless of 
their established function as gene expression regulators, increasing evidence 
suggests that most miRNAs are not master regulators (few examples of those are 
described in the next chapter), but rather act as a buffering system for stochastic 
cell to cell variability ensuring robustness against environmental and genetic 
variations. In spite of numerous overexpression and deletion studies performed in 
cell culture185-190,193,194, which indicated crucial roles for miRNAs, in vivo knockouts 
of several specific miRNAs showed mild or no apparent phenotypes95,105,191,192 
supporting their role as buffering agents. It is important to note that although 
miRNAs lead to mild changes in gene expression (max ~2-fold)119,129,162,176,195-197, 
miRNA genes often arise from gene duplication events producing homologous 
miRNAs that share the same seed sequence193,194,198-200. When co-expressed 
these miRNA families can co-regulate targets enhancing their silencing effects. In 
addition, combinatorial regulation by multiple miRNAs can occur since most 3’-
UTRs have on average four miRNA binding sites92,93,95,105,201. Overall, miRNA 
silencing as a general mechanism of gene expression regulation is of importance 
to cells. In fact, individual mice knockouts of the enzymes involved in miRNA 
processing: Drosha196, Dgcr8119 and Dicer129; of AGO2202; and mutant mice of 
GW182/TNRC6 proteins203, the downstreat effectors of AGOs are embryonic 
lethal. Conditional knockouts of Dicer in cell culture lines exhibit an expected 
reduction in mature sRNAs and severe developmental defects, such us defective 
differentiation and centromers silencing130,204. Drosha depletion in cell culture 
systems abolishes production of canonical miRNAs205 and conditional depletion in 
mice leads to defective spermatogenesis and male infertility206. AGO1-AGO4 
depletion in mouse embryonic stem cells (mESC) abrogates miRNA silencing and 
leads to apoptosis207. Another line of evidence for the importance of miRNA is the 
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evolutionary conservation of seed-target base pairing across species93,198-201 that 
supports a selective advantage conferred by miRNAs.  
1.3.1 miRNA functions in development 
Most miRNAs function as fine-tuners of gene expression, however some miRNAs 
have more prominent physiological roles. A few well-characterized examples are 
outlined in the following paragraphs. 
Lin-4, the first miRNA discovered, regulates developmental timing in C. 
elegans by targeting lin-14 mRNAs92,93,201,208. Lin-14 encodes a transcription factor 
that is necessary to complete the first larval stage209-212. Both lin-4 loss of function 
mutants and lin-14 gain of function mutants lose the ability to differentiate and 
keep going through early stage fates93,201,213-216. To ensure proper development 
fluctuations lin-14-mRNA levels are promptly regulated by oscillations in lin-4 in a 
feed-forward loop208,217. 
Similarly, let-7, the second miRNA discovered, contributes to stem cells 
differentiation by inhibiting cell cycle progression and self-renewal209,211,212,218. 
miRNAs belonging to the let-7 family target c-Myc, ras, high mobility group A 
(HMGA) , Janus protein tyrosine kinase (JAK), signal transducer and activator of 
transcription 3 (STAT3) and Np95/ICBP90-like RING finger protein (NIRF), 
oncogenes involved directly or indirectly in promoting cell proliferation219. By 
targeting these genes let-7 halts cell proliferation and acts as a tumor 
suppressor219.  
Depletion of the miR-143/145 cluster under normal conditions causes no 
apparent phenotype. However, depletion upon injury impairs the ability of the 
intestinal epithelium and of blood vessels to regenerate due to altered insulin-like 
growth factor signaling213-216,220. Additional examples of miRNA knockouts, which 
manifest phenotypes only under stress conditions, are reviewed by Vidigal and 
Ventura (2015)217. 
In Zebrafish, the miR-430 family controls fluctuations in chemokine receptor 
signaling, ensuring fidelity in germ cells migration218,221. The same family also 
takes part in maternal mRNA clearance during the maternal to zygotic 
transition220,222. Clearance of maternal mRNAs is as well mediated by miRNAs in 
other species, such as X. laevis, C. elegans and D. melanogaster223-225.  
 12 
miR-128 is a good example of additive effects of miRNAs due to targeting 
of multiple functionally related mRNAs. In fact, depletion of miR-182 in mice 
induces de-repression of several members of the mitogen-activated protein kinase 
pathway (MAPK) leading to fatal epilepsy221. An analogous example is miR-205, 
whose depletion in mice causes neonatal death and results in compromised 
epidermal and hair follicle growth, due to targeting of several modulators of the 
phosphoinositide 3 kinase (PI3K) signaling pathway222.  
1.3.2 Misregulated functions in disease  
As miRNAs modulate virtually all biological processes, including cell growth, 
proliferation and differentiation, organismal metabolism and development, they are 
deregulated in a variety of diseases226-233. A large and growing body of literature 
has investigated the roles of miRNAs in cancer, neurodegenerative, viral, immune 
and cardiac diseases (reviewed in231,233-236). In the majority of cases, aberrant 
miRNA expression associates with the disease229,237-239. In short, the function of 
miRNAs is conserved in disease, but their expression patterns are altered as a 
cause or consequence of the pathology. This observation raised hope for using 
miRNAs as prognostic and diagnostic biomarkers of specific diseases240. 
Additionally, the discovery that nucleotides mimicking or inhibiting the activity of 
miRNAs could be delivered in vivo, promoted the development of therapeutic 
strategies based on miRNAs241.  
To note, the first genetic disorder to be linked to miRNAs was Fragile X 
Syndrome (FXS)226-228,232. This pathology manifests with severe cognitive and 
intellectual disabilities and is associated with a CGG trinucleotide repeat 
expansion within the 5’-UTR of the fragile X mental retardation 1 (FMR1) gene 
encoding for the FMR1 RNA binding protein232,234-236,242. In wild type conditions the 
Drosophila homolog of FMR1, dFXR, associates with components of active 
miRISC as was shown by cofractionation and affinity purification experiments 
226,227 and contributes to sRNA-mediated repression226. Contrariwise, the disease 
mutant loses the ability to associate with RISC as was shown by a shift of the 
mutant in the cytosolic soluble fraction of a Superose gradient226. In the following 
paragraphs I will outline a few examples of human disease-associated miRNAs.  
The first link between cancer and miRNA deregulation came from the 
observation that 65% of B-cell chronic lymphocytic leukemia (B-CLL) patients had 
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deletion of genes encoding miR-15 and miR-16243. Moreover the expression levels 
of miR-15 and miR-16 were downregulated in patients without the genetic 
deletion243.  In fact miR-15 and miR-16 repress the anti-apoptotic gene bcl-2, thus 
promoting tumor cell death244. Expression profiles of several types of cancer 
showed a correlation between aberrant miRNAs expression and the occurrence or 
stage of cancer245,246. Cancer-related miRNAs are classified as tumor suppressor, 
such as miR-15, miR-16 and let-7, or oncogenes, such as miR-21 and miR-
155243,244,247. 
Viruses often encode their own miRNAs or modulate and take advantage of 
host miRNAs. For example, miR-122 has been found to be necessary for hepatitis 
C virus (HCV) replication in vitro and in vivo, although its levels are not affected by 
the viral infection248,249. On the other hand the Epstein-Barr virus (EBV) 
upregulates the expression of the host miR-155250, which spares the infected cells 
from apoptosis251. Similarly the Kaposi’s sarcoma associated herpes virus (KHSV) 
encodes for miR-K12-11 that targets the same set of genes as miR-155252.  
In the autoimmune disease multiple sclerosis (MS) the expression of miR-
145 is a hallmark of the disease, which allows to discriminate between patients 
and healthy controls253.  
Aging-related neurological diseases such as Parkinson (PD) and 
Alzheimer’s (AD) also showed distinct profiles of miRNA expression. In PD 
patients, the expression of miR-30b, miR-30c and miR-26a correlates with the 
susceptibility of the disease254. Additionally, miR-133b might contribute to the 
onset of PD since it is involved in a feedback loop essential for maintenance of 
dopaminergic neurons255. In AD patients the expression of miR-29a, miR29-b-1 
and miR-9 is downregulated256, thereby the expression levels of their target 
BACE1, a protein involved in AD pathogenesis257, is upregulated.  
miR-208 is a cardiac-specific miRNA. Upon cardiac stress miR-208 
expression, together with other stress-induced stimuli, leads to upregulation of β-
myosin heavy chain (β-MHC) that promotes cardiac remodeling and 
hypertrophy258. Delivery of anti-miR-208 molecules prevented pathological cardiac 
remodeling259. 
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1.4 Mechanisms of miRNA-mediated repression 
miRNA-mediated repression is achieved via two mechanisms: translational 
repression and mRNA degradation, involving mRNA deadenylation, decapping 
and 5’-3’ decay81,242,260,261. Genome-wide analysis of the effects of miRNAs on 
mRNA and protein expression levels indicated that at steady state miRNA-
mediated degradation accounts for 66-90% of overall miRNA silencing in several 
mammalian cultured cells162,176,183,184,262,263. In addition, structural and biochemical 
studies have elucidated many molecular details of miRNA-silencing. The 
structures of some of its key players: human AGO2 in complex with miRNA 
mimics264-266; subunits of the deadenylase complexes CCR4-NOT and PAN2-
PAN3, such as CNOT9267,268, CNOT1 in complex with the RNA helicase 
DDX6267,268 and PAN3269; and lastly DDX6 in complex with the enhancer of mRNA 
decapping EDC3270 clarified the mode and sequence of events leading to miRNA-
mediated repression.  
In bilaterian animals miRNA silencing acts via the recruitment of the miRNA 
induced silencing complex (miRISC) to target mRNAs232 (Figure 2). The core 
components of miRISC are Argonaute proteins (AGO1-AGO4 in mammals) and 
GW182/TNRC6 protein (TNRC6A-C in mammals). miRNAs guide miRISC to 
partially or fully complementary mRNA targets232. Fully complementary targets are 
silenced by cleavage via catalytically active AGOs (only AGO2 in mammals)232,242. 
However, in bilaterian animals the majority of miRNAs are only partially 
complementary to mRNA targets, thereby impeding cleavage by AGO242. Under 
these circumstances, AGO proteins recruit a member of the GW182 protein 
family271-274, which acts as a platform for the recruitment of downstream effector 
complexes, such as the CCR4-NOT and PAN2-PAN3 deadenylase complexes275-
277. One of the major advances in the field was the discovery that the CCR4-NOT 
complex is directly recruited to miRISC by the C-terminal domain of GW182 
proteins and mediates both translational repression and mRNA decay275-277. 
Chekulaeva and colleagues demonstrated that the direct recruitment of CCR4-
NOT to GW182 proteins is mediated by a series of short linear motifs containing 
an invariant tryptophan residue (Trp, W), and thus named W-motifs, dispersed 
throughout the C-terminal domain of GW182 proteins275. Point mutations of seven 
tryptophan residues within W-motifs to alanine abrogated both translational 
repression and mRNA decay275. This discovery revealed that the same set of 
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proteins mediates both miRNA silencing mechanisms, explaining why the two 
mechanisms of miRNA-mediated silencing - translational repression and mRNA 
deadenylation – are coupled.  
Interestingly miRNA-mediated translational repression and deadenylation, 
decapping and decay can be uncoupled in some cellular contexts, such as 
oocytes, early embryos, cell-free extracts and neuronal cells225,263,278-285. Under 
these circumstances, translationally repressed and possibly deadenylated miRNA 
targets can escape decay and eventually reinitiate translation263,281,283.  
 
Figure 2. Modes of miRNA silencing in bilaterian animals Sequence of molecular 
events leading to miRNA-mediated translational repression and deadenylation, decapping 
and decay supported by structural and biochemical studies. First, miRNAs lead AGO 
proteins to target mRNAs as pinpointed by structures of human AGO2 bound to miRNA 
mimics264-266.  AGO recruit GW182 proteins via two W-binding pockets264. GW182 proteins 
interact with PABPC proteins via a PAM2 motif286,287 and with the PAN2-PAN3269,288-290 
and CCR4-NOT deadenylation complex via W-motifs present in their C-terminal 
unstructured domain267,268. CNOT1 via its MIF4G domain interacts with both the catalytic 
module CNOT6-CNOT7291,292, which can promote shortening of poly(A) tails, and with the 
RNA helicase DDX6267,268,293, which can promote translational repression. DDX6 
additionally interact with the decapping factor EDC3270 that in turns bind to the DCP1-
DCP2294,295 complex thereby leading to decapping (it is not yet known whether DDX6 can 
interact simultaneously with CNOT1 and EDC3). Finally, decapping factors recruit the 5’-3’ 
exonuclease XRN1296,297. Cap removal promotes access of XRN1 to target mRNAs, 
thereby inducing mRNA decay.  
The following chapters will further describe the most important players of miRNA 
silencing and the current knowledge on the mechanisms of miRNA-mediated 
translational repression and degradation. 
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1.4.1 Components of the RNA Induced Silencing Complex (RISC) 
The term RNA induced silencing complex (RISC) was first used by the Hannon lab 
in the year 2000 to describe a ribonucleoprotein complex involved in RNAi298,299. 
By purifying mRNA cleavage products from dsRNA-treated Drosophila S2 cells, 
Hammond and colleagues identified RISC, a sequence specific nuclease that co-
fractionates with a ~25 nucleotide long RNA, which confers specificity to the 
enzyme298,299. Their observation came right after Tuschl and Zamore recapitulated 
RNAi in vitro using Drosophila melanogaster embryo lysates300,301. Their findings 
indicated that target mRNAs are at least partially degraded by a nuclease300,301. 
Genetic screens performed in C. elegans identified Argonaute (AGO) proteins as 
components of RNAi and possibly of RISC302-304. The first biochemical evidence 
identifying AGO as a central component of RISC came from the Hannon lab147,299. 
Purification of RISC from Drosophila extracts and mass spectrometry analysis 
revealed a yet unknown protein, CG7439, later named AGO2, whose activity 
matched perfectly the one of RISC299. Similarly, the Wang lab and soon after the 
Siomi lab, revealed that Drosophila AGO2 and siRNAs were core components of 
RISC301,305. Affinity purification of the human homologue of AGO2 allowed the 
detection of the slicing activity of AGO2 proteins304. Purification of additional 
members of the AGO family demonstrated that in humans only AGO2 is 
catalytically active, while the paralogues AGO1, AGO3 and AGO4 are 
not146,147,271,273,274,306,307.  Conversely, a similar study performed in Drosophila 
showed that both dmAGO1 and dmAGO2 are catalytically active, although 
dmAGO1 has lower slicer activity305. In vitro reconstitution of a minimal RISC 
composed of recombinant human AGO2 and a single stranded siRNA was 
sufficient to catalyze specific cleavage of a target RNA. Importantly, AGO2 with 
three mutated amino acids (Asp, Asp, His; DDH triad) as well as a form of AGO2 
supplemented with duplex, instead of single stranded, siRNAs could not direct 
target cleavage, pinpointing the region involved in cleavage and the requirement 
for single stranded RNAs304. 
When miRNAs associate with AGO, the complex is referred to as miRISC. 
Core components of miRISC in metazoans are not only AGO proteins, either 
catalytically active or inactive, but also members of the GW182/TNRC6 protein 
family. GW182 proteins are required for miRNA silencing and were described as 
direct interactors of AGO proteins146,271,273,274,307,308. In fact, artificial tethering of 
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either AGO or GW182 proteins to a reporter mRNA 3’-UTR repressed protein 
synthesis309-311. It was later discovered that the ability of GW182 proteins to 
silence is due to the recruitment of downstream effectors of silencing such as the 
CCR4-NOT deadenylase complex (reviewed in90,261). In the following subchapters 
I will describe in more details the components of animal miRISC.  
1.4.1.1 AGO Protein Family 
Argonaute (AGO) proteins were first discovered in the plant Arabidopsis thaliana 
and are given their name after the shape of the leaves of the mutant that allowed 
their discovery, which indeed resembled an argonaute octopus308. AGO proteins 
play a well-established role in RNAi by directly binding sRNAs, thus recruiting 
effector complexes to target RNAs and mediating their regulation147,207,271,309,312,313. 
However, they have also been implicated in processes such as transcriptional 
regulation and splicing (reviewed in314). They are conserved across species and 
kingdoms, from archaea to bacteria to higher eukaryotes. The AGO protein family 
is divided in three subfamilies or clades: PIWI proteins, which are germline-specific 
and associate with piRNAs; AGO proteins, which are ubiquitously expressed and 
associate with siRNA or miRNAs and the nematode-specific WAGO 
subfamily146,147,315. Multiple copies of genes encoding for AGOs exist across 
species. Humans, for instance, express eight AGO paralogs; D. melanogaster five 
and C. elegans twenty-six. Four human AGOs belong to the PIWI subfamily 
(HIWI1-3 and HILI) and four to the AGO subfamily, named respectively AGO1-
4147,316,317. Mammalian AGO1-4 play partially redundant roles in siRNA and 
miRNA-mediated silencing; they all can silence when tethered to a reporter 
mRNA, they all can rescue an AGO knockout mouse embryonic stem cell line and 
they interact with similar subsets of proteins, small RNAs and mRNA 
targets147,207,271,309,312,313,317. Among the mammalian four AGOs, only AGO2 has 
cleavage activity146,147,264,318-323. Despite their functional redundancies pinpointed 
in cell culture systems, AGO2 mice knockout are embryonic lethal, and 
heterozigotes for AGO2 depletion exhibit severe defects in embryonic 
development possibly due to the peculiar slicing activity of this AGO member147.  
AGO proteins have a molecular mass of about 100 kDa. They are 
organized in four globular domains: an N-terminal domain, a Piwi-Argonaute-Zwille 
(PAZ) domain, a MID domain and a PIWI domain (Figure 3). PAZ, MID and PIWI 
are evolutionary conserved, while the N-terminal diverged the most. The crystal 
 18 
structures of archaeal, eubacterial and eukaryotic AGO proteins revealed a bilobal 
architecture, with each lobe bearing two globular domains: N-terminal and PAZ, 
MID and PIWI. Although the relative position of the lobes differs between 
prokaryotes and eukaryotes, the architecture and domain organization is 
conserved265,317,323,324. The PAZ domain hosts a conserved hydrophobic pocket 
that binds the 3’-end of small RNAs, while a pocket at the interface between the 
MID and PIWI domains hosts the small RNA 5’-end264,318-323,325,326. MID domains of 
different species show different preferences for nucleotide binding, thereby 
determining the specificity for the 5’-nucleotide327,328. Human AGO2 has a 
preference for guide RNAs starting with U or A nucleotide327. In addition, the 
phosphate-ribose backbone of positions 2-8 of the small RNA are in contact with 
AGO, while the bases are oriented and available for target binding via hydrogen 
bonds265,323,324,329. This finding provided evidence for why perfect complementarity 
of the seed region is crucial in target recognition. The PIWI domain has an RNase 
H-like fold and hosts the catalytically active site coordinated by divalent 
cations264,325,326. RNase H recognizes and cleaves DNA-RNA duplexes325. This 
feature is retained in prokaryotic AGOs, which were found to be DNA-guided 
RNases321,326. However, eukaryotic AGOs evolved the ability to bind to, and in 
case of catalytically active AGOs cleave, RNA-RNA duplexes. The catalytic site is 
composed by a DDH triad (Asp-Asp-His) that was reported to be necessary, but 
not sufficient, for target cleavage146,147,304. In mammals, both AGO2 and AGO3 
have the catalytic motif, but only AGO2 can slice perfectly matched targets 
between nucleotides 10 and 11 relative to the 5’-end of the guide RNA147,322,325. 
Later studies showed that two additional residues, E and F (Glu and Phe) 328,330 
and an unstructured loop in the N-terminal domain329 are important for slicing. 
Moreover the PIWI domain hosts two tryptophan (W)-binding pockets that mediate 
direct binding of AGOs to GW182 proteins264,331, allowing further downstream 
processing. The residues forming W-binding pockets are conserved across AGO 
proteins participating in miRNA silencing, such as human AGO1-AGO4 and 
Drosophila Ago1264. Contrariwise, these residues are less conserved in Drosophila 
Ago2, which in fact does not interact with GW182 proteins, and in the PIWI clade 
of AGO proteins311,332. The structural study of human AGO2 revealed that the two 
W-binding pockets host tryptophan residues that are at least 8-10 amino acids 
apart (20-25 Å)264. Interestingly, multiple W-containing motifs present in GW182 
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proteins follow this spacing requirement, suggesting several tryptophans mediate 
high affinity binding with AGO via consecutive or cooperative binding264. In 
agreement with this observation, a peptide array of TNRC6B peptides showed that 
human AGO2 binds with high affinity peptides containing two W residues spaced 
by 10 amino acids331. Residues flanking W tend to have small side chains and 
contribute weakly to interactions with AGO. Intriguingly, only a subset of W 
residues, usually located in the N-terminal unstructured regions of TNRC6/GW182 
proteins mediate interactions with AGO, while others located mainly in the 
unstructured C-terminus lack AGO-binding properties331,333-340. Generally, 
tryptophan-containing motifs are a conserved strategy used by AGO-interacting 
proteins to bind to the PIWI domain. Till and colleagues named protein regions 
containing such AGO-binding motifs “AGO-hooks”333. 
 
Figure 3. Argonaute (AGO) protein domains and structure (A) Homo sapiens AGO2 
domain organization: N, N-terminal domain; PAZ, Piwi-Argonaute-Zwille; MID and PIWI 
domain. HsAGO2 is chosen as a representative example of the AGO family. (B) Structure 
of Homo sapiens AGO2 (blue and gray) in complex with a miRNA (green); PDB code: 
4W5O266. Each domain is color-coded according to (A). Red dots indicate the position of 
the two W-binding pockets on the surface of the PIWI domain. 
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1.4.1.2 GW182 Protein Family 
GW182 proteins were first described as a 182 kDa autoantigen found in the serum 
of patients suffering from an autoimmune motor and sensory neuropathy341. The 
protein was named GW because of the multiple Gly-Trp repeats within its amino 
acidic sequence271-274,307,310,341,342. Researchers found GW182 to be enriched in 
cytoplasmic speckles that they called GW-bodies (also known as processing 
bodies, P-bodies)341,343; sites enriched in proteins involved in mRNA 
degradation344,345. Shortly after, several studies from independent groups 
demonstrated that GW182 proteins are functional interactors of AGO proteins 
required for miRNA silencing271-274,307,310,342. GW182, AGO and miRNAs were 
shown to coimmunoprecipitate and colocalize in both mammalian cells273,307 and 
C. elegans274. Moreover in vitro binding assays between the C. elegans homologs 
of AGO1 (ALG-1) and GW182 (AIN-1) suggested a direct interaction between 
these two proteins274. Multiple experiments indicated a key function of GW182 
proteins in miRNA-mediated repression. In fact, disrupting GW182-AGO 
interactions or depleting GW182 proteins in mammalian and D. melanogaster S2 
cells and in C. elegans severely impaired miRNA silencing272-274,310 and lead to a 
decrease in the number of P-bodies272,273. Similarly, transfection of a dominant 
negative AGO or AGO mutants lacking the ability to load miRNAs also inhibited 
miRNA silencing and P-bodies formation indicating that AGO and GW182 act in 
the same pathways and that miRNA-mediated repression and P-body formation 
are linked272,273,307. Experiments in which GW182 proteins were tethered to an 
mRNA reporter lead to its repression also in absence of AGO proteins, providing 
evidence that GW182 are the effector proteins acting downstream of AGO335-338.   
The GW182 protein family is present in metazoans. To date, no orthologues 
have been found in plants or fungi311,346. Vertebrates express three paralogues 
named trinucleotide repeat-containing 6 proteins (TNRC6): TNRC6A, TNRC6B 
and TNRC6C. D. melanogaster encodes for only one member known as Gawky 
(GW182), and C. elegans and most of other nematodes express two divergent 
members named AIN-1 and AIN-2346-348. Except for AIN-1 and AIN-2, orthologues 
of GW182 share a similar domain organization. They feature an N-GW (N-terminal 
GW-rich AGO-binding domain), a UBA (ubiquitin-associated)-like domain, a Q 
(glutamine)-rich region, a PAM2 motif (poly(A)-binding protein interacting motif 2) 
and an RRM (RNA recognition motif)349,350 (Figure 4). The N-GW domain is 
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responsible for AGO binding, while PAM2, RRM and the flanking disordered 
regions constitute the C-terminal effector domain, which is responsible for 
silencing of mRNA targets via CCR4-NOT binding275-277,335-338,351. Aside from 
recruiting the CCR4-NOT deadenylase complex, a study reported that GW182 
proteins function as coactivators of the enzymatic activity of CNOT in vitro277. 
GW182 proteins are mainly disordered except for two globular domains: UBA and 
RRM. The UBA domain is formed by three α helices involved in binding 
ubiquitinated substrates311,337,348. The RRM domain folds into four antiparallel β-
sheets and two α-helices and is usually involved in RNA binding331,340,346,349. 
However, the structure of Drosophila RRM revealed an additional helix that 
prevents RNA binding351, hence GW182 proteins require interactions with AGO (or 
other RBPs) to be recruited to mRNA targets. The RRM domain is dispensable for 
localization to P-bodies and for interactions with AGOs351. Nevertheless, GW182 
RRM partially contributes to miRNA-mediated repression probably by mediating 
protein-protein interactions331,351. The Q-rich region mediates P-bodies 
localization, but is dispensable for silencing and PAM2 mediates the interactions 
with PABP proteins, which bind to the mRNA poly(A) tail311,333,334,337. An additional 
study identified a type of proline-rich motif located in the C-terminal region of 
GW182 proteins and named it P-GL motif352. Though, P-GL motifs and UBA and 
RRM domains are highly conserved across GW182 orthologues, none of these 
regions is crucial for silencing. In fact mutations or depletion of these regions did 
not severely affect GW182-mediated repression in reporter assays335-
338,346,351,353,354. The following paragraph will further describe the two functional N-
terminal and C-terminal regions involved in AGO-binding and CNOT-binding, 
respectively. 
As mentioned in the previous subchapter, AGO-GW182 interactions are 
mediated by short linear motifs containing GW (Gly-Trp) repeats located in the 
unstructured N-terminal region of GW182 proteins276,277,331,333,340,346,355. Pfaff et 
al.331 identified the minimal requirements for AGO-binding. The authors of the 
study showed that a subset of W flanked by amino acids with small side chains 
engage in interactions with AGO. In the context of a peptide array, one W (W 623 
of TNRC6B) is sufficient for AGO binding, however two W residues spaced by ten 
amino acids have higher affinity, suggesting they might bind sequentially to the 
two hydrophobic pockets within the PIWI domain of AGO proteins331.  Additionally, 
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proteins other than GW182 use the same type of motifs to mediate AGO 
binding290,333,334.  
Intriguingly, W-motifs, short tryptophan-containing motifs found mostly 
within TNRC6 CED recruit the PAN2-PAN3 and CCR4-NOT deadenylase 
complexes, which then mediate translational repression and/or mRNA 
decay275,277,290. W-motifs act in an additive manner to silence mRNA targets275. 
Resolution of the structure of CNOT9 identified two Trp-binding pockets 
responsible for direct CNOT-GW182 binding267,356. However, additional W-motif 
binding pockets are thought to be present on other CNOT subunits although they 
have not been identified yet267,268. Interaction with PAN2-PAN3 is mediated by a 
single Trp, which fits into a hydrophobic pocket formed by a PAN3 dimer290. The 
identification of W-motifs clarified what is the mode of action of nematodes GW182 
orthologs, AIN-1 and AIN-2, which lack the typical GW182 domain organization, 
but possess multiple W-motifs357. It also provided an explanation for why multiple 
Trp-containing N-terminal and C-terminal fragments of Gawky could silence when 
tethered to an RNA336,355.  Similarly to AGO-interacting proteins, also other CCR4-
NOT-interacting proteins evolved short linear motifs (SLIMs) containing aromatic 
residues that fit into CNOT hydrophobic pockets underlining the importance of 
SLIMs in mediating protein-protein interactions358,359. Despite the similarities 
between AGO-binding and CNOT-binding Trp-containing motifs they exhibit 
exquisite specificity for their binding partners. Which features allow the 
discrimination between binding partners is still unclear. 
In addition, GW182 proteins interact with PABPC proteins via the PAM2 
motif and partially via the disordered regions downstream of PAM2286,360.  Both 
binding sites are required for binding in Drosphila GW182, while PAM2 alone is 
sufficient in mammalian TNRC6 proteins286,287,360-362. PABPC are highly conserved 
eukaryotic proteins known to stabilize mRNA and enhance translation by 
interacting with eIF4G at mRNA 5’-end and thereby forming so-called mRNA 
closed-loop structure363-366. Additionally GW182-PABPC interactions are 
conserved across species suggesting they are functionally important357. However, 
the role of GW182-PABPC interactions in miRNA silencing is not entirely clear. 
Some evidence showed that AGO binds more efficiently to polyadenylated mRNAs 
in vitro367 and repression of polyadenylated mRNAs is stronger in human and 
Drosophila cells368-370, suggesting PABPC promotes recruitment of RISC to 
 23 
targets. Another possibility is that GW182 prevents PABPC from stimulating 
translation. In fact, it has been reported that once PABPC binds to GW182 it can 
no longer bind to EIF4G, a cap-binding protein; potentially disrupting a “closed-
loop” structure that facilitates translation361,362. PABPC was shown to be required 
for miRNA-mediated repression in rabbit reticulocytes371 and its depletion from 
mammalian cell free extracts361 abolished miRNA-mediated deadenylation. In 
addition, mutations of PABPC binding regions in GW182 proteins partially impair 
repression in human cells and aggravate the inability of W-motifs mutants to 
rescue GW182-depleted cells275,353,370. However, these effects are mild and by 
contrast, tethering of PAM2 mutants efficiently silence target mRNAs suggesting 
PABPC may indeed facilitate miRISC recruitment to mRNA targets275,352,353,360,370.  
Moreover depletion of PABPC from Drosophila cell-free extracts372 and in 
zebrafish embryos352 does not abolish silencing, indicating PABPC role in 
silencing is not essential. Accordingly, miRNAs can silence mRNA reporters 
lacking poly(A) tails, hence PABPC, in human and Drosphila cells275-
277,352,368,370,372-374. Thus, the emerging picture is that GW182-PABPC interactions 
may enhance miRNA-silencing, at least in some cellular contexts where poly(A) 
tail length is coupled with translational efficiency. 
 24 
 
Figure 4. GW182 protein domains and RRM structure (A) Domain organization of 
GW182 protein family. N-GW: GW-repeat–rich region (grey); UBA: ubiquitin associated 
domain (green); PAM2: PABP associated motif 2 (light blue); RRM: RNA-recognition motif 
(red); W stands for W-motifs. The C-terminal effector domain (CED) is composed of RRM, 
PAM2 and the unstructured flanking regions with W-motifs. Human paralogues TNRC6A-
C are shown together with the D. melanogaster homologue GW182 and the C. elegans 
functional analogues AIN1 and AIN2 (B) Structure of D. melanogaster GW182 RRM 
domain (red and grey); PDB code: 2WBR351. The C-terminal alpha helix shown in gray, 
and the absence of aromatic residues crucial for RNA binding, prevent binding of the RRM 
to RNA and is conserved throughout GW182 homologues351. 
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1.4.1.3 PAN2-PAN3 & CCR4-NOT deadenylase complexes 
Two deadenylase complexes, PAN2-PAN3 and CCR4-NOT, account for most of 
general and miRNA-mediated mRNA deadenylation (reviewed in375). The 
contribution of PAN2-PAN3 to overall deadenylation is unclear, but a bulk of 
evidence suggests it is minor compared to CCR4-NOT-induced deadenylation, 
which is indeed sufficient for mRNA deadenylation267,268,275-277,311,353,370,375-378. The 
current models of mRNA deadenylation and decay suggests that PAN2-PAN3 
initiates shortening of poly(A) tails377,379. Once shortening has reached a certain 
threshold CCR4-NOT takes over and catalyzes the removal of poly(A) tails in a 
processive manner376,380,381.  Deadenylated mRNAs can then be decapped and 
degraded by the 5’-3’ exonuclease activity of XRN1375,376,382,383. 
The PAN2-PAN3 complex is formed by three subunits: the catalytic subunit 
PAN2 and a homodimer of PAN3 subunits269,290. PAN3 subunits homodimerize via 
a coiled-coil region connecting an N-terminal pseudo-kinase domain with a C-
terminal globular domain269. The N-terminus of the dimer forms a W-binding 
pocket, which mediates binding to GW182 proteins269. Instead the C-terminal 
domain of the dimer binds to the catalytic PAN2 subunit269,288,290. The PAN2-PAN3 
complex is recruited to mRNA targets via interactions with the PAN3 adaptor 
dimer. PAN3 interacts directly with PABPC proteins, via a PAM2 motif, and with 
RNA, via a zinc-finger domain289,375,384Additionally, interactions between PAN2-
PAN3 and GW182 contribute to the recruitment of the deadenylase complex to 
miRNA targets. Depletion of PAN2-PAN3 or overexpression of a catalytically 
inactive form of PAN2 only partially alleviate silencing in human and Drosophila 
cells276,377. Yet, depletion of PAN2-PAN3 aggravates the alleviation of silencing 
observed upon CNOT1 depletion, supporting a role for PAN2-PAN3 in the 
degradation of miRNA reporters276. 
The CCR4-NOT deadenylase complex (mammalian carbon catabolite 
repression 4-negative on TATA-less) is a multi-subunits complex that weighs 
approximately 1 MDa (Figure 5). It is highly conserved in eukaryotes and 
regulates all layers of gene expression ranging from transcription to mRNA export, 
to mRNA deadenylation, translational repression and decay, to protein 
ubiquitination and degradation by the proteasome (reviewed in382). In mammals 
the complex has seven core subunits: CNOT1, which is the biggest subunit that 
acts as a central scaffold, CNOT2, CNOT3, CNOT6 or CNOT6L, CNOT7 or 
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CNOT8, CNOT9 and CNOT10 (reviewed in382). CNOT1 consists of a series of α-
helixes related to HEAT repeat domain, two domains homologous to the middle 
domain of the eukaryotic initiation translation factor eIF4G, MIF4G-like (MIF4G-L) 
and MIF4G, a CNOT9/CAF40 binding domain (CN9BD) and a C-terminal NOT1 
superfamily homology domain (reviewed in90).  The HEAT domains interact with 
the CNOT10-CNOT11 module, while the MIF4G domain docks the formation of 
the catalytic module composed by the two catalytically active deadeanylases: 
CNOT7, or its paralogue CNOT8, (also known as CAF1 and POP2, respectively) 
and CNOT6, or its paralogue CNOT6L, (also known as CCR4a and 
CCR4b)291,292,375.  Via a different surface of its MIF4G domain CNOT1 also recruits 
the RNA helicase DDX6, which functions in translational repression267,268. Thus, 
interactions with the catalytic module do not exclude interactions with DDX6267,291. 
DDX6 additionally interacts with decapping factors, such as EDC3 and 
EDC4267,268,297,385. The decapping proteins EDC4 in vertebrates and Dcp1 in 
Drosophila recruit the exonuclease XRN1 promoting further decay of mRNA 
targets296,297. Hence, the MIF4G domain allows coupling of deadenylation with 
decapping and 5’-3’ decay and provides insights into how CCR4-NOT can mediate 
translational repression in absence of deadenylation. Next to the MIF4G domain, 
the CN9BD binds CNOT9 in a 1:1 stoichiometry267,268. Via CNOT1-CNOT9 the 
CCR4-NOT complex is recruited to GW182 proteins. Two W-motifs present in the 
C-terminus of GW182 proteins bind to two hydrophobic pockets on the CNOT9 
subunit267,268. Similarly to the two W-binding pockets of AGO proteins264, CNOT9 
pockets can host two W spaced by 8-10 amino acids (20-25 Å apart)267,268. It is 
likely that CCR4-NOT bears additional W-binding pockets for GW182 proteins, 
although they have not been identified yet. This hypothesis is supported by the 
finding that a CNOT1 mutant unable to bind to CNOT9 still retains the ability to 
bind to GW182 proteins267,268 and by the observation that sequential mutations of 
up to seven W-motifs within GW182 proteins cause a progressive alleviation of 
repression275. Lastly, the SHD domain located in the C-terminal region of CNOT1 
binds the CNOT2-CNOT3 module386,387, which provides an additional binding 
surface for RNA binding proteins, such as Nanos and Drosophila Bicaudal-
C358,388,389. The central role of CCR4-NOT in mRNA deadenylation and decay is 
supported by the fact that upon depletion of CNOT subunits, deadenylation and 
decay of mRNA and miRNA targets is abrogated311,375,376,390. Accordingly, 
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overexpression of CNOT6 and CNOT7 catalytic mutants prevents miRNA-induced 
deadenylation and results in stabilization of miRNA targets267,275,370,377,390-393. 
Additionally, CCR4-NOT can repress translation independently of deadenylation 
and decay267,275,370,391,393,394. The same holds true also in the context of the miRNA 
pathway275-277,353,370,378,395.  
 
Figure 5. The CCR4-NOT deadenylase complex (A) Schematic representation of the 
mammalian CCR4-NOT complex and its main functions. The catalytic module 
comprehend CNOT6/CNOT6L and CNOT7/CNOT8 deadenylase subunits; CNOT4 is 
shown in yellow since it does not stably associate with CCR4-NOT in human and 
flies396,397. Scheme based on382,398. (B) Schematic illustration of CNOT1 domain 
organization including the binding sites for other CNOT modules and for the RNA helicase 
DDX6. HEAT, folded α-helical repeat domain; MIFG-L (MIF4G-like) and MIF4G, domains 
structurally related to the middle eIF4G domain; CN9BD, CNOT9/CAF40 binding domain; 
SHD, superfamily homology domain. Illustration based on90.  
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1.4.2 Subcellular localization of miRISC 
miRISC components play primarily cytoplasmic functions399. However, a growing 
body of evidence identified miRISC components also in the nucleus, suggesting 
possible uncharacterized nuclear roles400-404. In the next paragraphs I will describe 
the evidence supporting localization of miRISC to distinct cell compartments. 
P/GW-bodies are dynamic cytoplasmic foci composed of aggregates of 
proteins and translationally repressed mRNAs344. They contain the key 
components of mRNA degradation, miRNA silencing, non-sense mediated decay 
(NMD) and translational repression280,405-407. As the name suggests, GW182 
proteins are found in P/GW-bodies in addition to the CCR4-NOT complex, AGO 
proteins, miRNAs and their targets, decapping enzymes and the 5’ to 3’ 
exonuclease XRN1339,406,408. P/GW bodies are depleted from ribosomes and 
initiation factors except for the cap-binding protein eIF4E and its inhibitor 
eIF4ET409,410. A necessary requirement in P/GW-body assembly is the presence of 
a pool of repressed mRNAs272,411,412 that can later be reactivated for translation278-
280. Characterization of these mRNP granules raised the question on whether they 
are sites required for mRNA catabolism. Upon depletion of P/GW bodies 
Drosophila S2 cells still exhibit functional miRNA silencing, mRNA decay and NMD 
pathways413. On the other hand microscopically visible P/GW bodies are disrupted 
by the inhibition of siRNA or miRNA-mediated repression307,413,414, suggesting P/G 
bodies are rather a consequence than a cause of small RNA silencing413. miRNA-
loaded AGO proteins are also localized to another type of cytoplasmic mRNP 
granules named stress granules342,415-417. Stress granules are aggregates of 
stalled translation initiation complexes forming upon stress418-420. They are 
enriched in components of the translational machinery and can be clearly 
distinguished from GW/P-bodies406,413. Nevertheless, upon certain stresses they 
can dock or overlap with P/GW granules and share their components421-423.  
Membrane fractionation analysis identified active miRISC as an enriched 
component of endosomes and multi vesicular bodies (MVBs), late endosomes that 
can fuse with lysosomes or with the plasma membrane, thus connecting miRNA 
silencing and endosomal trafficking424,425. It has been proposed that MVBs 
promote GW182 turnover, and therefore modulate miRNA silencing424,425. These 
observations were in agreement with the initial identification of AGO2 as a 
membrane-bound protein426. 
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In 2013 three studies reported that specific forms of active RISC localize to the 
rough endoplasmic reticulum (ER)427-429. In Drosophila S2 cells a form of miRISC 
lacking GW182 proteins, named polysomal miRISC (P-miRISC), co-sediments 
with the ER427. P-miRISC is composed of AGO1, miRNAs and Loqs-PB and is 
induced upon serum starvation. The authors of the study found that miRNA 
silencing under starvation increased 5- 10-fold compared to non-stress conditions 
and was independent of GW182 proteins427. In Arabidopsis thaliana, AMP1, an 
integral membrane protein of the rough ER, recruits miRNA loaded AGO1 and 
promotes translational repression of miRNA targets428. In humans, the homologue 
of Loqs-PB, TRBP, associates with the ER and recruits AGO in complex with 
sRNAs via protein-protein interactions429.  Recently, a study performed in 
Drosophila cells reported that active miRISC containing GW182 copurifies with 
ribosome complexes in an RNA-dependent manner430.  
Additionally, AGO and TNRC6 proteins can shuttle between the cytoplasm 
and the nucleus. Increasing evidence points at a role for AGO proteins in nuclear 
RNAi400,402,431,432, while the nuclear role of TNRC6 proteins is mostly unknown. 
The nuclear import of AGO proteins has been suggested to involve Importin 8433. 
Instead, nuclear import of TNRC6 proteins is mediated by the Importin β 
pathway404. The first line of evidence supporting the presence of TNRC6 proteins 
in the nucleus showed that TNRC6B actively shuttles to the nucleus333. Later 
studies showed that also TNRC6A is imported into the nucleus403,404. Nuclear 
levels of AGO and TNRC6 proteins have been suggested to be mutually 
dependent, indicating the existence of a mechanism that fine tunes the 
cytoplasmic and nuclear levels of both protein families404.       
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1.4.3 miRNA-mediated translational repression 
miRNA-mediated translational repression is one of the two modes of miRNA 
silencing. In the following chapters I will first give a brief overview of eukaryotic 
translation and then a summary of the current knowledge of the mechanism of 
miRNA-induced translational repression. 
1.4.3.1 Basics of eukaryotic translation 
Translation is a multi-steps process consisting of initiation, which is the rate 
limiting step, elongation, termination and ribosomes recycling434 (Figure 6). In the 
initiation step the small ribosomal subunit 40S associates with a set of eukaryotic 
initiation factors, eIF1, eIF1A and eIF2-GTP-Met initiator tRNA (tRNAi), eIF3 and 
eIF5 to form a 43S pre-initiation complex (PIC). The 43S PIC binds to the m7G 
cap-structure at the 5’-end of mRNAs. This crucial interaction is mediated by eIF3, 
within the 43S PIC, and the cap-binding complex eIF4F. eIF4F is composed by 
three subunits: eIF4E, which is the protein directly binding to the mRNA 5’-cap; the 
DEAD box RNA helicase eIF4A; and eIF4G, a scaffold that binds to eIF4E, eIF4A 
and helps recruiting the 43S PIC435. Once the cap is recognized, 43S PIC scans 
the mRNA in a 5’ to 3’ direction until it finds a start codon. Both 43S recruitment 
and scanning are helped by the unwinding activity of the eIF4A helicase, which is 
essential to unfold secondary RNA structures435. Recognition of the start codon by 
the tRNAi anticodon arrests ribosomal scanning and induces a conformational 
change of 43S. This rearrangement leads to the release of eIF1, which 
consequently allows the irreversible hydrolysis of GTP from eIF2-GTP-Met-tRNAi 
stimulating the formation of the 48S initiation complex. 48S can then associate 
with the 60S ribosomal subunit forming an elongation competent 80S 
ribosome436,437. During elongation the ribosome moves towards the 3’-end of the 
bound mRNA helped by several eukaryotic elongation factors (eEF) while 
catalyzing the formation of a polypeptide chain438. The 80S ribosome hosts three 
pockets for tRNA-binding named exit site (E), peptidyl site (P) and aminoacyl site 
(A) oriented in a 5’-E-P-A-3’ direction in respect to the mRNA439. The incoming 
aminoacyl-tRNA binds to the complementary mRNA codon in the A site. The P-
site hosts the tRNA bound to the growing polypeptide chain and the E-site hosts a 
deacetylated tRNA. Once a peptide bond is formed between the amino acid 
carried by the tRNA in the A site and the polypeptide chain in the P-site, the 
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growing peptide is transferred to the A-site. Upon ribosome translocation the 
peptidyl tRNA is transferred to the P-site. The now unloaded tRNA that was in the 
P-site is relocated to the E-site, from which the previous deacetylated tRNA has 
been released. Lastly, a new amynoacil tRNA enters the A-site and the process is 
repeated until the ribosome encounters a stop codon. When a stop codon (UAA, 
UGA, or UAG) enters the A site termination occurs439-441. The proteins eRF1 and 
eRF3 ensure the fidelity of termination and the release of the polypeptide 
chain442,443. The deacetylated tRNA is then released; the ribosome dissociates in 
its 40S and 60S subunits and is recycled for another round of translation. In some 
cases the 40S subunits stays bound to the mRNA where it can resume scanning 
and reinitiate translation444.  
The 5’-m7G cap and 3’-poly(A) are two mRNA features that enhance 
translation initiation efficiency434. This is explained by the fact that components of 
the eIF4F cap-binding complex help the recruitment of the ribosomal 40S subunits 
and that poly(A) tails are bound by PABP proteins, which directly interact with the 
cap binding complex eIF4F via eIF4G363,365,445. The interactions between a 3’-end 
binding protein and a 5’-end binding protein potentially result in the circularization 
of an mRNA, which is suggested to help translation by facilitating ribosome 
recycling436. Another explanation is that PABP tethers eIF4F to the mRNA 
bypassing the need for de novo recruitment of cap-binding proteins436,446. 
Irrespective of the mechanism, the interactions between 5’-end and 3’-end binding 
proteins are crucial for efficient translation. In fact histones mRNAs, which lack 
poly(A) tails, are efficiently translated thank to interactions between the protein 
module SLBP-SLIP1 (stem loop binding protein-SLBP interacting protein 1), which 
recognizes stem-loop structures near the 3’-end and the cap-binding complex 
eIF4F447.   
Translation initiation can also be cap-independent. A subset of mRNAs, 
especially viral mRNAs, uses internal ribosome entry sites (IRES) to directly recruit 
the ribosomes. Structurally related types of viral IRESs have different 
requirements for translation initiation. Picornaviruses IRES, such as poliovirus and 
encephalomyocarditis virus (PV, EMCV) do not require eIF4E binding, but need all 
the other canonical initiation factors448-450. HCV-like IRESs as hepatitis C virus 
(HCV) function independently of eIF1, eIF1A, eIF4A, eIF4B, eIF4F, but require 
eIF3451,452. Dicistrovirus intergenic regions IRESs, such as cricket paralysis virus 
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(CrPV), directly recruit the 40S subunit without the need of any canonical initiation 
factors and the initiator tRNA. The P site of the 40S subunit is instead occupied by 
an IRES domain mimicking codon-anticodon base pairing453,454. Cellular IRESs do 
not exhibit structural similarity and their mechanism of action is mostly unknown. 
However, they are thought to require all canonical factors except for eIF4E, 
similarly to picornaviruses IRESs455,456. In some cases, IRES-mediated initiation 
also requires IRES trans-activating factors (ITAFs); RNA binding proteins (RBPs) 
that might stabilize the optimal IRES 3D structure456.  
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Figure 6. Eukaryotic translation Schematic illustration of the steps occurring during 
eukaryotic translation. Figure from Nature review by Jackson et al., 2010436. 
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1.4.3.2 Translational repression by miRNAs: initiation vs. post-initiation 
mechanisms 
The past years have seen contradictory observations supporting models 
postulating miRNA-mediated translational repression occurrence at the translation 
initiation step or at the post-initiation steps. In the following paragraph I will briefly 
summarize the historical controversy and the emerging consensus on the 
mechanism of miRNA-mediated translational repression. 
Six-eight years after the first miRNA was described in C. elegans, two 
groups reported a model of miRNA-mediated translational repression by studying 
the miRNA lin-4 in C. elegans. Both groups observed that lin-4 inhibited proteins 
synthesis from its mRNA targets lin-14 and lin-28, despite target mRNA levels did 
not vary considerably457,458. Since lin-4 targets were detected in a polysome-
associated fraction, the authors suggested that inhibition of translation occurs 
post-initiation457,458. Accordingly, later studies performed in mammalian cell culture 
observed that miRNAs repress protein synthesis without affecting target mRNA 
expression levels nor their co-sedimentation with a translationally active polysomal 
fraction180,459-461. In addition, miRISC and miRNA targets were both found to be 
associated with polysomal fractions459,460,462,463. The authors interpreted this piece 
of evidence as an additional argument in support of inhibition at post-initiation 
steps459. A third line of evidence in support of this model comes from the study on 
the expression of internal ribosome entry site (IRES)-driven mRNAs. Two reports 
showed that miRNAs repress HCV and CrPV IRES-driven translation of 
mRNAs171,461. Given that HCV IRES function independently of several translation 
initiation factor (eIF) factors, but eIF3, and CrPV IRES do not require any 
conventional eIFs, Petersen and colleagues461 concluded that miRNA repress 
translation of these targets independently of the cap structure, thus at post-
initiation steps. One issue of the study by Petersen and colleagues was that the 
authors did not test repression of the IRES-driven mRNAs at the mRNA level. 
Hence, they could not exclude whether miRNAs induced degradation of their 
targets. The authors proposed that miRNAs cause ribosome drop off, as miRNA 
targets dissociated from polysomes more rapidly than a control insensitive to 
miRNAs when translation was inhibited using the eIF4A inhibitor hippuristanol461. 
Alternatively, Nottrott et al. (2006)460 proposed a model in which miRNAs induce 
co-translational protein degradation. Yet, an independent study by Pillai and 
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colleagues412 showed that targeting of nascent polypetides to the ER, as a 
strategy to protect them from proteolysis, does not prevent miRNA-mediating 
repression arguing against the model proposed by Nottrot et al. (2006). 
In parallel, several other studies provided contrasting evidence. Two groups 
reported 412,464 that endogenous let-7 miRNA as well as synthetic miRNAs cause 
their targets to shift to lighter polysome fractions in HeLa cells412,464.  Subsequent 
studies showed that miR-122 causes its endogenous CAT-1 mRNA target to 
associate with lighter polysomal fraction in Huh7 cells279. Similar shifts were 
observed for miR-16 reporters in HEK 293T cells and for endogenous targets of 
let-7 in HeLa cells465,466. Another study performed in C. elegans also demonstrated 
that miRNAs cause a decrease in the number of ribosomes associated with their 
targets467. Genome-wide studies looking at transcriptome and translatome 
changes upon miRNAs induction noticed that miRNA targets associate with fewer 
ribosomes183,184,262,284. Additionally, the distribution of ribosomes along the length 
of translationally repressed miRNA targets remained uniform; arguing against 
ribosome drop-off or inhibition at elongation step, which would imply higher 
ribosomal density at the 5’-end of the transcript compared to the 3’-end183,284. A 
second line of conflicting evidence came from experiments on cap-independent 
reporters. Translation of miRNA reporters driven by EMCV412,468, HCV412, CrPV 
IRESs464 or by an ApppG-cap structure464 was refractory to miRNA-mediated 
repression in cell cultures. Similarly tethering of translation initiation factors, such 
as eIF4E or eIF4G, upstream of miRNA reporters coding sequence would prevent 
miRNA silencing412. This bulk of evidence suggested that miRNA-mediated 
repression targets translation initiation. Accordingly, in vitro studies supported a 
model of miRNA-mediated inhibition of translation initiation. miRNAs were shown 
to interfere with the formation of the 48S and 80S ribosomal complexes in 
embryonic D. melanogaster extracts469 and in mouse Krebs-2 ascites lysate470. 
Additionally, several studies demonstrated that miRNAs cannot silence IRES-
driven mRNAs as well as mRNAs with artificial Appp-cap structures in cell-free 
extracts, suggesting a critical role of the m7G cap in miRNA silencing371,469-473. 
miRNA-mediated translational repression of miRNA reporters in ascites extracts 
was gradually released in presence of increasing amounts of eIF4F, pointing at 
displacement of cap binding proteins as a potential repressive mechanism470. 
Furthermore, use of specific cap analogues was shown to augment miRNA-
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mediated repression of target mRNAs without affecting the expression of non-
targets474.  
The emerging consensus in the miRNA field is that miRNAs can inhibit 
translation initiation by targeting the cap binding complex eIF4F90. To date, the 
best-characterized model of miRNA-mediated translational repression involves the 
recruitment of AGO and GW182 proteins, the CCR4-NOT deadenylase complex 
and RNA helicases, such as the decapping activator DDX6 and the initiation factor 
paralogues eIF4A1 and eIF4A290. Several groups have shown that the CCR4-
NOT complex can silence independently of its deadenylase activity and of mRNA 
poly(A) tails, indicating that it mediates translational 
repression267,268,275,276,353,370,391,393. Consistently, tethering of CNOT subunits 
induces translational repression of poly(A)- minus reporters without causing their 
decay275,276,391,393. CNOT1, the scaffold subunit of the CCR4-NOT complex, 
recruits the DEAD-box RNA helicase DDX6 via its MIF4G domain, which has been 
shown to contribute to translational repression267,268,293. The binding CNOT1-DDX6 
induces a conformational change of DDX6 that promotes its ATPase activity, 
which is required for miRNA-mediated translational repression267. DDX6 also binds 
to decapping factors, such as EDC3, EDC4, LSm14, PatL1, and to eIF4E 
transporter (4E-T), an eIF4E binding protein that represses translation by targeting 
the cap-binding protein complex eIF4F via a yet unclear mechanism475-477. 
Although it is by now clear that human DDX6 and its D. melanogaster ortholog 
Me31B repress translation, activate decapping, and play a role in miRNA 
silencing; a detailed mechanism of repression is still not defined267,268,293,478-480. 
Another documented strategy to induce miRNA-mediated translational repression 
involves the RNA helicase eIF4A, which is crucial in unwinding highly structured 
5’-UTR, thus promoting scanning of the 43S complex. However, conflicting 
evidence prevented a clear understanding of how eIF4A contributes to this 
process. One group reported that miRNAs repress translation initiation by 
preventing ribosomal scanning and that miRNA reporters with unstructured 5’-UTR 
are refractory to miRNA inhibition371. Another study by Meijer and colleagues481 
reported that eIF4A2, but not eIF4A1, is recruited to miRISC by interactions with 
the MIF4G domain of CCR4-NOT and blocks scanning of the 43S complex. 
Questions have been raised about these findings when structural studies 
demonstrated that CNOT1 MIFG domain binds DDX6, but not eIF4A2267,268,293. 
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Secondly, eIF4A2 knock out in human cells revealed that eIF4A2 is not required 
for miRNA-mediated repression482.  Moreover, studies performed in human and 
Drosophila cell-free extracts showed that eIF4A1 and eIF4A2 are both released 
from miRNA targets, instead of being recruited, thereby repressing 
translation483,484. Consistently, tethering of GW182 in Drosophila lead to 
displacement of eIF4A and depletion of eIF4A from S2 cells impaired miRNA-
mediated translational repression483. The role of CCR4-NOT in this process is still 
unclear483,484. Interestingly, at least in Drosophila, dissociation of eIF4A can also 
occur independently of GW182, supporting the existence of a GW182-independent 
mechanism of miRNA silencing in insect cells372,427,483,485. Arguing against 
inhibition of scanning as a mode of miRNA-mediated translational repression is a 
recent study by the Izaurralde group486. Using luciferase reporters with short 5’-
UTRs (<10 nt) and the TISU 5’-UTR (translation initiator of short 5’-UTRs), whose 
translation is cap-dependent but scanning-independent487, the authors could show 
that miRNAs repress these targets independently of scanning in human and 
Drosophila cells486. In addition, modifying the 5’-UTR secondary structure did not 
affect the degree of translational repression indicating eIF4A helicase activity is 
not required for miRNA-mediated translational repression486. As a strategy to 
uncouple miRNA-mediated translational repression from deadenylatyon and decay 
researchers have long taken advantage of miRNA reporters without poly(A) 
tails275,276,352,370-374,412,464,470,473,485. Using poly(A)- miRNA reporters Kuzuoğlu‐
Öztürk and colleagues confirmed that interactions between 
AGO(dmAGO1)/GW182/CCR4-NOT/DDX6 are necessary for miRNA-mediated 
translational repression in both human and Drosophila cells486. Despite dmAGO1 
was reported to also induce miRNA-mediated translational repression 
independently of GW182485, disrupting W-binding pockets responsible for GW182 
binding abolished repression486. The authors suggested that another AGO-binding 
proteins might be recruited via the same pockets and mediate repression in 
flies486. Lastly, miRNA-mediated translational repression via DDX6 was also 
reported to occur independently of CCR4-NOT in mouse embryonic stem cells488. 
In this case DDX6 recruitment depends on the module GW182-EED (mammalian 
hyperplastic disc EED protein)488.  
Irrespective of the inconsistencies, multiple studies support a role for 
miRNAs in inhibiting translational repression at the initiation step by modulating 
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directly or indirectly one of the three components of the eIF4F cap-binding 
complex: eIF4E, eIF4G or eIF4A. Nevertheless, the detailed dynamics of this 
process and whether one or more mechanisms are at play in a context or species-
specific manner remains to be established.  
1.4.4 miRNA-mediated deadenylation and decay 
miRNAs accelerate mRNA degradation90. The first biochemical studies reporting 
this finding in animals observed a negative correlation between miRNA expression 
levels and the mRNA levels of specific miRNA targets489-492. Genome-wide studies 
could provide evidence for miRNA-induced mRNA decay as a widespread 
mechanism of miRNA-mediated repression. In fact, expression of definite miRNAs 
in multiple cell lines and primary cells was shown to cause downregulation of 
hundreds of target transcripts162,176,183,184,262,489. Accordingly, depletion of specific 
miRNAs caused an opposite effects: upregulation of hundreds of miRNA 
targets162,176,490. This mode of miRNA silencing was also supported by the 
observation that miRNA target expression levels increase upon depletion of 
essential components of the miRNA pathway, such as AGO, GW182 and 
Dicer220,310,311,378,479,493,494.  
miRNAs promote degradation of their targets via the canonical mRNA 
decay pathway220,310,311,373,378,390,479. The canonical mechanism of mRNA 
degradation involves mRNA deadenylation followed by decapping and 5’ to 3’ 
degradation by the exonuclease XRN1 or 3’ to 5’ degradation by the exosome and 
subsequent removal of the cap by the scavenger enzyme DcpS495,496.  
In the context of the miRNA pathway, GW182 proteins have been shown to 
directly recruit the deadenylase complexes PAN2-PAN3 and CCR4-NOT to 
miRNA targets, allowing their priming for degradation275-277,310,311,377,390. The two 
deadenylase complexes, PAN2-PAN3 and CCR4-NOT, act consecutively to 
deadenylate target mRNAs298,375. Depletion of PAN2-PAN3 or overexpression of a 
catalytic mutant of PAN2 had mild effects on miRNA-mediated 
deadenylation276,377,390. Conversely, depletion of CCR4-NOT as well as 
overexpression of dominant negative forms of its catalytic subunits (CNOT6 and 
CNOT7) severely impaired miRNA-mediated deadenylation and decay, indicating 
CCR4-NOT is the major deadenylase of miRNA silencing311,336,377,378,390,392,485. 
Similarly, point mutations of W-motifs within GW182 proteins prevented CCR4-
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NOT binding, causing abrogation of mRNA repression in tethering assay and 
rescue assays275. Interestingly, GW182 was shown to not only recruit CCR4-NOT 
to miRNA targets, but also to act as a co-activator of its deadenylase activity in 
Krebs extracts277. Aside from the catalytic CNOT module, the main subunit 
CNOT1 can directly recruit the RNA helicase DDX6 via its MIF4G domain267,356. A 
structural study solved the details of the interactions between the RecA-like 
domain of DDX6 and an FDF-motif in the enhancer of decapping EDC3270. EDC3 
is one of the several cofactors of the decapping enzyme DCP2 and the decapping 
activator DCP1270,310,311,476,479.  DDX6 also binds additional decapping and decay 
factors containing and FDF-motif, such as PatL1, LSm14, and 4E‐T. Thus, 
sequential interactions between CCR4-NOT/DDX6/EDC3 link the deadenylation 
step to decapping. After cap removal the major cytoplasmatic 5’ to 3’ 
exoribonuclease XRN1 is free to access the 5’ monophosphate end of mRNA 
targets and degrade them310,311,378,479,491,497.  The decapping cofactors EDC4 in 
human cells and Dcp1 in Drosophila cells recruit XRN1, connecting decapping to 
5’ to 3’ mRNA decay296. Depletion of cofactors involved in cap removal was shown 
to cause an increase in the abundance of miRNA targets, accumulating in their 
deadenylated forms479. 
Hence, the CCR4-NOT complex can couple deadenylation to decapping to 
5’-3’ exonuclelytic degradation by XRN1, leading to mRNA degradation (reviewed 
in383). Apart from members of the GW182 family several additional proteins, such 
as Nanos, Drosohila CUP, Bicaudal, Smaug, PUM and vertebrates Roquin and 
TTP proteins, can recruit the CCR4-NOT complex to target RNAs, thereby 
enhancing deadenylation and decay of their bound mRNAs358,359,388,498-503. 
1.4.5 Kinetics of miRNA silencing 
In 2012 three individual studies sought out to investigate the order of events 
leading to the establishment of miRNA-mediated repression284,392,504. Two studies 
addressed the dynamics of miRNA silencing using inducible miRNA reporters in 
human392 and Drosophila S2 cell lines504. A third study looked at the expression of 
the endogenous targets of miR-430 in zebrafish embryos, taking advantage of the 
known expression pattern of miR-430, which is induced ~2.5 hours post 
fertilization (hpf)284. Controlling the timing of miRNA reporters/miR-430 expression 
enabled the authors to follow the effects of miRNAs on the expression of their 
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targets at specific time points.  Béthune et al.392 generated HeLa cell lines 
expressing inducible luciferase reporters either sensitive to the endogenous 
miRNA let-7 (wt) or insensitive (mutated let-7 binding sites) as a negative control. 
By comparing the expression of the wt and mut reporters upon induction, the 
authors observed that up to 2 h post-induction wt reporter mRNA levels were 
unaltered, but protein synthesis was already repressed. Between 3 and 48 h 
protein inhibition was accompanied by a decrease in target mRNA levels, 
demonstrating that miRNA-mediated translational repression precedes mRNA 
decay and mRNA decay is the predominant mechanism of miRNA silencing at 
steady state. Similar results were obtained with reporters sensitive to miR-21 
bearing fewer miRNA binding sites. Overall, the results indicated that translational 
repression prevails on newly synthesized miRNA targets, irrespective of the 
miRNA and of the number of miRNA binding sites; while mRNA decay dominates 
at steady state. By measuring poly(A)-tail length of wt and mut reporters at 
different time points post-induction the authors observed that miRNA-dependent 
deadenylation can be observed after translational repression and before mRNA 
decay. Moreover upon knockdown of the CCR4-NOT deadenylase complex or 
overexpression of dominant negative mutants of its catalytic subunits, miRNA 
targets would undergo translational repression, but not deadenylation or decay. 
This study provided evidence that miRNA silencing is a three steps process. First, 
miRNAs inhibit translation in absence of mRNA decay and independently of 
deadenylation. Translational repression is then followed by mRNA deadenylation 
either as a consequence of translation inhibition or because it occurs at a slower 
rate. Third, deadenylation leads to mRNA decay. Analogously, Djuranovic et al.504 
demonstrated a similar mechanism of miRNA silencing in Drosophila S2 cells. 
Using natural and artificial inducible miRNA reporter, sensitive to either 
endogenous or ectopically expressed miRNAs, they could demonstrate the same 
sequence of events. miRNA-mediated translational repression occurs at early 
stages (first 6 h after induction) independently of deadenylation, mRNA 
deadenylation follows (10 h) and later on (24 h) mRNA is degraded. 
Using mRNA-Seq and ribosome profiling in wt and in Dicer knock out (thus, 
with impaired small RNAs processing) zebrafish embryos, Bazzini and 
colleagues284 showed that the protein outcome of miR-430 targets decreased at 4 
hours post fertilization (hpf), while their mRNA levels were stable. At 6 hpf both 
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mRNA and protein levels decreased. Comparably to Bethune and Djuranovic 
studies, the authors could demonstrate that (I) translational repression precedes 
decay; (II) for a specific target of miR-430 deadenylation could be detected only 
after translational repression; and (III) a miR-430 reporter with an internal poly(A) 
tail could be repressed, irrespective of deadenylation. A later report by Subtelny et 
al.263 confirmed that miRNAs, other than miR-430, first induce translational 
repression and then degradation in zebrafish embryos. However, using poly(A)-tail 
length profiling in combination with RNA-Seq and ribosome profiling the authors 
showed that several miRNA targets were both translationally repressed and 
deadenylated, providing an in vivo example where deadenylation is uncoupled 
from degradation.  
In 2014 a study tested if the dynamics of miRNA silencing observed using 
miRNA reporter genes could be recapitulated by endogenous miRNA targets in 
several mammalian cell types184. Using inducible miRNA systems, the authors 
concluded that (I) the time lag between translational repression and mRNA decay 
is shorter than the one observed for reporter genes; (II) translational repression of 
endogenous miRNA targets is weaker than the one of reporters and hardly 
detectable for lowly expressed miRNAs. 
Collectively these data provide evidence that miRNA silencing involves 
translational repression, deadenylation and decay. Undoubtedly, miRNA-mediated 
translational repression precedes miRNA-mediated decay and is independent of 
deadenylation. Interestingly, translational repression, deadenylation and decay 
can be uncoupled artificially using reporters lacking poly(A) tails or catalytically 
inactive CCR4-NOT subunits; or in vivo as it seems to occur in zebrafish embryos 
at pre-gastrulation stages. It is well established that mRNA deadenylation is a 
prerequisite for miRNA-mediated mRNA decay311,377,392, yet it is still unclear 
whether translational repression is required for degradation to occur90.   
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1.4.6 Modulation of miRNA silencing 
To ensure proper regulation of gene expression in response to different cellular 
stimuli, miRNA silencing is regulated at multiple levels: miRNA transcription, 
nuclear export, miRNA processing and turnover, subcellular localization, post-
translational modifications (PTMs) of miRISC components and by accessory 
proteins91,505.  
1.4.6.1 Modulation by post translational modifications of miRISC 
Several PTMs have been reported for AGO proteins. The first AGO2 modification 
to be described was phosphorylation of the S387 residues, reported to facilitate 
AGO2 localization to P-bodies506 and to enhance miRNA-mediated repression507. 
Mass spectrometry analysis identified several phosphorylation sites in AGO2508. 
Among them, phosphorylation of the conserved residue Y529, positioned in the 5’ 
sRNA-binding pocket of AGO2, has been shown to decrease the efficiency of 
sRNA loading508.  Under hypoxic conditions, EGFR signaling induces elevated 
phosphorylation of AGO2 Y393, which inhibits miRNA maturation from pre-
miRNAs by altering interactions with Dicer509. As hypoxia characterizes the 
environment of several solid tumors, this modification was shown to correlate with 
poor survival of breast cancer patients509. AGO2 hydroxylation at P700 under 
hypoxic conditions was reported to enhance AGO2 stability or localization to P-
bodies and miRNA silencing510,511. In contrast, AGO2 sumoylation at K402 was 
related to a decrease in AGO2 stability512 and ADP-ribosylation of AGO2 has been 
shown to alleviate miRNA-mediated repression513. Additionally, it was reported 
that upon T-cell activation AGO proteins are ubiquitinated and marked for 
proteasomal degradation and that miRNA levels decrease514. Notably, unloaded 
AGO proteins are less stable than their corresponding guide RNA-loaded 
form515,516. 
Despite GW182/TNRC6 proteins were first identified as phosphoantigens 
localizing to cytoplasmic foci341, little is known about the function of such PTMs. 
The intrinsically disordered regions of GW182/TNRC6 proteins containing W-
motifs are enriched in serine and threonine residues, which are the main targets of 
phosphorylation517. Huang et al.518 reported that upon phosphatase treatment 
interactions between TNRC6C and PABPC were reduced, suggesting a potential 
mechanism for PABP displacement.  
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Little is known about how PTMs in the CCR4-NOT complex and PABPC 
proteins modulate miRNA silencing. The yeast homologue of CCR4-NOT can be 
phosphorylated in the CNOT1, CNOT4 and CNOT7 subunits519. CNOT4 
phosphorylation is required for the yeast stress response, however the functions of 
the other phosphorylations are not clear519. PABPC proteins are target of 
extensive PTMs, such as acetylation and di-methylation of lysine residues, mono-
methylation and phosphorylation520. The phosphorylation state of PABPC has 
been reported to modulate interactions with poly(A) tails and translation initiation 
factors521.  
1.4.6.2 Modulation of miRNA processing 
As explained previously miRNA processing is a two steps process that leads to the 
production of mature miRNAs. The first step of miRNA maturation involves the 
microprocessor, whose minimal components are the RNA helicase III Drosha and 
the dsRNA binding protein DGCR8116,522-525. The second step involves the RNase 
III enzyme Dicer124-128. Modulations of the levels and activity of these proteins 
affects miRNA processing. Drosha and DGCR8 can regulate each other with a 
mode that is conserved across the animal kingdom526. DGCR8 stabilizes Drosha 
by binding to it526,527, while Drosha cleaves a hairpin-containing exon in DGCR8 
mRNA, thereby destabilizing it120,526,528. PTMs modulate the activity of Drosha and 
DGCR8. For instance phosphorylation of Drosha by glycogen synthase kinase 3β  
(GSK3β) is necessary for its nuclear localization529,530. Acetylation of Drosha was 
shown to prevent its degradation by the proteasome531. Deacetylation of DGCR8 
by histone deacetylase 1 (HDAC1) was reported to increase the affinity for pri-
miRNAs binding532. Phosphorylation of DGCR8 by the kinase ERK increased its 
stability533. Additionally, DGCR8 can be sequestered from the microprocessor by a 
phosphorylated form of methyl-CpG-binding protein 2 (MeCp2)534. DGCR8 is 
released upon dephosphorylation of MeCp2 induced by neuronal activation534. 
Among the accessory proteins that work together with the microprocessor, p68 
(DDX5) and p72 (DDX17) are two RNA helicases that have been shown to be 
necessary for the maturation of a subset of pri-miRNAs196. TGF-β and BMP 
signaling pathway were reported to promote the maturation of pri-miR21 and pri-
miR199a535. Upon TGF-β and BMP signaling, SMAD proteins translocate in the 
nucleus where they can directly interact with p68536, which promotes the activity of 
the microprocessor and increase levels of pre-miRNAs, while leaving unchanged 
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the corresponding pri-miRNA levels535. The tumor suppressor p53 is another 
cofactor shown to promote maturation of pri-miRNAs via interactions with the 
helicase p68537,538. Conversely the estrogen pathway leads to inhibition of the 
microprocessor539,540. Binding of estradiol (E2) to the estrogen receptor α (ERα) 
leads to displacement of Drosha-p68/p72 from the ERα targeted pri-miRNAs539.  
Another way of regulating miRNA biogenesis is mediated by RBPs, which 
recognize and bind to specific sequences of the pri-, pre-miRNAs and sequester 
them from the processing pathway or promote their maturation. For example the 
RBPs LIN-28 and the KH-type splicing regulatory factor (KSRP) bind in a mutually 
exclusive way to two sequences of the let-7 precursor loop to either prevent or 
promote541 its maturation, respectively542.  LIN-28 can block maturation via the 
microprocessor and via Dicer thank to the recruitment of the terminal poly(U) 
polymerases TUT4 and TUT7, which urydilate pre-let-7 and trigger its 
degradation543-545. Similarly to KSRP, the heterogeneous nuclear ribonucleoprotein 
1A (hnRNP1A) enhances processing via the microprocessor by binding to the loop 
of pri-mir-18a and relaxing the stem region546,547. The RBP TDP43 was also 
reported to bind to Drosha and increase microprocessor activity548,549. 
Dicer activity is regulated by accessory proteins. In Drosophila 
melanogaster Loquacious proteins (Loqs-PA and Loqs-PB) were shown to be 
necessary for the maturation of most miRNAs by binding to Dcr-1, whereas Loqs-
PB is specifically required for a subset of miRNA isoforms550-552. The mammalian 
Loqs homologue, TRBP, and the cofactor PACT, also associate with Dicer and 
were reported to increase the efficiency of Dicer processing of certain pre-
miRNAs550,553-557. However, none of the two proteins seem to be necessary for 
Dicer function, which can in fact work alone555.  Moreover phosphorylation of 
TRBP was reported to increase processing of miRNAs promoting growth and to 
downregulate processing of the let-7 family558.  
Additionally, miRNA sequence and structure can modulate processing. A C 
to T single nucleotide polymorphism (SNP) in pri-miR-15a~16-1 decreases 
processing by Drosha and consequently reduces the levels of mature miR-16559. 
Target specificity can also be affected by SNPs in miRNA genes and some SNP 
variants are associated with different types of cancer560-564. RNA editing, such as 
conversion of adenosine to inosine catalyzed by adenosine deaminases (ADARs) 
was shown to diminish the efficiency of Drosha and Dicer processing of pri-
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miR142565 and pri- and pre-miR-151566. O-methylation of the 5’-phosphate of pre-
miR-145 and pre-miR-23b by the RNA methyltransferase BCDIN3D was shown to 
alter Dicer binding, thereby decreasing pre-miRNA processing and consequently 
mature miR levels567. 
1.4.6.3 Modulation of miRNA stability 
The abundance of miRNAs, thus their effect on gene expression, is also regulated 
by miRNA turnover568. In certain cellular contexts miRNAs have long half-lives up 
to several days258,569-571, by contrast miRNA half-lives are considerably shortened 
in neuronal cells572-574. One strategy to destabilize miRNAs in mammalian cells is 
their degradation by highly complementary mRNA targets, named target RNA-
directed miRNA degradation (TDMD)571,575-579. TDMD induces miRNA tailing, 
which is the template-independent addition of nucleotides at the 3’-end of miRNAs, 
and their 3’-5’ trimming and decay571,578,580. Although association of miRNAs and 
AGO proteins stabilizes miRNAs by protecting their 5’ and 3’ termini264,265, miRNA 
tailing occurs when miRNA are still associated with AGOs578. AGOs additionally 
interact with the exonuclease DIS3L2 responsible for miRNA decay579. This 
mechanism competes with miRNA-mediated decay of miRNA targets and is 
particularly prominent in neurons578. It was initially reported as a strategy 
employed by a number of viruses to downregulate host miRNAs disadvantageous 
to viral replication154,580-582.  
Notably, RNA tailing can trigger either stabilization or destabilization of pre- 
and mature miRNAs232. For instance, polyurydilation of pre-let-7 by the terminal 
urydil transferases TUT4 and TUT7 prevents processing by Dicer and enhances 
decay583 via the 3’-5’ exonuclease DIS3L2584,585.  Conversely, monourydilation of 
group II pre-let7 by TUT7, TUT4 and TUT2 promotes let-7 maturation158. 
Adenylation of miRNAs induced by the pox viral protein VP55 causes degradation 
of tailed miRNAs586. By contrast adenylation of the hepatic miRNA-122 has been 
reported to stabilize this miRNA587.  
Members of the miR-16 family, which target genes involved in the cell cycle 
G1-S transition, have been reported to rapidly increase during G0 arrest and to 
rapidly decrease upon cell cycle re-entry with a yet unknown mechanism588. 
Several nucleases have been associated with miRNA degradation. The 
endoribonuclease MCP-induced protein 1 (MCPIP1/ZC3H12A) has been reported 
to cleave pre-miR146a and 135b589. Endoplasmic reticulum stress induces 
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cleavage of a subset of pre-miRNAs (pre-miR17, 34a, 96 and 125b) by the 
kinase/endoribonuclease IRE1α leading to derepression of pro-apoptotic caspase 
2590. Similarly an interferon-mediated response induces the polynucleotide 
phosphorylase PNPase old-35 (PNPT1) 3’-5’ exonuclease to degrade a subset of 
miRNAs in melanoma cells591. Loss of 3’-5’ exonuclease ERI1 was shown to 
correlate with increased expression of certain miRNAs592. miR-382 was shown to 
be degraded by the 3’-5’ exonucleolytic activity of the exosome with the minor help 
of XRN1593. Other nucleases have been implicated in miRNA decay in other 
species. In C. elegans, the 5’-3’ exonuclease XRN1 and XRN2 have been 
reported to degrade mature miRNAs when miRISC is not associated with its 
targets594,595. In A. thaliana, small degrading nucleases (SDNs) have been 
implicated for the first time in active miRNA degradation596.  
Lastly, miRNAs can be sequestered from their targets by competing 
endogenous RNA molecules (ceRNAs) that have complementary binding sites. 
For example, long non-coding RNAs (lncRNAs), such as HULC lncRNA 
upregulated in liver cancer cells can titrate miR-372 away from its targets597. 
Similarly, lncRNA MD1 competes for binding of miR-133 and contributes to muscle 
differentiation598. Likewise, a brain specific circular RNA (circRNA) has been 
reported to act as a sponge for miR-7599,600.  However, the idea of ceRNAs has 
been recently challenged by a study showing that the physiological concentration 
of a ceRNA required to sequester miRNAs in wild type conditions is unrealistic601. 
1.4.6.4 Modulation by accessory proteins 
miRNA silencing is also modulated by accessory proteins, which either antagonize 
or promote miRNA-mediated repression.  
The RNA binding protein (RBP) HuR, a member of the embryonic lethal 
abnormal vision (ELAV) protein family, was reported to alleviate miR-122 mediated 
repression of CAT-1 mRNA in the Huh7 hepatoma cell line279. Upon stress, HuR 
translocates from the nucleus to the cytoplasm where it is free to bind AU-rich 
sequences in the 3’-UTR of CAT-1 mRNA. The binding induces miRISC 
dissociation285, release of the CAT-1 mRNA from P-bodies and association of 
CAT-1 mRNA with polysomes279. Similarly, the germline specific RBP Dead end 1 
(DND1) was reported to alleviate miR-430 mediated repression of NANOS1 and 
TDRD7 mRNAs in primordial zebrafish germ cells by binding to sequences 
overlapping with miR-430 binding sites602,603. Overexpression of DND1 in human 
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HEK293 cells also antagonizes p27 and LATS2 mRNA repression by miR-221 and 
miR-327, respectively603. The apolipoprotein B mRNA-editing enzyme polypeptide-
like 3G (APOBEC3G) alleviates miRNA-mediated repression independently of its 
deaminase activity in human cells465. Expression of APOBEC3G was shown to 
correlate with the release of miRNA reporters from P-bodies and their active 
translation465. 
In contrast, C. elegans Pumilio family (PUF) homolog PUF-9 promotes let-7 
mediated silencing of hbl-1 mRNA604. Likewise, in flies and humans Pumilio 
enhances miRNA silencing of the oncogene E2F3605. Moreover in humans, 
several PUF-binding motives are found in proximity of miRNA-binding sites 
suggesting extensive interaction between PUF proteins and miRISC606.  
The TRIM–NHL family of E3 ubiquitin ligase proteins was shown to interact 
with miRISC607. Mammalian TRIM32 and C. elegans NHL-2 were reported to 
enhance the activity of a subset of miRNAs, including let-7, without altering their 
levels608,609. Both proteins promote neuronal differentiation608,609; interestingly 
TRIM32 is asymmetrically distributed in neuronal progenitors608. Conversely, D. 
melanogaster Mei-P26 leads to a reduction in mature miRNA levels610. TRIM71 
was attributed a role in degradation of AGO2 via ubiquitination611. However, these 
findings were later challenged by the observation that TRIM71 enhances miRNA 
repression of the Cdkn1 gene thereby promoting embryonic stem cells 
proliferation612. 
HuR also has a dual role in modulating miRNA silencing. In fact it can 
enhance let-7 mediated repression of MYC mRNA613. 
The RBP polypyrimidine tract binding protein (PTB) competes with miRISC 
binding of a subset of mRNAs involved in neuronal differentiation and enhances 
miRISC binding of a different subset of mRNAs by modifying their 3’-UTR 
structure614. PTB depletion caused alleviation of miRNA-mediated repression of 
neuronal genes and resulted in the transdifferentiation of fibroblasts into 
neurons614.    
In neuronal cells reversible modulation of miRNA silencing is an important 
mechanism to maintain synaptic plasticity and long-term memory281,615. The 
neurotrophic factor BDNF has been reported to partially alleviate Limk1 mRNA 
repression by miR-134 in rat hippocampal neurons281. The RNA helicase MOV10, 
involved in miRNA silencing, or its Drosophila homolog Armitage have been 
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shown to be degraded at synapses upon neuronal stimulation, thereby promoting 
the expression of dendritically localized mRNAs282,616,617.  
Generally, RBPs are likely candidates for regulating miRNA silencing since 
their binding sites are mainly localized in 3’-UTRs, similarly to miRNAs, and 
hundreds of different RBPs are encoded by the genome (reviewed in618). 
1.5 RNAi across species 
Silencing of RNA molecules via small complementary RNAs is a widespread 
process, known as RNA interference (RNAi), present across most forms of life44. 
Small RNAs act as guides for the recruitment of a set of protein to target nucleic 
acids619,620. RNAi was first described in eukaryotes24 where it consists of three 
major pathways: siRNA-mediated, piRNA-mediated and miRNA-mediated 
pathways621. Despite differences in the biogenesis of these sRNAs, degree of 
complementarity to targets and modes of action, they all share some components 
of the RNAi molecular machinery, suggesting gene regulation via RNAi appeared 
in a common ancestor of Eukarya44,619. Also prokaryotes possess an ancestral 
form of RNAi, however prokaryotes and eukaryotes RNAi seem to have evolved 
independently since the respective RNAi machineries are not homologous44. 
Nevertheless, the mechanistic principles and its function as a defense mechanism 
are shared features between prokaryotic and eukaryotic RNAi622.  
RNAi-like mechanisms in prokaryotes are functional analogues of 
eukaryotic miRNA, siRNA and piRNA pathways. Similarly to miRNAs, a subset of 
small RNAs (on average longer than eukaryotic sRNAs) identified in archaea and 
bacteria exhibit partial complementarity to mRNA targets and leads to translation 
inhibition or degradation of targets via the RNA chaperone Hfq623,624. In addition, 
most bacteria and archaea evolved an sRNA-based adaptive immunity that 
protects cells from foreign and mobile genetic elements, such as bacteriophages 
and plasmids, resembling the function of siRNAs and piRNAs625. This interference 
pathway involves clustered, regularly interspaced short palindromic repeats 
(CRISPRs) interspaced by stretches of DNA derived from the genomes of past 
invaders, which encode sRNAs that guide CRISPR associated (Cas) nucleases to 
target invasive nucleic acids622,626-629. 
Amongst eukaryotes, the core conserved components of RNAi are 
Argonaute proteins, including both AGO and PIWI subclades, and Dicer-like 
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proteins generally having an RNase III domain and a helicase domain44. Many 
species also express RNA-dependent RNA polymerases44. Interestingly, the RNAi 
machinery seem to originate from the assembly of simpler prokaryotic and viral 
proteins with roles in processes other than prokaryotic RNAi: the helicase domain 
of Dicer and AGO from archaea630,631, the RNaseIII domain from bacteria632 and 
RdRP from viruses633,634. Multiple paralogues of these proteins emerged in 
eukaryotes via duplication events and, together with accessory proteins, 
contributed to the evolution of different RNAi pathways44,619. Given a non-
homogenous distribution of these proteins across species, multiple losses might 
have occurred throughout evolution619,635. Several unicellular eukaryotes including 
Trypanosoma cruzi, Leishmania major, Cyanidioschyzon merolae, Plasmodium 
falciparum and the budding yeast Saccharomyces cerevisiae do not express the 
RNAi machinery619. It is hypothesized that these organisms lost, independently 
from each other, the RNAi components suggesting that RNAi is dispensable in 
unicellular eukaryotes619. Conversely, RNAi in multicellular eukaryotes seem 
essential as suggested by the embryonic lethality of Dicer mutants129,636. Yet, 
siRNAs, and Dicer and AGO homologues were found in other unicellular 
eukaryotes as the fission yeast S. pombe637 and in the budding yeasts S. castelli 
and K. polysporus638,639. Additionally, siRNAs were reported to be produced by 
several fungi, plants, protozoans and metazoans species637,640-643 leading 
researchers to hypothesize that siRNA-mediate pathways against viruses and 
transposons were the most ancestral modes of RNAi. By contrast, regulation of 
endogenous gene expression by miRNAs was only reported in multicellular 
species644. Thereby, miRNAs were thought to have appeared together with 
multicellularity. Interestingly, the discovery that the unicellular alga 
Chlamydomonas reinhardtii expresses plant-like miRNAs argued against this 
hypothesis and suggested that at least a common eukaryotic ancestor between 
plants and unicellular algae already developed siRNA and miRNA-mediated RNA 
silencing101,102. Despite many eukaryotic organisms express miRNAs, the number 
of miRNA-encoding genes differ largely amongst genomes and seem to rise with 
increasing organismal complexity, ranging from dozens of genes in sponges to 
nearly 1500 genes in humans232.  
Given substantial differences between plants/algal and animals miRNA 
genes, miRNA biogenesis and miRNA targeting101,102,645, miRNA pathways have 
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been thought to have evolved separately in the two lineages645. miRNA sequences 
and their respective targets diverged across the animal and plant kingdoms108. 
Despite some miRNA families being conserved within animals (thirty miRNA gene 
families including the oldest conserved let-7 family)194,646 and within plants (miR-
165 and miR-166 families)647, no overlap is present between the two kingdoms, 
exception made for the miR-884 family and their UBP1-like mRNA targets648. In 
addition, most of plant miRNAs are encoded from single transcription units located 
in intergenic regions96. Plants lack a Drosha homolog and are processed in two 
nuclear steps by the Dicer homologue Dicer-like 1 (Dcl-1) helped by the dsRNA 
binding protein hyponastic leaves 1 (HYL1) and Serrate649. Although homologs of 
Serrate are present in animals (named ARS2)650,651, HYL1 homologues have only 
been found in plants. Most mature plant miRNAs have high complementarity to 
their targets, thus mostly act via AGO-mediated target slicing199,649,652. Additionally, 
plants lack the key miRISC component GW182. Contrariwise, animal miRNA 
genes are mostly found within introns and often form clusters, transcribed as a 
single primary transcript653. They are processed in two steps; firstly in the nucleus 
by the microprocessor Drosha-Pasha/DGCR8 and secondly in the cytosol by Dicer 
and its partners Loquacious/TRBP and PACT55. The majority of animal miRNAs 
have only partial complementarity to targets and mostly mediates translational 
repression and mRNA deadenylation and decay via the AGO-GW182 miRISC 
complex81,652. Yet, most studies performed in animals looked at a subgroup of 
metazoan called bilaterians (animals with bilateral symmetry such as humans, flies 
and worms), which does not include the older phyla of Porifera (sponges), 
Ctenophora (comb jellies), Placozoa (Trichoplax) and Cnidaria (corals, sea 
anemons, hydroids and jellyfish), which diverged more than 600 million years ago 
(Mya) from the rest of metazoa654. Thus, the term “animal” has been used 
improperly in this context and to gain evolutionary insights into miRNA-mediated 
regulation is important to also look at more ancient animal species. sRNAs and 
most of the components of the RNAi machinery have not been found in Placozoa 
and Ctenophora655-657. However, studies performed in cnidarians and sponges 
identified piRNAs, miRNAs and siRNAs (with piRNAs being the most abundant 
sRNAs)655,658,659 and homologues of the RNAi machinery654. Two cnidarian 
species, namely Hydra and the sea anemone Nematostella vectensis were shown 
to express about 100 miRNAs without sequence similarities to any of the most 
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conserved bilaterian or plant miRNA families, exception made for Nematostella 
miR-100, which is conserved among bilaterians655,658,659. Unlike bilaterians and 
similar to plants, Nematostella miRNAs tend to have high complementarity to their 
targets and mediate target slicing659. Both Nematostella AGO1 and AGO2 in fact 
possess the five residues previously found to be important for AGO slicing activity 
in bilaterians304,330,654. Analogously to plants, most cnidarian sRNAs are 
methylated, possibly by the ubiquitously expressed protein HEN1; whose 
expression is instead restricted to the germline in bilaterians655,658,659. Furthermore, 
cnidarians, sponges and ctenophores express a homologue of plant Dicer partner 
HYL1, but no homologues of Loquacious/TRBP and PACT654. However, unlike 
plants Nematostella also possesses a GW182 homolog654, a protein required for 
miRNA-mediated deadenylation and translational repression in Bilateria. Of note, 
plant miRNAs are also able to mediate both slicing and translational repression649, 
although via the non-GW182 SUO protein family414. Together these findings 
argued against the independent evolution of miRNA pathways in animals and 
plants. They instead suggested that animals and plants miRNA pathways might 
have had a common ancestor and that slicing might have been the predominant 
ancestral mode of action of miRNAs, leaving open the question as to what role 
GW182 plays in cnidarians. 
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1.6 Aim of the Study 
The aim of this study was to gain further mechanistic and evolutionary insights on 
miRNA-mediated regulation of gene expression. The miRNA field has been 
extremely prolific and extensive research efforts have brought a clearer 
understanding of the detailed modes of miRNA silencing. Despite these efforts, 
multiple layers of modulation of miRNA silencing keep emerging and it is not yet 
clear whether miRNA-mediated repression might function differently in different 
contexts and species. Given that members of the GW182 protein family are crucial 
components of miRISC in animals, research presented in this thesis focuses on 
these proteins. Specifically, W-motifs dispersed throughout GW182 proteins 
mediate miRNA-silencing by recruiting the CCR4-NOT deadenylase complex. With 
this in mind, I sought out to identify the W-motif-specific interactome of one of the 
three mammalian paralogues of GW182 proteins, TNRC6C. The aim was to 
identify novel factors interacting with W-motifs that could function as competitors of 
the CCR4-NOT complex and thereby modulate miRNA silencing. Further, I aimed 
to investigate the evolution and conservation of the mechanisms of miRNA-
mediated silencing between bilaterians and cnidarians, focusing on the role of 
GW182 orthologue in the cnidarian Nematostella vectensis. Because the modes of 
miRNA silencing differ substantially in plants and bilaterian animals, it was 
important to explore the mechanism of miRNA-mediated repression in non-
bilaterian animal species, which separated more than 600 million years ago from 
the rest of the metazoan lineages. 
 
 53 
2. Results 
2.1 Identification of the W-motif-dependent interactome 
of human TNRC6C protein 
2.1.1 Importance of W-motifs for mRNA repression 
miRNA silencing is mediated by short tryptophan-containing T/LWG/S repeats, 
named W-motifs because of their invariant tryptophan residue, dispersed 
throughout disordered regions of TNRC6/GW182 proteins275 (Figure 7A and 7B).  
These motifs act in an additive manner to recruit the CCR4-NOT and PAN2/PAN3 
deadenylation complexes and are necessary and sufficient to mediate translational 
repression and deadenylation of target mRNAs. In case of human TNRC6 
homologs, TNRC6A, TNRC6B and TNRC6C, most of the silencing W-motifs are 
located in the C-terminal effector domain (CED) as shown in Figure 7A and in 
Figure S1 for TNRC6C275-277. Indeed, disruption of W-motifs by point mutations of 
tryptophan to alanine (WA) in TNRC6A CED, TNRC6C CED and in the 
Drosophila homologue dmGW182 abrogates mRNA repression275,355. To test 
whether mimicking the aromaticity of the tryptophan residues is sufficient to 
restore repression, a tryptophan to tyrosine (WY) mutant of TNRC6C CED was 
tested in tethering assays. HEK293 cells were co-transfected with plasmids 
encoding a Renilla luciferase (RLuc) mRNA containing five boxB hairpins in its 3’-
UTR, and TNRC6C CED or its W-motifs mutants (7W7Y and 7W7A) fused with 
HA-tag and lambda (λ) phage N peptide, which binds the boxB sites309,660. Firefly 
luciferase (FLuc) without boxB serves as transfection control (Figure 7C). An 
untethered TNRC6 CED, lacking the N peptide, was used as a negative control for 
RLuc-5boxB repression. As expected, TNRC6C CED represses the tethered 
mRNA more than 5 fold, while the 7W7A mutant led to a pronounced alleviation of 
repression. Interestingly, the 7W7Y mutant shows an intermediate phenotype, 
leading to a partial alleviation of repression (~2.5 fold). This result further supports 
the key role of W-motifs in mRNA repression and indicates that aromaticity of the 
central residue of W-motifs is an important feature of repression (Figure 7D). 
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Figure 7. Disruption of W-motifs by Tyr or Ala point mutations progressively 
alleviates mRNA repression by TNRC6C CED (A) Schematic representation of human 
TNRC6C and its C-terminal Effector Domain (CED) used in this study. Individual domains 
and regions of TNRC6C: N-GW, GW-repeat–rich region; UBA, ubiquitin associated-like 
domain; RRM, RNA-recognition motif; PAM2, PABP associated motif. The CED includes 
PAM2, RRM domain and the unstructured regions flanking the RRM, which contain 
several W-motifs. The positions of seven Trp residues within W-motifs are depicted with 
asterisks. Those residues were either mutated into Ala or Tyr in the 7W7A and 7W7Y 
mutants, respectively. Numbers correspond to the amino acid position. (B) Graphic 
representation of a human W-motif obtained by aligning experimentally validated W-motifs 
of TNRC6A and TNRC6C 275. The sequence was derived with MEME suite661, see also 
Figure S2. (C) Schematic representation of reporter constructs used in tethering 
experiments: RLuc-boxB encodes for Renilla luciferase (RLuc) coding sequence fused to 
a 3’UTR with five boxB sites that specifically bind to λN peptide; FLuc encodes for Firefly 
luciferase (FLuc) coding sequence without boxB sites and serves as a control309. (D) 
7W7Y and 7W7A CED mutants progressively alleviate repression of tethered mRNA. 
Human HEK293 cells were co-transfected with plasmids encoding RLuc-boxB, FLuc, and 
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NHA-CED or its indicated 7W7Y, 7W7A mutants. As negative control, a plasmid encoding 
untethered HA-CED was used. RLuc activity was normalized to that of FLuc and 
presented as a percentage of RLuc produced in the presence of the untethered HA-
fusion. Values represent means ± SD from 3 individual experiments (n=3). Expression 
levels of HA-fusion proteins were estimated by western blotting with antibodies directed 
against HA-peptide.  
2.1.2 Classes of W-motif-specific Interactors identified by quantitative 
Mass Spectrometry analysis of TNRC6C and its mutants 
To identify novel interactors of TNRC6C proteins recruited via W-motifs, HEK293 
cells were transfected with plasmids expressing GST-fusions of either wild-type 
(wt) CED, CED with mutated W-motifs (7W7A and 7W7Y) or GST alone as a 
control on background binders. The content of GST pull-downs was analyzed by 
quantitative proteomics using stable isotope labeling of amino acid in cell culture 
(SILAC) coupled to liquid chromatography-tandem mass spectrometry (LC-
MS/MS) in collaboration with Dr. Marieluise Kirchner (Figure 8A). By comparing 
the interactome of TNRC6C CED wt and the two mutants, we were able to identify 
proteins that are pulled by TNRC6C CED via its W-motifs. 80 proteins were 
identified as at least 1.3 fold enriched with TNRC6C CED wt as compared to both 
mutants and to the GST control, indicating they are W-motif-specific (Figure 8B 
and Table S1). As expected, subunits of the CCR4-NOT complex were found 
enriched with the wt CED. Gene ontology (GO) and Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathways enrichment analysis performed with DAVID662,663 
identified RNA degradation as the most enriched pathway, which is consistent with 
the main function played by TNRC6 proteins in miRNA-mediated repression. 
Interestingly, endocytosis resulted as another enriched pathway among W-motif 
specific interactors. In agreement with this, the most enriched GO cellular 
components terms (GO CC) were cytosol, coated pit and plasma membrane 
(Figure 8C). Quantitative proteomic experiments illustrated in figure 8 were done 
in collaboration with Dr. Marieluise Kirchner, who ran the samples on the Mass 
Spectrometer, processed the raw data with MaxQuant, and supervised the data 
analysis I performed.   
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Figure 8. Identification of a TNRC6C W-motif specific interactome (A) Experimental 
strategy: GST-TNRC6C CED wt, 7W7A and 7W7Y mutants (or GST tag alone) were 
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transiently transfected in differentially SILAC labeled HEK293 cells (heavy, medium and 
light). Nuclease-treated HEK293 lysates were used in GST pull-down followed by Mass 
Spectrometry. For the forward experiment CED wt was labeled with heavy amino acids 
(dark grey) and the 7W7A mutant was labeled with light amino acids (light grey). For the 
reverse experiment the SILAC labels were swapped. (B) SILAC-MS results. The data are 
presented as a log2 enrichment of a given interactor with wt TNRC6C CED relative to 
mutants. On the left, forward experiment (x) is plotted against reverse (y). On the right, the 
same data are presented as enrichments relative to the two different mutants: wt/7W7Y 
enriched interactors (x) are plotted against wt/7W7A enriched interactors (y). Values 
represent means from 4 to 9 individual experiments. The cutoff to define the enrichment 
was set at log2=0.4 (~1.3-fold change). All the interactors that passed the cutoff are 
displayed in blue. The bait, CED wt, is represented in black. Subunits of the CCR4-NOT 
complex (positive control) are shown in red. (C) Gene ontology analysis on W-motif-
specific CED interactors. wt CED-enriched interactors (mean log2FC≥ 0.4; one sample t-
test p-value< 0.05) were subjected to GO and KEGG Pathways enrichment analysis using 
DAVID662,663. The enrichment was calculated over the total proteins identified by Mass 
Spectrometry. The bar graph shows the most enriched enriched GO terms (cellular 
component, CC: and Biological Process, BP) and KEGG pathways, and their respective 
enrichment scores (-log10 p-value).  
Amongst the 80 enriched W-motif-specific interactors of TNRC6C CED, MS 
identified proteins involved in vesicular trafficking (Figure 9A). In particular, 
components of the clathrin-coated vesicles (CCVs), such as clathrin (CLTC, 
CLTA) and subunits of the adaptor protein of class 2 complex (AP2), were 
significantly enriched with TNRC6C CED, but not with its mutants (Figure 9B). 
Clathrin heavy chain (CLTC) is also one of the most abundant interactors of wt 
CED (Figure 9C). Importantly, interactions between wt TNRC6C CED and CCV 
components could be validated using GST pull-down of TNRC6C CED and its 
mutants followed by western blotting (Figure 9D). Consistently, previous 
proteomic analysis on CCVs isolated from HeLa cells identified TNRC6A, 
TNRC6B and Argonaute 2 (AGO2) proteins as components of clathrin-coated 
vesicles664. In addition, affinity purification of AGO2 from mouse embryonic 
fibroblasts (MEF) followed by Mass Spectrometry665 identified clathrin as an AGO2 
interactor. Our data suggest that recruitment of the AGO-TNRC6 complex to CCVs 
is mediated by W-motifs of TNRC6 proteins, as interaction with CCV components 
was lost upon mutation of W-motifs.  
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Figure 9. TNRC6C CED interacts with vesicular trafficking proteins via its W-motifs 
(A) SILAC-MS results. Scatter plots identifying proteins involved in vesicular trafficking 
(shown in red) as enriched interactors of wt TNRC6C CED over its mutants. Data were 
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analyzed and presented as in Figure 8B. (B) SILAC-MS results. Scatter plot showing wt 
CED W-motif-specific interactors (x; mean log2 enrichment wt CED/mut CED) and their 
significance (y; -log10 p-value) (one sample t-test; p-value < 0.05). Significant interactors 
are shown in blue. Vesicular trafficking proteins are highlighted in red. (C) Estimate of W-
motif-specific interactors abundance. The mean log2 enrichment wt CED/mut CED (x) is 
plotted against the intensity (y). Enriched interactors are shown in blue and vesicular 
trafficking proteins are shown in red. (D) Validation of interactions between wt TNRC6C 
CED and vesicular trafficking proteins identified in (A). Nuclease-treated cell lysates from 
HEK293 expressing GST-fusions of TNRC6C CED were used in GST pull-downs, and 
inputs (6%) and GST pull-downs were analyzed by western blotting using the indicated 
antibodies. 
Additional classes of TNRC6C W-motifs specific interactors could be identified 
with this approach (Figure 10). For instance two DEAD-box RNA helicases, 
DDX20 and DDX46, were able to interact with TNRC6 CED, but not with its 
mutants. Despite two recent studies identifying DDX6 as a direct interactor of 
CNOT1 that promotes translational repression267,268, we could not identify this 
protein as enriched in our dataset. Similarly, three metabolic enzymes involved in 
nucleotides metabolism and amino acid biosynthesis (CAD, PHGDH and PYCRL) 
interact with TNRC6C via its W-motifs. Moreover mitochondrial proteins such as 
intermembrane chaperones (TIMM proteins) and ADP/ATP translocases or 
metabolite carriers (SLC25A proteins), and kinases and phosphatases were 
among wt CED interactors. Interestingly, by comparing the wt CED-enriched 
interactors with 7W7A and 7W7Y interactors we were able to observe that the 
7W7Y mutant preserves the interactions with PABP1 and PABP4, and PCBP1 
proteins (Figure 10, right). PABP proteins bind poly(A) RNA stretches and PCBP 
proteins bind poly(C) RNA stretches, and are both involved in RNA stabilization. 
This observation may indicate that these protein families could be responsible for 
the residual repressive activity of 7W7Y CED. Despite all CED domains, wt, 7W7Y 
and 7W7A mutants, have an intact PAM2 motif (Figure 7A and Figure S1), which 
is responsible for direct interaction with PABPs286,360, our SILAC-MS data shows 
that PABP binding to 7W7A CED is significantly impaired.  Secondary regions in 
TNRC6 CED have already been attributed PABP binding abilities 275,286,360,362. 
Thus, our data suggest W-motifs constitute these secondary regions that reinforce 
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interactions with PABPs and that Y-motifs can also suffice in mediating PABPs 
binding. 
 
Figure 10. Additional classes of W-motif-specific interactors identified by 
quantitative Mass Spectrometry Different classes of W-motif-specific interactors 
identified by quantitative Mass Spectrometry are shown with different colors. Metabolic 
enzymes (CAD, PHGDH, PYCRL) in light red; mitochondrial proteins (TIMM and SLC25A 
proteins) in green; kinases and phosphatases in blue; poly(A) binding proteins (PABPC1 
and PABPC4) in light blue; poly(C) binding proteins (PCBP1) in purple and DEAD-box 
RNA helicases (DDX20, DDX46) in orange.  The data are presented as described in 
Figure 8B. All enriched proteins are shown in black.  
Overall this analysis identified previously unstudied interactors of TNRC6C 
proteins. Given that W-motifs are indispensable for miRNA silencing, these novel 
interactors are likely to play a role in the regulation of miRNA-mediated repression. 
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2.2 Addressing the role of clathrin-coated vesicles in 
regulation of miRNA silencing 
In light of the finding that several proteins involved in vesicular trafficking are W-
motif-specific binders of TNRC6C, the next questions to ask were where these 
interactions are taking place within a cell, and what their functional meaning is. 
More specifically, if and how they modulate miRNA-mediated repression. 
2.2.1 Clathrin-coated vesicles as novel interactors of TNRC6 and AGO2 
proteins 
Clathrin-coated vesicles (CCVs) are a type of vesicles in charge of sorting cargos 
between the plasma membrane, trans-Golgi network, and endosomal 
compartments (reviewed in666). Clathrin forms a spherical scaffold that coats the 
vesicles, while a heterotetrameric complex of proteins, called adaptor proteins (AP 
proteins), crosses the clathrin scaffold and is capable of binding clathrin, 
membranes lipids and proteins, and accessory proteins on the external side the 
vesicles. Depending on which class of AP proteins binds to clathrin, CCVs mediate 
different membrane trafficking pathways. Clathrin, together with AP2, mediate 
specifically the formation of endocytic vesicles from the plasma membrane (Figure 
11A), while AP1 and AP3 CCVs mediate trans-Golgi trafficking (Figure S3A) 
(reviewed in666). The SILAC-MS/MS data indicated that clathrin and AP2 are W-
motif-specific interactors of TNRC6C, while AP1 and AP3 subunits did not pass 
the established cutoffs; suggesting these interactions might be occurring 
selectively on endocytic CCVs. However coexpression of AP1 subunits and GST-
fusions of TNRC6C CED wt and 7W7A mutant, followed by GST pull-down and 
western blotting also showed W-motif dependent interactions with AP1 subunits 
(Figure S3 B), indicating TNRC6 might weakly interact also with AP1-CCVs.  
Given that all four subunits of AP2: AP2A, AP2B, AP2M and AP2S, are interacting 
with wt CED, clearly supporting the idea that endocytic CCVs interact with 
TNRC6C, the focus was placed on AP2-CCVs. AP2A and AP2B are the biggest 
subunits of AP2 and share the same domain organization. They have a trunk 
domain, which binds to the plasma membrane with the help of AP2M, and to the 
receptors to be internalized; a hinge unstructured region that connects the trunk to 
the appendages, and in case of AP2B contributes to the interaction with the 
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clathrin triskelion; and appendage domains that protrude from the clathrin coat and 
are free to bind accessory proteins (Figure 11A; reviewed in667). 
To investigate whether TNRC6 interactions with CCV proteins are occurring 
on the vesicles, CCV-enriched fractions were isolated from HeLa cells as 
illustrated in Figure 11B. The presence of TNRC6 proteins was tested via western 
blot. In agreement with a previous proteomic study664, CCVs were found to interact 
with endogenous TNRC6A and AGO2 proteins (Figure 11C). Due to unavailability 
of specific antibodies against TNRC6B and TNRC6C their presence could not be 
tested.  
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Figure 11. TNRC6A and AGO2 proteins associate with Clathrin-coated vesicles 
(CCVs) (A) Schematic drawing representing the formation and structure of CCVs. The 
clathrin coat and its triskelion shape are shown in red, and adaptor proteins (AP) are 
represented by a black T-shape protruding from the clathrin-coat. The four subunits 
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forming AP complexes, AP2A (α), AP2B (β), AP2M (µ) and AP2S (σ) and their domains 
(trunk, hinge and appendages) are illustrated. (B) Scheme summarizing the procedure 
adopted to isolate CCVs and the modification introduced; adapted from Borner et al., 
(2012)664. (C) CCVs were isolated from HeLa cells as illustrated in (B). Input (~0.2%), 
CCVs supernatant (~0.3%) and the CCV-enriched fraction were analyzed by western 
blotting using the indicated antibodies. For proper comparison the same protein content 
was loaded in input and CCV-enriched lanes. 
TNRC6-CCVs interactions were detected by either pulling down TNRC6C CED 
and probing for components of CCVs or by isolating CCVs and probing for TNRC6 
proteins. However, it was still not clear whether these interactions occur on the 
outer surface of CCVs or within the vesicles. To discriminate between these 
possibilities flag-tagged AP2A appendage and AP2B appendage-hinge domains, 
which protrude from the clathrin-coat, were overexpressed in HEK293 cells, 
together with GST-fusions of TNRC6 CED wt or 7W7A. The presence of AP2 
appendages was then tested in GST pull-down by western blotting with αflag 
antibody (Figure 12). AP2A appendages interacted with wt TNRC6 CED, but not 
with the 7W7A mutant where W-motifs are disrupted; suggesting CCV-TNRC6 
interactions are located on the outer vesicles coat and are mediated by contacts 
between TNRC6C W-motifs and the appendage regions of AP2A proteins.  
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Figure 12. AP2A appendage interacts with TNRC6C CED via W-motifs HEK293 cells 
were co-transfected with plasmids encoding GST-fusions of TNRC6C CED and plasmids 
encoding flag-tagged AP2A appendage or AP2B appendage-hinge regions. Nuclease-
treated cell lysates were used in GST pull-down, and inputs (~6%) and GST pull-downs 
were analyzed by western blotting with the indicated antibodies. TNRC6C 7W7A was 
used as negative control.  
Next, to test whether TNRC6 and AGO, two core components of the miRISC 
complex, on CCVs are also associated with miRNA targets, CCV-enriched 
fractions were isolated from HeLa cell lines expressing doxycycline inducible 
miRNA reporters, and their RNA content was analysed (Figure 13A). One of the 
HeLa line carries a stably integrated inducible FLuc/RLuc-hmga2 reporter where 
RLuc is fused to the 3’-UTR of the hmga2 gene targeted by let-7 miRNA, which is 
endogenously expressed in HeLa cells (for simplicity called RLuc-hmga2 wt)392. A 
second HeLa line carries a FLuc/RLuc-hmga2 construct fused to a mutated hmga2 
3’-UTR with disrupted let-7 sites that serves as a negative control (RLuc-hmga2 
mut) 392. In both cell lines FLuc is used as a normalization control. Thus, if TNR6C 
proteins associated with CCVs are bound to a let-7 loaded form of AGO2 and to 
the corresponding target mRNA, one would expect an enrichment of wt RLuc-
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hmga2 mRNA on CCVs when compared to mut RLuc-hmga2 mRNA. However, no 
significant difference could be observed between normalized wt and mut RLuc 
mRNAs on CCVs relative to their corresponding inputs (Figure 13B and Figure 
S4). These results may suggest that TNRC6-AGO complexes interacting with 
CCVs are not associated with miRNA targets, and are consequently inactive in 
miRNA silencing.  
 
Figure 13. No enrichment of wt miRNA reporter mRNA is detected on the isolated 
CCVs (A) Schematic representation of FLuc/RLuc-hmga2 dox-inducible reporters 
expressing FLuc insensitive to miRNAs and RLuc fused to the wt 3’UTR of hmga2, thus 
sensitive to let-7 miRNA (wt, blue) or its mutant version with disrupted let-7 sites (mut, 
red). Reporters were previously described in275,392 (B) CCV-enriched fractions were 
isolated from HeLa cell lines carrying stably integrated inducible FLuc/RLuc-hmga2 wt or 
mut miRNA reporters illustrated in (A). Expression of miRNA reporters was induced for 1 
day prior to CCVs isolation. RNA was isolated from inputs and CCV-enriched fractions 
and reporter RNA expression levels were analyzed by qRT-PCR. RLuc mRNA levels were
normalized to that of FLuc and presented as ratios of RLuc isolated from CCVs over RLuc 
isolated from inputs (wt ratio, shown in blue, was set to 1; mut ratio is shown in red). 
Values represent means ± SD from 3 technical replicates. 
2.2.2 Knockdown of components of the clathrin-coated vesicles 
enhances miRNA-mediated repression 
To understand whether the interactions between TNRC6 proteins and CCVs affect 
miRNA-silencing, components of CCVs were knocked down in HeLa cells 
transiently or stably expressing the previously described FLuc/RLuc-hmga2 
inducible reporters sensitive to let-7 miRNA (chapter 2.2.1). Their effects on 
miRNA-mediated repression were tested 4 h after inducing the expression of 
miRNA reporters using luciferase reporter assay (Figure 14A). In the initial setup, 
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HeLa cells were co-transfected with either wt RLuc-hmga2 or mutant RLuc-hmga2 
reporter and siRNAs against TNRC6A/B/C, CLTC and AP2A1/2 gene transcripts 
or a scramble siRNA (Figure 14A, left). In a second setup, HeLa cells stably 
integrating the same set of inducible hmga2 reporters were transfected with 
siRNAs against the same genes (Figure 14A, right). In both cases, in the control 
samples let-7 efficiently repressed wt RLuc-hmga2 mRNA, when compared with 
the mutant reporter (compare the blue bar with the red bar in the scramble sample 
in Figure 14A).  As expected, upon depletion of endogenous TNRC6 proteins, 
repression of the wt RLuc-hmga2 reporter  was alleviated. Intriguingly, depletion of 
AP2A1/A2 proteins caused a decrease of nearly twofold in the expression of the 
let-7 regulated reporter. Instead, depletion of CLTC did not significantly affect 
miRNA silencing. To ensure that tested proteins were indeed efficiently depleted, 
their expression levels were assessed by qRT-PCR and by western blotting 
(Figure 14B and 14C). 
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Figure 14. Knockdown of AP2A proteins enhances miRNA-mediated repression (A) 
siRNAs against the indicated genes were either co-transfected with plasmids encoding the 
dox-inducible let-7 miRNA reporters (hmga2-wt and hmga2-mut) illustrated in Figure 13A 
(left plot; means ± SEM, n=6) or transfected in HeLa cells stably carrying the same 
inducible miRNA reporters (right plot; means ± SEM, n=3). In both cases expression of 
the reporters was induced for 4 h with doxycycline. RLuc activity was normalized to FLuc 
and expressed as a percentage of RLuc activity produced by hmga2-mut reporter in 
samples transfected with scramble siRNA (set to 100%).  Knockdown of TNRC6 proteins 
was used as a positive control on alleviation of miRNA-mediated repression. (B) 
Knockdown efficiency was estimated by qRT-PCR. Total RNA was reverse transcribed 
and cDNA was amplified using primers specific for AP2A1, AP2A2 and CLTC. mRNA 
levels of the indicated genes were normalized to GAPDH levels and expressed as a 
percentage of the corresponding mRNAs in the scramble control (set to 100%). Values 
represent means ± SD of 2 individual experiments. (C) Knockdown efficiency was 
estimated by western blotting using the indicated antibodies. 
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Given that W-motifs are necessary for miRNA silencing, proteins recruited via 
these motifs may promote or alleviate repression. As knockdown of AP2 proteins 
enhanced silencing, I reasoned AP2 could compete with the well-known repressor 
complex CCR4-NOT for W-motifs binding. To test this possibility, HEK293 cells 
depleted of either the CCR4-NOT complex (CNOT1-CNOT9 KD) or CCV 
components (AP2A-CLTC KD), and control cells treated with a scramble siRNA 
were transfected with plasmids encoding GST-TNRC6C CED wt and GST-7W7A 
mutant as a negative control. Nuclease-treated cell lysates were used in GST pull-
downs, and analyzed by western blotting (Figure 15A). In the control samples, wt 
TNRC6C CED interacts with subunits of CCR4-NOT (CNOT9 and CNOT1) and 
components of CCVs (AP2A and CLTC), while 7W7A CED loses the ability to 
interact with both CCR4-NOT and CCV components, as expected. Depletion of 
CCR4-NOT increases AP2A binding to wt CED (~3- to 4-fold, Figure 15B and 
15C), supporting competitive or alternative interactions. Nonetheless, upon 
depletion of AP2A-CLTC no significant difference in CCR4-NOT binding could be 
detected between the knockdown sample and the scramble control. These results 
suggest CCR4-NOT is a stronger W-motifs interactor than AP2A, and competition 
occurs only in one direction. 
 It is indeed important to mention that depletion of AP2A proteins did not 
affect miRNA-mediated repression of bulged RLuc-3xb luciferase reporters 
bearing an artificial 3’-UTR sensitive to let-7412 (Figure S5). I will further comment 
possible reasons for the discrepant results observed when using RLuc-hmga2 
reporters and RLuc-3xb reporters in the discussion session.  
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Figure 15. Knockdown of CCR4-NOT allows increased AP2A binding to TNRC6C 
CED (A) HEK293 cells were co-transfected with plasmids encoding GST-fusions of 
TNRC6C CED and siRNAs against CNOT1-CNOT9, AP2A-CLTC or a scramble siRNA as 
control. Nuclease-treated cell lysates were used in GST pull-down, and inputs (6%) and 
GST pull-downs were analyzed by western blotting using the indicated antibodies. 
TNRC6C 7W7A was used as negative control on CCR4-NOT, and AP2A and CLTC 
binding (B) AP2A levels shown in (A) were quantified with ImageJ software. Quantification 
of AP2A band intensities normalized to GST band intensities is shown for inputs and GST 
pull-downs. Normalized intensity ratios are relative to input control (CED wt co-transfected 
with scramble siRNA; set to 1). (C) AP2A binding to TNRC6C CED increases 3- 4-fold 
upon CCR4-NOT KD. Normalized fold change of AP2A binding in pull-down samples 
expressed relatively to the wt pull-down control are shown (pull-down of CED wt co-
transfected with scramble siRNA was set to 1; means ± SEM; n= 2, individual 
experiments).  
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As interactions between TNRC6C and CCVs could also indicate potential function 
for TNRC6 proteins in the CCV pathway, I collaborated with Dr. Caroline Bruns 
(Hauchke lab, FMP, Berlin) to test this hypothesis. To evaluate whether TNRC6 
proteins modulate clathrin-mediated endocytosis, Dr. Caroline Bruns tested the 
effect of depleting TNRC6 proteins on the uptake of transferrin (Tfn) receptor, 
which is a well-accepted proxy of clathrin-mediated endocytosis. The evidence 
indicates no significant difference between the control samples and samples 
depleted from TNRC6A proteins. Thus, these data did not support the hypothesis 
of TNRC6 involvement in regulation of endocytosis (Figure S6).  
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2.3 Conservation of the players and mechanism of 
miRNA-mediated repression 
miRNA silencing is a layer of post-transcriptional gene regulation active in diverse 
eukaryotic lineages. Given that miRNA pathways differ substantially between 
plants and bilaterian animals, their study in more ancient clades is important to 
infer the evolution of this regulatory mechanism. The starlet sea anemone 
Nematostella vectensis, a representative of Cnidaria that diverged ~600 Mya from 
bilaterians, was shown to frequently cleave its miRNA targets via nearly perfect 
matches659. While this mechanism exhibits unexpected resemblance to the mode 
of action of plant and algae miRNAs, Nematostella and other cnidarians possess 
genes encoding for GW182 homologs as bilaterians do (Figure 16;654). Here, I 
sought out to investigate what is the function of Nematostella GW182. The 
following chapters (2.3.1—2.3.5) were adapted from my first-author manuscript 
(Mauri et al., 2016)668. Direct quotes are delimited by inverted commas: “ “. 
 
 
Figure 16. Phylogenetic distribution of GW182 proteins Schematic phylogenetic tree 
of Metazoa at the phylum level (based on669,670). Phyla where GW182 proteins were 
functionally and biochemically studied appear in purple and the studied protein appear 
within brackets. Phyla where GW182 homologs are found in the genome, but have not 
been functionally studied yet appear in red. Cnidaria appear in blue. Phylogenetic groups 
of multiple phyla are indicated by a triangle. The illustrated polytomy of sponges and 
comb jellies is due to the current uncertainty regarding their relative phylogenetic 
positions. This figure and figure legend was a panel of Figure 1 in Mauri et al., 2016.    
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2.3.1 Nematostella GW182 represses mRNAs via W-motifs within its C-
terminal domain 
“Proteins of the GW182 family show relatively low global sequence conservation, 
but are characterized by a conserved domain organization that includes an N-
terminal GW-rich region, an ubiquitin-associated (UBA) domain, a glutamine-rich 
(Q-rich) region, PABP-associated motif 2 (PAM2) and a C-terminal RNA 
recognition motif, flanked by tryptophan-motifs-containing regions (reviewed in90). 
Nematostella GW182 (nvGW182), in addition, contains an N-terminal DNAJ 
domain that has been proposed to assist loading of small RNA duplexes into AGO 
proteins together with HSP70654 (Figure 17A and Figure S7). The N-terminal GW 
repeats bind AGOs311,331,333,335,355, and the C-terminal part of the protein (CED) 
recruits the CCR4-NOT and PAN2/PAN3 deadenylation complexes to repress 
mRNA275-277. Chekulaeva et al.275, previously identified tryptophan-containing 
WG/S/T and G/S/TW repeats (W-motifs) as the key silencing elements, both 
necessary and sufficient for the direct recruitment of deadenylases and for mRNA 
silencing. The structural aspects of this recruitment were dissected in further 
studies by Filipowicz, Conti, Weichenrieder, and Izaurralde groups267,268. 
Importantly, the function of these motifs was shown to be conserved between 
human and Drosophila275.  As nvGW182 contains similar motifs in its C-terminal 
region (W; Figure 17A and Figure S7), the working hypothesis is that it may 
function via a similar mechanism.  
To test if the function of nvGW182 in mRNA repression is conserved, RNA-
protein tethering assay were performed in human HEK293 cells and the effect on 
mRNA expression was analyzed. Tethering was achieved by co-expressing 
Renilla luciferase mRNA containing five boxB hairpins in its 3´-UTR (RLuc-5boxB; 
shown previously in Figure 7C), and nvGW182 protein or its deletion mutants 
fused with HA-tag and lambda phage N peptide, recognizing the boxB sites309,660. 
As untethered controls that were not expected to repress RLuc-5boxB, analogous 
HA-fusions lacking N peptide were used. As expected, human homologs TNRC6A, 
B and C, used as positive controls, led to efficient repression of tethered mRNA 
(Figure 17B; ~10- to 5-fold). Importantly, tethering of nvGW182 leads to ~3.5-fold 
repression. To identify the domains of nvGW182 that function in repression, C- 
and N-terminal deletions (nvΔCED and nvCED, respectively) were generated and 
their ability to repress tethered mRNA was tested. Consistently with the prior 
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mapping studies in human and Drosophila335-338, nvCED effectively represses 
mRNA (~5-fold), while nvΔCED has practically no effect (Figure 17B and Figure 
S8).” 
 
Figure 17. nvGW182 represses tethered mRNA via its C-terminal effector domain 
(CED) (A) Schematic representation of Nematostella vectensis GW182 (nvGW182), its 
human homologs TNRC6A, B and C, and their deletion mutants. DNAJ domain (yellow); 
N-GW: GW-repeat–rich region (grey); UBA: ubiquitin associated domain (green); PAM2: 
PABP associated motif 2 (light blue); RRM: RNA-recognition motif (red). The C-terminal 
effector domain (CED) is formed by RRM, PAM2 and the unstructured flanking regions 
with tryptophan-containing motifs, or W-motifs (W). The numbers correspond to the amino 
acid positions. (B) Repression of RLuc-boxB mRNA by NHA-nvGW182 and its deletion 
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mutants. Human HEK293 cells were co-transfected with plasmids encoding RLuc-boxB, 
FLuc, and full-length NHA-nvGW182 or indicated NHA-nvGW182 deletion mutants. As 
positive controls, plasmids encoding human NHA-TNRC6A, NHA-TNRC6B and NHA-
TNRC6C were co-transfected. As negative controls, plasmids encoding untethered HA-
fusions were used. RLuc activity was normalized to that of FLuc and presented as a 
percentage of RLuc produced in the presence of the corresponding untethered HA-
fusions (open bars). Values represent means ± SD from 5 to 6 individual experiments 
(n=5-6). Expression levels of HA-fusion proteins were estimated by western blotting with 
antibodies directed against HA-peptide. This figure and figure legend was a panel of 
Figure 1 in Mauri et al., 2016.    
Next, I tested if nvCED mediates repression via presumptive W-motifs (Figure 
18A; W-motifs are shown in bold). For that, W residues in W-motifs were mutated 
(W → A) starting from the C-terminus and the effect of these mutations on 
expression of the tethered mRNA was analyzed (Figure 18B). Mutations of W-
motifs indeed led to alleviation of repression by nvCED. As most alleviation was 
achieved when mutating the four N-terminal W-motifs, I decided to test if these 
motifs are the most critical for repression. For that, nvCED with sequential 
mutations of the four N-terminal W-motifs were generated (Figure 18C). These 
mutations lead to partial alleviation of repression (~2.5-fold), and repression was 
completely abrogated only when all eleven motifs were mutated (11W11A). These 
results suggest that W-motifs act in an additive manner to mediate silencing. 
Importantly, W-motifs were also required for mRNA silencing in the context of the 
full-length nvGW182 (Figure 18D). Western blot analysis of the NHA-nvCED and 
NHA-nvGW182 confirmed that the differences in their repressive potential cannot 
be attributed to differences in expression levels (Figure 18B-D). 
 76 
 
Figure 18. nvGW182 represses tethered mRNA via W-motifs (A) Sequence of the 
nvGW182 CED (nvCED) with tryptophans in presumptive W-motifs shown in bold. (B) 
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Mutations of W residues (WA) in W-motifs alleviate repression by the nvCED. Plasmids 
encoding either wt NHA-nvCED or its indicated mutants were co-transfected into HEK293 
cells, together with RLuc-5BoxB and FLuc. As negative control, untethered HA-nvCED 
was used. Mutants 1W1A through 11W11A contain up to eleven mutated W residues (for 
details, see Materials and Methods). Schematic representations of nvCED constructs are 
drawn below the corresponding bars. Asterisks indicate presumptive W-motifs; W 
residues are shown in black and WA mutations in red. Data were analyzed and 
presented as in Figure 17B (means ± SD; n=4-10). Expression of NHA-fusion proteins 
was estimated by western blotting. (C) W-motifs additively contribute to repression by 
tethered nvCED. Experiment was performed as in (B), except that nvCED with four N-
terminal W-motifs mutated were used (means ± SD; n=4). (D) W-motifs contribute to 
repression by the full-length nvGW182. Experiment was performed as in (B), except that 
full-length nvGW182 was used instead of nvCED domain (means ± SD; n=4-12). This 
figure and figure legend corresponds to Figure 2 in Mauri et al., 2016.    
2.3.2 W-motifs of Nematostella GW182 recruit the CCR4-NOT complex 
To understand how nvGW182 mediates repression, proteins interacting with 
nvGW182 and its repressive domain nvCED were identified. Either full-length 
GST-nvGW182 or its deletion mutants (GST-nvΔCED, GST-nvDNAJ, GST-
nvCED) were expressed in HEK293 cells; pulled down with a GST tag and 
analyzed by mass spectrometry (Figure 19A-D; Tables S2-S5). Similarly to their 
mammalian counterparts275-277,286,361,362, the full-length nvGW182 and wt CED 
associated with components of the human CCR4-NOT complex, CNOT1, CNOT2, 
CNOT3, CNOT9 and PABP proteins. 
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Figure 19. Quantitative Mass Spectrometric analysis of proteins associated with 
nvGW182 and its deletion mutants nv∆CED, nvDNAJ and nvCED Subunits of the 
CCR4-NOT complex and PABP proteins interact with nvGW182 via its CED. Human 
AGO2 (labeled in blue) is not capable of interacting with nvGW182 or with its domains. (A) 
Volcano plot showing nvGW182-enriched interactors over GST control. The logarithmic 
ratios of protein intensities were plotted against negative logarithmic p-values of a two 
sample t-test (two sided).  A hyperbolic curve separates significantly enriched proteins 
(shown in red) from common binders (FDR≤ 0.05; S0=0.1; n=2, biological replicates). 
CCR4-NOT subunits and PABP proteins are labeled in red if enriched or in grey if not 
enriched, AGO2 is labeled in blue and the baits are shown in red. (B-D) Volcano plots 
showing, from left to right, nv∆CED, nvDNAJ and nvCED-enriched interactors (shown in 
red) over GST control. Only proteins identified in (A) as nvGW182 binders (log2 ratio 
nvGW182/GST> 0; 1337 proteins total) were considered for the analysis. Analysis was 
done as described in (A). CCR4-NOT subunits and PABP proteins are labeled in red if 
enriched or in grey if not enriched, AGO2 is labeled in blue and the baits are shown in red. 
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As silencing was mediated by W-motifs present in nvCED, the 11W11A nvCED 
mutant was included as a negative control. Importantly, interactions with the 
CCR4-NOT subunits were lost in nvCED 11W11A mutant, demonstrating that 
nvGW182 recruits deadenylases via W-motifs (Figure 20A). As both wt and 
11W11A mutant nvCED proteins contain the PAM2, they both interacted with 
PABP. The PAN2/PAN3 deadenylation complex was not detected among the 
interactors of nvGW182, although it was previously found to bind human and 
Drosophila GW182 via W-motifs275,276. Thus, interaction with PAN2/PAN3 might 
not be conserved in Nematostella. Alternatively, it is possible that PAN2/PAN3 
was not detected in the nvCED pull-downs because it is a weaker interactor than 
CCR4-NOT. To validate the results of the mass spectrometry, the content of GST 
pull-downs was analyzed by western blotting. Indeed, both CNOT7/CAF1 and 
CNOT9 interacted with the wt nvCED, but not with the 11W11A mutant variant 
(Figure 20B). When only four N- or C-terminal W-motifs were mutated (N-4W4A 
and C-4W4A), nvCED retained most of its affinity to the CNOT7 subunit (Figure 
20C), suggesting an additive role of W-motifs in the CCR4-NOT recruitment. 
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Figure 20. nvGW182 recruits subunits of the CCR4-NOT complex via its W-motifs 
(A) Quantitative mass spectrometric analysis of proteins associated with nvGW182. The 
GST-nvGW182 full-length constructs, the nvCED domain only, as wild type and 11W11A 
mutant variant, were expressed in HEK293 cells and affinity purified using GST. GST 
alone was used as a negative control. On the left, relevant interactors for each variant are 
listed along with their corresponding enrichment factor (the log2 ratios of label-free 
quantification values (LFQ intensity) over corresponding LFQs detected in pull-down of 
GST tag alone). On the right, volcano plot showing proteins with differential binding to 
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nvCED and nvCED11W11A variant. The logarithmic ratios of protein intensities were 
plotted against negative logarithmic p-values of a two sample t-test (two sided).  A 
hyperbolic curve separates significantly enriched proteins from common binders. Selected 
interactors recruited via W-motifs of nvCED are labeled in red (FDR≤ 0.05; S0=0.1; n=2, 
individual experiments). (B) Validation of CCR4-NOT-nvCED interactions identified in (A). 
Nuclease-treated cell lysates from HEK293 expressing GST-fusions of the indicated 
proteins were used in GST pull-downs, and inputs (6%) and GST pull-downs were 
analyzed by western blotting using the indicated antibodies. Human TNRC6CΔCED was 
used as positive control for AGO2 binding. TNRC6C CED and TNRC6C 7W7A CED were 
used as positive and negative controls for CNOT7 and CNOT9 binding. Asterisks (*) 
indicate unspecific bands. (C) W-motifs function additively to recruit the CCR4-NOT 
complex. The experiment was performed as in (B), except that nvCED with four N-
terminal (N-4W4A) or C-terminal (C-4W4A) W-motifs mutated were used for pull-downs. 
nvCED and nvCED 11W11A were used as positive and negative controls for CNOT7 
binding, respectively. Schematic representations of nvCED domains are shown below the 
corresponding lanes. Asterisks indicate W-motifs; W residues are shown in black and W→
A mutations in red. This figure and figure legend corresponds to Figure 3 in Mauri et al., 
2016.     
2.3.3 Nematostella GW182 represses translation and mediates mRNA 
degradation via the CCR4-NOT deadenylase complex 
“The CCR4-NOT complex includes two deadenylation enzymes, CNOT6/CNOT6L 
and CNOT7. To test if the deadenylation activity of the recruited CCR4-NOT 
complex contributes to nvGW182-mediated repression, catalytically inactive 
mutants of CNOT6 (CNOT6cat) and CNOT7 (CNOT7cat) subunits were used377. 
These mutants function as dominant negative and their overexpression leads to 
mRNA stabilization because of decrease in deadenylation rates. Therefore, if 
function of nvGW182 involves CCR4-NOT-mediated deadenylation, I expect that 
interfering with CNOT6 and CNOT7 deadenylation activity would affect repression 
by nvGW182. Indeed, when co-expressing increasing amounts of CNOT6cat and 
CNOT7cat, partial alleviation of repression by nvGW182 and nvCED is observed 
(Figure 21A) accompanied by stabilization of tethered mRNA (Figure 21B). In 
bilaterians GW182 mediates not only mRNA deadenylation via CCR4-NOT, but 
also translational repression267,275. To test if Nematostella protein functions 
similarly, I tested the silencing effects of nvGW182 and of nvCED on the tethered 
RLuc-boxB reporter mRNA and on its protein product by qRT-PCR and luciferase 
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assay, respectively, and compared their expression levels (Figure 21C). This 
analysis confirmed that inhibition of protein production (filled bars) couldn’t be fully 
explained by changes in mRNA levels (open bars), suggesting that nvGW182 
affects both mRNA stability and translation. Importantly, no silencing was 
observed with the 11W11A nvCED mutant, defective in CCR4-NOT recruitment, 
indicating a role for W-motifs in both mRNA decay and translational repression. 
Altogether, these results suggest that the mechanism by which GW182 protein 
represses mRNA may be conserved between Nematostella, flies and mammals.” 
 
Figure 21. nvGW182 represses translation and mediates mRNA degradation via 
CNOT6/CNOT7 deadenylases (A) The deadenylation catalytic activity of the CCR4-NOT 
complex contributes to nvGW182-mediated silencing. HEK293 cells were co-transfected 
with RLuc-boxB, FLuc, tethered NHA-nvGW182 or NHA-nvCED, and increasing amounts 
of CNOT6 and CNOT7 catalytic mutants (CNOTcat). Untethered HA-fusions were used as 
negative controls (means ± SD; n=3-6). (B) Interfering with the CCR4-NOT deadenylation 
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activity leads to stabilization of nvGW182-bound mRNAs. RLuc and FLuc mRNA from 
nvGW182-tethering experiments shown in (A) were estimated by qRT-PCR. Filled bars: 
+CNOTcat; open bars: -CNOTcat. RLuc values were normalized to FLuc mRNA. Untethered 
HA-fusions were used as negative controls (means ± SD; n=2). (C) nvGW182 silences 
tethered mRNA via translational repression and stimulation of mRNA decay. RLuc and 
FLuc mRNA and protein levels from nvGW182-tethering experiments were estimated by 
qRT-PCR (RNA, open bars) and luciferase assays (protein, filled bars). Data were 
normalized and presented as in (A and B). This figure and figure legend corresponds to 
Figure 4 in Mauri et al., 2016.    
2.3.4 Nematostella GW182 interacts with Nematostella AGOs, but fails 
to bind human AGOs 
In order to function in the miRNA silencing pathway, GW182 proteins need to be 
recruited to an mRNA via direct interaction with AGO:miRNA complex, which is 
happening via the N-terminal GW repeats311,331,333,335,355. Intriguingly, mass 
spectrometry performed on the GST pull-downs of nvGW182 or its N-terminal 
regions (nvΔCED, nvDNAJ) did not detect any significant interaction with human 
AGO proteins (shown previously in Figure 19). This result was validated by 
western blotting on the GST pull-downs with αAGO2 antibody; the N-terminal 
domain of human TNRC6C (TNRC6C ΔCED) was used as a positive control for 
AGO2 binding (Figure 22A and previously in 20B). Indeed, a strong interaction 
between AGO2 and human TNRC6C ΔCED was detected, but not with nvGW182 
domains overexpressed in HEK293 cells. The possible explanations of this result 
are that (I) nvGW182 binds only Nematostella, but not human AGOs, because of 
low conservation of binding sites or (II) nvGW182 is recruited to mRNA via a 
different RNA-binding protein. To discriminate between these possibilities, HA-
tagged Nematostella AGOs, nvAGO1 and nvAGO2, were overexpressed in human 
HEK293 cells, together with GST-nvGW182 domains. Binding of nvAGO1 and 
nvAGO2 to nvGW182 was then tested in GST pull-downs (Figure 22A). Western 
blotting with αHA antibody showed that nvAGOs interact with the N-terminal 
domain of nvGW182 protein (nvGW182 ΔCED), but not with its human homolog 
(TNRC6C ΔCED). These results suggest that GW182-AGO interaction regions are 
not conserved between human and Nematostella. Consistently with this result, 
Nematostella AGOs were not able to repress tethered mRNA, unlike human AGO2 
(hsAGO2) used as a positive control (Figure 22B). 
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Figure 22. GW182-AGO interaction regions are not conserved between human and 
Nematostella (A) nvGW182 binds nvAGOs, but not human AGO2. GST-fusions of 
nvGW182 or its domains were co-expressed with HA-tagged nvAGO1 and nvAGO2 in 
HEK293 cells, pulled down with GST tag, and inputs (6%) and GST-pulldowns were 
analyzed by western blotting using the indicated antibodies. Human TNRC6CΔCED was 
used as positive control for human AGO2 binding. (B) Nematostella AGOs are not able to 
repress tethered mRNA in human cells. Human HEK293 cells were co-transfected with 
RLuc-boxB, FLuc, and NHA-nvAGO1 or NHA-nvAGO2. Human AGO2 (NHA-hsAGO2) 
was used as a positive control. As negative controls, plasmids encoding untethered HA-
fusions were used (means ± SD; n=3). This figure and figure legend correspond to panel 
A and B of Figure 5 in Mauri et al., 2016.    
Previous works331,339 have shown that human GW182 proteins have multiple 
regions capable of AGO binding. Interaction with AGO is mediated by tryptophan 
residues, but these AGO-binding motifs are functionally distinct from the CCR4-
NOT-binding W-motifs275,355. Analogously to human TNRC6 proteins, nvGW182 
has several tryptophan residues within its disordered N-terminal domain (Figure 
S7) suggesting interaction with AGO proteins may also occur via multiple 
tryptophan-containing motifs. To test this possibility, a set of N-terminal deletion 
mutants containing different amount of potential AGO-binding tryptophans was 
generated (asterisks; Figure 23A). In order to assess the ability of the generated 
nvGW182 deletions to recruit nvAGOs, GST pull-down assays were performed 
(Figure 23B). Deletion of N-terminal portions lead to gradual reduction of nvAGOs 
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signal, suggesting that nvGW182 recruits nvAGOs via multiple regions, similarly to 
human orthologs. 
 
Figure 23. Multiple tryptophan-containing regions of nv∆CED contribute to nvAGO 
binding (A) Schematic representation of nvΔCED deletion mutants used in (B). The 
numbers correspond to the amino acid positions. Asterisks represent putative AGO-
binding motifs. (B) Multiple regions of nvΔCED contribute to nvAGOs binding. GST-
fusions of nvΔCED deletion mutants were co-expressed with HA-nvAGOs in HEK293 
cells, nuclease-treated lysates were used in GST pull-downs and inputs (6%) and GST 
pull-downs were analyzed by western blotting using the indicated antibodies. This figure 
and figure legend corresponds to panel C and D of Figure 5 in Mauri et al., 2016. 
To understand whether the lack of inter-species interactions between AGO and 
GW182 proteins could be explained by a divergence in AGO sequences, human, 
Drosophila and Nematostella AGO proteins were aligned (Figure 24). The 
alignment shows how the residues forming the tryptophan binding pockets 
responsible for direct interactions with TNRC6 proteins in humans are mostly 
identical (pocket 1, orange and red residues; pocket 2 green residues). This 
observation, together with the results obtained from deletion mutants shown in 
Figure 23B suggests that the mode of interaction between AGO-GW182 proteins 
may be conserved. Probably, the structures of nvΔCED and/or nvAGOs are 
sufficiently different from their human counterparts, thus preventing inter-species 
interactions. 
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Figure 24. W-binding pockets of human AGOs are conserved in nvAGOs Amino acid 
sequence alignment of Nematostella AGOs (nvAGO1, nvAGO2), Drosophila AGOs 
(dmAGO1, dmAGO2) and human AGOs (hsAGO1, hsAGO2, hsAGO3, hsAGO4). The 
region aligning to aa 584-723 of hsAGO2 is displayed. Blue indicates amino acid 
conservation, the darker the blue the more conserved residues are. The residues forming 
two tryptophan-binding pockets hosting two W residues of TNRC6 proteins identified by 
Schirle et al., 2012264 are highlighted in yellow (pocket 1; central residue is shown in red) 
and in green (pocket 2; central residue is shown in dark green). Histograms indicative of 
sequence conservation and quality of the alignment, and a consensus AGO sequence are 
displayed below the alignment. Sequence alignment of AGO proteins was performed with 
Clustal Omega (EBI) and visualized with Jalview. 
Together, these results provide strong evidence that Nematostella GW182 can 
interact with human CCR4-NOT and Nematostella AGOs. Yet, they were obtained 
under overexpression conditions and in human cell cultures. To test whether those 
interactions also occur naturally in the sea anemone itself, Reuven Ahroni, in the 
laboratory of our collaborator Yehu Moran, performed immunoprecipitation (IP) 
from Nematostella embryonic lysates, using a custom antibody raised against 
nvAGO1 and a commercially available antibody against a region of human CNOT9 
that is 94% identical to its Nematostella homolog. Both IPs were then tested by 
western blot, and showed the presence of nvGW182 in nvAGO1 and CNOT9 IP, 
but not in control mock IP performed with unspecific rabbit IgGs (Figure 25). 
These results indicate that AGO, GW182 and CNOT9 interact with one another in 
Nematostella like in mammals267,268,275-277,361.  
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Figure 25. AGO, GW182 and CCR4-NOT natively interact in Nematostella 
Nematostella embryonic lysates were used in IP with αnvAGO1 and αCNOT9 antibody, 
and the co-immunoprecipitated proteins were analyzed by western blotting with α
nvGW182 antibody. Unspecific rabbit IgG was used as a negative control. This figure and 
figure legend corresponds to panel E of Figure 5 in Mauri et al., 2016. 
2.3.5 W-motifs of Nematostella GW182 contribute to bona fide miRNA 
silencing 
“As nvGW182 does not interact with human AGOs, it cannot be used to rescue the 
depletion of TNRC6 proteins in mammalian cells. To overcome this issue and test 
whether nvGW182 can function in miRNA silencing, I generated a chimeric 
construct containing the N-terminal AGO-binding domain of human TNRC6A 
protein and C-terminal CCR4-NOT-binding domain of nvGW182 (Figure 26A). 
This chimeric construct was generated in two versions: wt and 11W11A mutant 
that does not interact with CCR4-NOT. The constructs were used in GST pull-
downs to make sure that both wt and 11W11A chimeras are able to bind human 
AGO2 with the same efficiency (Figure 26B).  
Next, chimeric human/Nematostella GW182 were tested in a bona fide 
miRNA repression assay. For that, HeLa cells were depleted of the endogenous 
TNRC6A and B using stably integrated inducible shRNA constructs, and chimeric 
GW182 proteins were tested for their ability to rescue miRNA repression. To 
assess miRNA-mediated silencing, cells were co-transfected with the Fluc/RLuc-
hmga2 reporter, targeted by let-7 miRNA, which is endogenously expressed in 
HeLa cells (Figure 26C). In control cells let-7 efficiently repressed wt Rluc-hmga2 
mRNA, when compared with the mutant reporter from which let-7-binding sites 
were disrupted (compare Rluc-hmga2 wt with RLuc-hmga2 mut, filled bars).  Upon 
depletion of endogenous TNRC6 proteins (open bars), repression of the hmga2 
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reporter was alleviated. As shown previously, transfection of a plasmid encoding 
wt TNRC6A resistant to shRNA rescued the repression, and its unfuctional mutant 
TNRC6A 8W8A could not rescue275. Intriguingly, the chimeric protein carrying 
nvCED was also able to partially rescue miRNA-mediated silencing (wt chimera). 
Importantly, its function in miRNA silencing was dependent on the CCR4-NOT-
recruiting W-motifs, as 11W11A mutant was not able to complement the 
knockdown of TNRC6 proteins.” To summarize, these data suggest that W-motifs 
of nvGW182 mediate miRNA silencing in a genetic rescue experiment. In order to 
determine the consensus sequence of the CCR4-NOT-recruiting W-motif, shared 
between bilaterians and cnidarians, experimentally validated W-motifs in human, 
Drosophila275 and Nematostella GW182 proteins (Figure 18B-D)  were used as 
inputs for the MEME motif-searching algorithm661. The resulting consensus 
sequence of W-motif (Figure 26D and Figure S9) is rich in S, T and G residues, 
surrounding the invariant W suggesting W-motifs could be modulated by post-
translational modifications (PTMs) such as S/T phosphorylation. 
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Figure 26. Human/Nematostella GW182 chimera partially rescues miRNA silencing 
in human HeLa cells (A) Schematic representation of human/Nematostella GW182 
protein chimeras (h/nvGW182) used in (B) and (C). AGO-binding N-terminal region of 
human TNRC6A was fused to nvCED, either wt or 11W11A mutant. (B) h/nvGW182 
chimera binds endogenous human AGO2. Nuclease-treated lysates from HEK293 cells 
expressing GST-fusions of the indicated proteins and their domains were used in GST 
pull-downs, and inputs (6%) and GST pull-downs were analyzed by western blotting using 
the indicated antibodies. (C) W-motifs of h/nvGW182 chimera are required to rescue 
depletion of endogenous TNRC6 proteins. HeLa cell line carrying stably integrated 
inducible shRNAs construct against endogenous TNRC6A and B was used for TNRC6 
knockdown experiments (open bars); HeLa cells not expressing TNRC6-directed shRNAs 
was used as a control (filled bars). Expression of shRNAs was induced for 2 days prior to 
transfection of miRNA reporters and rescue constructs. Cells were transfected with RLuc-
hmga2 reporter containing let-7 sites or its mutant version (RLuc-hmga2 mut), and 
increasing amounts of plasmids expressing h/nvGW182 chimera or its 11W11A mutant. 
TNRC6A was used as a positive control. Values represent percentages of RLuc activity 
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produced by hmga2-mut reporter without TNRC6 depletion (means ± SD; n=3). (D) 
Graphic representation of the W-motif that recruits the deadenylation complexes and is 
conserved in human, Drosophila and Nematostella, The consensus was derived with the 
MEME suite661, see also Figure S9. This figure and figure legend was adapted from 
Figure 6 in Mauri et al., 2016. 
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3. Discussion 
3.1 Modulation of miRNA silencing via W-motif specific 
Interactome of TNRC6 proteins 
W-motifs are the effectors of miRNA-mediated silencing in animals. In fact proteins 
of the GW182 family recruit the downstream effectors of miRNA silencing 
specifically via these short type of linear tryptophan-containing motifs present 
throughout unstructured regions of the GW182/TNRC6 protein family275. The 
functional relevance and mode of interactions between GW182 W-motifs and the 
CCR4-NOT deadenylase complex have been well established267,268,275,277. Hence, 
previously unstudied interactors recruited via W-motifs are likely candidates to 
modulate or mediate miRNA-mediated repression. In this study, the W-motif-
specific interactome of human TNRC6C was identified and a potential role of 
clathrin-coated vesicles (CCVs) as modulator of miRNA-silencing has emerged.  
3.1.1 Speculative model for regulation of miRNA silencing by 
components of clathrin-coated vesicles 
GW182/TNRC6 proteins are crucial components of metazoans miRISC that direct 
miRNA silencing by binding to AGO and CCR4-NOT proteins81. Previous reports 
identified the C-terminal domain of GW182 proteins as their silencing domain 
(CED)335,337,338,340.  Through the action of multiple W-motifs, GW182 CED recruits 
the CCR4-NOT deadenylase complex, thereby leading to repression of mRNA 
targets267,268,275-277. Using TNRC6C CED wt and mutants where W-motifs were 
disrupted, a TNRC6C W-motif-specific interactome was identified (Figure 8). 
Since W-motifs are indispensable for miRNA-silencing, these novel protein-protein 
interactions are likely to modulate miRNA-mediated repression. Several 
components of the coat of clathrin-coated vesicles (CCVs) resulted enriched with 
wt CED as compared to 7W7A and 7W7Y CED mutants (Figure 9). For instance, 
binding of clathrin heavy and light chains (CLTC and CLTA) and of various 
subunits of adaptor proteins of class 2 (AP2 complex including AP2A, AP2B, 
AP2M, and AP2S) was lost when mutating the central tryptophan residue of W-
motifs to either alanine or tyrosine. Having identified not only one, but several 
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components of CCVs, further supported the idea that these interactors could be 
functionally relevant candidates. Consistently, previous studies identified CLTC as 
an interactor of TNRC6B in HeLa cells 331, and CLTC and AP2A proteins as RNA-
independent interactors of AGO in mouse embryonic fibroblasts (MEFs)665. Given 
that AGO and TNRC6 interact in the miRISC complex, and that the C-terminal 
domain of TNRC6C used in this study is incapable of binding AGO, our data 
suggests that interactions with CLTC and AP2A proteins are mediated by W-motifs 
of TNRC6 proteins. Thus, AGO proteins are indirectly recruited to AP2A-CLTC via 
TNRC6 proteins.   Additionally, AGO and TNRC6A/B were identified by MS as 
novel components of CCV coats664. By isolating CCVs from human HeLa cells, I 
could show that TNRC6 and AGO proteins co-sediment with these vesicles 
(Figure 11). Moreover, AP2A appendage regions protruding from the clathrin coat 
mediated interactions with TNRC6C CED via W-motifs (Figure 12), indicating 
TNRC6-CCV interactions are localized on the outer surface of the vesicles. 
Interestingly, the RNA isolated from CCV preparations obtained from HeLa cells 
expressing RLuc-hmga2 wt or mut let-7 reporters was not enriched in wt reporter 
mRNA (Figure 13). This result possibly suggests that the CCV-associated 
TNRC6-AGO module is not engaging in miRNA-mediated silencing. Accordingly, 
Frohn et al.665 observed that interactions between CLTC, AP2A and AGO2 are 2- 
to 4-fold stronger in a Dicer knock out MEF cell line as compared to wt MEF. Since 
Dicer knock out prevents the maturation of small RNAs, including miRNAs, this 
piece of evidence suggests that clathrin and AP2A interact better with a miRNA-
unloaded form of AGO2. 
Upon depletion of AP2A1/2 proteins, let-7-mediated silencing of RLuc-
hmga2 reporters became approximately twofold stronger (Figure 14), pointing to a 
potential role of AP2A proteins in opposing miRNA-mediated repression. An 
implication of these results is the possibility that CCVs sequester TNRC6-AGO2 
from the repression machinery (the CCR4-NOT deadenylation complex), thereby 
modulating the degree of miRNA-mediated silencing. Consistently, knockdown of 
two subunits of the CCR4-NOT complex, namely CNOT1 and CNOT9, promoted 
binding of TNRC6C CED to AP2A proteins by ~3- 4-fold (Figure 15). However, 
knockdown of AP2A/CLTC did not increase interactions with CCR4-NOT, arguing 
against the sequestration model. One possibility is that, since CCR4-NOT is 
abundant in cells (Figure 9D and Figure S13), TNRC6C CED could already be 
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saturated by CNOT interactions. As clathrin forms CCVs in association with 
different classes of adaptor proteins (AP1, AP2, AP3 and AP4), another possibility 
is that the knockdown of multiple AP families is required to observe increased 
CNOT binding. Alternatively, this observation could mean that the increase in 
miRNA silencing upon AP2A knockdown is mediated by a W-motif-binding factor 
other than CCR4-NOT. Hence, this evidence may suggest CCVs are sites of 
storage or recycle of TNRC6 and AGO proteins. It is also possible that the pool of 
CCV-interacting TNRC6-AGO complex has posttranslational modifications that 
prevent it from binding to the CCR4-NOT complex.     
It is worth noting that, in contrast to the results obtained using RLuc-hmga2 
reporters (Figure 14), AP2A depletion did not enhance let-7-mediated repression 
of RLuc-3xb reporters (Figure S5). One possible explanation for this discrepancy 
is that AP2A affects silencing of only a specific subset of miRNA targets, as was 
previously shown to be the case for enhancers of decapping479. Additionally, the 
endogenous hmga2 3’-UTR (with six endogenous let-7 binding sites) may 
recapitulate miRNA repression in vivo better than the artificial 3’-UTR of Rluc-3xb 
reporters (with three artificial let-7 binding sites). To test this hypothesis, one 
would need to perform additional assays using more reporters bearing 
endogenous 3’-UTRs. Another possibility is that the effect of AP2A knockdown on 
miRNA silencing can only be observed on newly synthesized targets. In fact RLuc 
hmga2 reporters were inducible and luciferase assays were performed 4 h post 
induction, when miRNAs silence via a combination of translational repression and 
mRNA decay392. RLuc-3xb reporters were instead analyzed at steady state, when 
mRNA decay is the prevalent mode of miRNA silencing. To investigate this 
possibility one would need to deplete AP2A proteins and perform kinetic analysis 
using inducible miRNA reporters in order to monitor reporters mRNA and protein 
expression levels at different time points. 
Taken together, these results have shown that CCVs recruit TNRC6-AGO2 
complexes via interactions between AP2A appendages and TNRC6 W-motifs. 
Despite AP2A depletion enhanced silencing of RLuc-hmga2 reporters, it did not 
increase interactions with the CCR4-NOT complex. However, depletion of CCR4-
NOT promoted interactions between AP2A and TNRC6C proteins. Possibly, 
different modifications of TNRC6 proteins control the switch between CCVs and 
CCR4-NOT interactions. Earlier studies already suggested a link between 
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vesicular trafficking and miRNA-mediated repression by identifying miRISC as a 
component of endosomes and multi vesicular bodies (MVBs)424,425. The authors of 
these two studies proposed that MVBs modulate miRNA silencing by promoting 
GW182 turnover424,425. Similarly, interactions between TNRC6-AGO and CCVs 
could represent a cellular strategy to store and recycle core components of 
miRISC. Indeed CCV-bound TNRC6-AGO complex seems to be freed from its 
miRNA targets (Figure 13). A speculative model illustrating the possible functions 
of CCV-TNRC6 interactions is shown in Figure 27. Moreover, clathrin-mediated 
vesicular trafficking is more prominent in neuronal cells and brain tissues, 
specifically AP2-CCVs mediate recycling at synaptosomes671; and AP1 and CLTC 
have been shown to contribute to the establishment of cell polarity in mice and 
worms666. These observations leave open the intriguing possibility that this 
mechanism could primarily regulate the neuronal concentrations of TNRC6-AGO 
proteins available to engage in interactions with miRISC, thereby controlling 
neuronal miRNA-mediated regulation of gene expression. 
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Figure 27. Speculative model illustrating CCVs modulation of miRNA silencing 
miRNA-loaded AGOs directly recruit TNRC6 proteins to target mRNAs. TNRC6 recruit the 
CCR4-NOT deadenylase complex to promote translational repression and the decay of 
target mRNAs through direct interactions with W-motifs. Alternatively, TNRC6 W-motifs 
direct the TNRC6-AGO complex to CCVs via interactions with AP2A proteins. (A) CCVs 
may free miRNA targets from the repressor complex TNRC6-AGO, thus alleviating miRNA 
silencing. (B) Another option is that CCVs are storage or recycling sites for TNRC6 and 
AGO proteins that are not actively participating in miRNA silencing. Possibly, 
modifications of TNRC6 proteins determine which pool of TNRC6 proteins interacts with 
CCVs and which pool interacts with the CCR4-NOT complex.  
 
 
 
 
 96 
3.1.2 Potential roles for other classes of identified W-motif interactors 
in miRNA silencing 
Using a quantitative SILAC-based proteomic approach and loss of functions 
mutants of TNRC6C CED, multiple sets of proteins that bind TNRC6C via W-
motifs were identified in this study. Only components of CCVs were characterized 
in more detail, but additional groups of interactors such as RNA helicases, 
translational regulators, metabolic enzymes, mitochondrial proteins, phosphatases 
and kinases, ribosomal proteins and RNA binding proteins (RBPs) were 
discovered (Figure 10 and Table S1). Thus, this study provides a repository of 
additional modulators of miRNA silencing for future research. I will now speculate 
on the possible functional roles of these interactions.  
Two DEAD-box RNA helicases, DDX20 and DDX46, bind TNRC6C CED in 
a W-motif specific manner (Figure 10, in orange). Generally RNA helicases 
function in unwinding RNA secondary structure and therefore are essential player 
of RNA metabolism. DDX20 has been implicated in transcriptional regulation 
(reviewed in672), while DDX46 was already found to interact with AGO complexes 
independently of RNA673. Despite the fact that two recent studies identified DDX6 
as a direct interactor of CNOT1 that promotes translational repression267,268, this 
protein was not enriched in our dataset. Exportin 1 (XPO1) was nearly 1.5-fold 
enriched with wt TNRC6C CED. In light of the recent evidence demonstrating that 
XPO1 mediates nuclear export of TNRC6 and AGO proteins404, it is tempting to 
suggest that W-motifs mediate this shuttling via XPO1. GW182/TNRC6 proteins 
are also found in P-granules. A C. elegans genetic screen revealed that certain 
nucleoporins (Nup) are required for P granules integrity674. Interestingly the human 
orthologue of one of these proteins, Nup93, was a TNRC6C enriched interactor 
together with Nup205. Nuclear pore proteins are enriched in FG (phenylalanine-
glycine) repeats found within intrinsically disordered regions and contain short 
stretches of hydrophobic amino acids, spaced by hydrophilic residues675. The high 
local concentration of FG repeats has been shown to form elastic and reversible 
hydrogel-like structures675, leading the authors of the study to propose a model of 
nuclear transport whereby gel-like structures at nuclear pores filter nuclear 
trafficking to and from the nucleus. Specificity of transport is achieved by the ability 
of nuclear transporters to transiently break the FG-mediated hydrophobic non-
covalent bonds675. Similarly, TNRC6 proteins are characterized by stretches of 
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numerous W-motifs, suggesting they might mediate interactions via a similar 
mechanism. Along the same line, two innovative studies led by Han, Kato and 
colleagues demonstrated that disordered regions with aromatic-containing motifs, 
comparable to W-motifs, drive the formation of granules by self-aggregating and 
assuming a polymeric amyloid-like structure676,677. The authors suggest that such 
polymerisation could be the mechanism underlying formation of various RNP 
granules in the cell, such as P-bodies, stress granules, Cajal bodies and others, 
and therefore mediate compartmentalization of multiple cellular processes676,677. 
Importantly, increasing evidence shows that disordered regions can form 
pathological aggregates, especially in neurodegenerative diseases678,679 
strengthening their physiological relevance. Han, Kato and colleagues also 
observed that exposing cell lysates of different species and of different cell types 
to biotinylated-isoxazol (b-isoxazol) would selectively precipitate RNA granules 
components enriched in KH (K protein homology) and RRM (RNA recognition 
motif) domains, and low complexity (LC) sequences (disordered motifs)676,677. 
Intriguingly, among the precipitated proteins they could find TNRC6B and C as 
well as ~20% of W-motifs enriched interactors identified by our SILAC approach 
(Table S6)676,677.  Some examples are FMR1 (fragile X mental retardation 
syndrome), FXR1 (fragile X related 1) and PCBP1 (poly(C) binding protein 1) 
proteins, which contain KH domains; and poly(A) binding proteins PABPC1 and 4, 
which have four RRM domains. FMR1 and its autosomal homolog FXR1 are RNA 
binding proteins involved in RNA transport and translational regulation680 and are 
known to interact with components of miRISC226-228. C14orf166 has also been 
proposed as a regulator of RNA transport681. PABPCs and PCBPs proteins bind 
poly(A) or poly(C) RNA stretches, respectively and modulate RNA stability. 
PABPCs have long been known to bind TNRC6 proteins and PAN2-PAN3 
deadaenylase complex via a PAM2 motif (here present in wt and mut CEDs), 
however their role in general miRNA silencing is dispensable (see chapter 
1.4.1.3). Here we show mutations of W-motifs to alanine disturb PABP-TNRC6C 
interactions.  Importantly, PABPs and PCBP1 interactions were preserved by the 
7W7Y mutant indicating that an aromatic tyrosine residue within the motifs is 
sufficient to promote binding; and suggesting PABPs and PCBP1 could be 
responsible for the residual repressive activity of 7W7Y CED (Figure 7D). These 
findings argue that W-motifs in TNRC6 proteins could function via alternative 
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mechanisms: by recruiting CCR4-NOT, as it has been established275 when in 
soluble state; and by oligomerizing into large RNP granules, possibly P-bodies, 
with other proteins. One strategy to control the reversible formation of these 
aggregates is through phosphorylation of serine and threonine residues in LC 
sequences, which was shown to promote FUS (fused in sarcoma) hydrogels 
disassembly in vitro677. Given that W-motifs are S/T-rich and TNRC6 are 
extensively phosphorylated341, phosphorylation is likely to regulate TNRC6 
interactions, and thus functions. Possibly because of this reason, kinases and 
phosphatases were another category of W-motif enriched interactors (Figure 10, 
in blue). 
Notably, three metabolic enzymes involved in nucleotides metabolism and 
amino acid biosynthesis, CAD (Glutamine-dependent carbamoyl-phosphate 
synthase; aspartate carbamoyltransferase; dihydroorotase), PHGDH (D-3-
phosphoglycerate dehydrogenase) and PYCRL (pyrroline-5-carboxylate reductase 
3) also exhibit preferential binding for W-motifs. A growing body of evidence 
supports the existence of moonlighting enzymes, i.e. enzymes with a role other 
than their catalytic metabolic activity, and of a REM (RNA-enzyme-metabolite) 
network that connects cellular metabolism with gene regulation (reviewed in682). 
Hence, one possibility is that CAD, PHGDH and PYCRL are moonlight enzymes 
playing an additional role in RNA metabolism by interacting with TNRC6 proteins. 
A second possibility is that a catabolic process such as miRNA-silencing, which 
leads to mRNA decay, is coupled to recycle of the mRNA degradation products 
generated by the miRNA pathway. Lastly, a group of mitochondrial proteins, such 
as inter-membranes chaperones (TIMM13, 8A and 8B proteins); ADP/ATP 
translocases (SLC25A5 and A6 proteins); phosphate and 2-oxoglutarate/malate 
carriers (SLC25A3 and A11 proteins) and a single strand DNA binding protein 
SSBP1, were identified as W-motif specific TNRC6C binding partners. Since 
mitochondria are the cells energy providers, and regulate processes as apoptosis, 
calcium homeostasis and production of ROS (reactive oxygen species), the 
function of these interactions might have to do with metabolic aspects similarly to 
metabolic enzymes. Alternatively, miRNA have been reported to modulate 
mitochondrial gene expression and AGO has been found in mitochondria 
(reviewed in683), suggesting these interactions may mediate miRISC uptake and 
function within mitochondria.  
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3.2 Evolutionary Aspects of miRNA-mediated Repression 
3.2.1 Evolution of the modes of miRNA silencing  
Earlier studies have shown that multiple cnidarian species, including Nematostella 
vectensis, and sponges possess the miRNA pathway655,658,659. Unlike mammals 
and flies and similarly to plants, Nematostella miRNAs tend to have high 
complementarity to their targets and mediate target slicing659. This finding 
suggested that slicing might have been the ancestral mode of action of miRNAs in 
animals. However, unlike plants Nematostella also possesses a GW182 homolog, 
a protein required for miRNA-mediated deadenylation and translational repression 
in Bilateria. Using human cultured cells I could show that nvGW182 functions via a 
similar mechanism as its bilaterian homologs: it recruits the CCR4-NOT 
deadenylation complex via its W-motifs, to affect both mRNA stability and 
translation. Interestingly, also the helicase DDX6, which was shown to contribute 
to miRNA-mediated translational inhibition in mammals267,268,293 is highly 
conserved in Nematostella (72% identity and 85% similarity between human and 
Nematostella, Figure S10). Interactions between AGO, GW182 and CCR4-NOT 
could also be observed in vivo in Nematostella (Figure 25). Thus, the set of 
experiments presented in section 2.3 supports a model where the mechanism of 
miRNA silencing via W-motifs is conserved between cnidarians and bilaterians 
(Figure 28).  
Figure 28. Modes of miRNA silencing across species Speculative model illustrating 
the mechanisms of miRNA-mediated silencing in bilaterian animals (recruitment of the 
CCR4-NOT complex via W-motifs of GW182), land plants (slicing by AGO and 
translational repression via an unknown mechanism that depends on AGO), and 
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cnidarians (both slicing and GW182-dependent mechanism). This figure and figure legend 
was adapted from panel D of Figure 6 in Mauri et al., 2016.  
It still remains to be elucidated why and how Nematostella miRNAs employ two 
different mechanisms of action: AGO-mediated slicing and AGO/GW182/CCR4-
NOT-mediated deadenylation and translational repression. The most likely 
possibility is that the latter mechanism is employed by a subset of Nematostella 
miRNAs that are only partially complementary to their targets and therefore cannot 
mediate slicing. It is unlikely that only one of two Nematostella AGOs possesses 
slicing activity, and the second relies on nvGW182-dependent mechanism, 
because both nvAGO1 and nvAGO2 possess the five residues previously found to 
be important for AGO slicing activity in bilaterians304,330,654. Alternative 
explanations are that the Nematostella miRNA-mediated repression system 
employs each of the two modes of action under different conditions or for different 
targets. A possible way of switching the mode of action would be modification of 
AGO catalytic site; as such modification can interfere with the slicing activity. 
Another possibility could be via conformational changes of AGOs upon binding of 
GW182 or other proteins, which would prevent target slicing.  
Being able to silence miRNA targets via AGO-mediated cleavage or via 
translational repression and degradation allows Nematostella to either quickly 
degrade miRNA targets or to reversibly silence them. These results suggest that a 
less stringent and reversible mechanism of function – mRNA deadenylation and 
translational repression – was already active in non-bilaterian animals. Since this 
mechanism became the predominant mode of silencing in bilaterians it might have 
been advantageous and therefore preserved by evolution.  
Previously, Chekulaeva and colleagues have demonstrated that W-motifs 
are both necessary and sufficient to recruit the deadenylation complexes and 
repress tethered mRNA, thereby playing a key role in miRNA silencing in human 
and Drosophila275. The results of section 2.3 indicate that the function of these 
potent elements is conserved in over 600 million years of evolution.  The 
consensus sequence of the W-motif, shared between bilaterians and cnidarians 
(Figure 26D) shows that these motifs are rich in serine and threonine residues, 
which makes them hotspots for phosphorylation341,518. Such reversible 
phosphorylation of W-motifs in TNRC6/GW182 proteins could interfere with their 
 101 
ability to recruit the CCR4-NOT complex and, thus, represent an interesting 
mechanism for regulation of miRNA silencing in response to various stimuli. 
Knowingly, W-motifs are not restricted to the GW182 family. They can in 
fact be found in a number of proteins involved in different aspects of RNA 
metabolism and in a wide spectrum of species, from yeast to human (Figure S11). 
Such proteins might recruit the CCR4-NOT complex to specific targets, thereby 
competing with GW182 for CNOT binding and consequently modulating miRNA 
silencing or regulating gene expression in a miRNA-independent way. 
Interestingly, Nanos and tristetraprolin (TTP) proteins have been reported to 
directly recruit CCR4-NOT via multiple short linear motifs (SLIMs) found within 
regions predicted as disordered358,359,502. Such SLIMs contain aromatic and 
hydrophobic residues, whose side chains are inserted into pockets on CNOT 
surfaces358,359,502. Striking features of W-motifs are also the location within 
unstructured regions of GW182 proteins, the aromatic and hydrophobic side chain 
of the invariant W residue and the ability to bind two hydrophobic pockets on 
CNOT9 and probably additional ones on CNOT1 surfaces267,268,275. Moreover, 
CCR4-NOT is a multifunctional complex broadly involved in RNA metabolism 
(reviewed in382). Thus, W-motifs or alternatively aromatic/hydrophobic SLIMs 
recruiting CCR4-NOT might represent a conserved protein-protein interaction 
platform employed by several cellular regulatory pathways.   
3.2.2 Conservation of miRISC components 
miRNA pathway components are conserved throughout bilaterian animals, which 
include the most commonly studied species of H. sapiens, M. musculus, D. 
melanogaster and C. elegans44. More ancient animal species, such as members 
of cnidarians, have been reported to encode for several bilaterian miRISC 
homologues, including Argonaute, GW182/TNRC6 and CCR4-NOT proteins, and 
interestingly for the plant-specific Dicer helper homolog HYL1654. These 
observations raised questions on how these miRISC components evolved and 
which functions they were playing in cnidarians. 
The results of cross-species experiments presented in this thesis showed 
that nvGW182 can interact with the human CCR4-NOT complex through multiple 
W-motifs embedded in the CED, but fails to recognize human AGOs (Figure 19, 
20B, 22A), pointing to a scenario where two domains of GW182 experienced 
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different evolutionary trajectories. The relative conservation of W-motifs in the 
CED (Figure 18) might be the result of the very high conservation of the CCR4-
NOT complex that is connected to numerous cellular pathways and hence has 
very low sequence flexibility (reviewed in382). In support of this view, tryptophan-
containing motifs are the only conserved feature of AIN1 and AIN2, the two C. 
elegans functional analogues of GW182 proteins, which lack the typical domain 
organization of GW182 homologues357 (Figure 4). In contrast, the N-terminal part 
of GW182 protein, which was shown to be crucial for AGO 
recognition311,331,333,335,355), seems to have evolved more rapidly. Although the 
presence of several GW AGO-binding motifs is conserved between human 
TNRC6 proteins and nvGW182 and AGO residues forming W-pockets are also 
conserved (Figure 24), human GW-motifs can only bind human AGOs and nvGW-
motifs can only bind nvAGOs (Figure 22A). The inability of nvAGOs to repress 
when tethered to mRNAs in human cells (Figure 22B) confirmed that they are 
unable to recruit TNRC6 proteins and consequently the downstream effectors of 
silencing. Additionally, co-expression of nvGW182 and nvAGOs failed to rescue 
miRNA silencing in human cells depleted from TNRC6A and B (Figure S12), 
raising the possibility that nvAGOs are not capable of loading human miRNAs.  
Nevertheless, the overall ability of nvGW182 to bind nvAGOs and CNOT9 
(also verified in Nematostella, Figure 25), and the well-documented ability of 
bilaterian GW182/TNRC6 proteins to bind their respective AGOs and the CCR4-
NOT complex267,268,271,275-277,357,361 support a parsimonious view that the last 
common ancestor of Cnidaria and Bilateria carried at least one GW182 and one 
AGO and those were forming a miRNA-mediated silencing complex together with 
units of the CCR4-NOT complex. Further, it is likely that AGOs and the N-terminal 
domain of GW182 proteins have gone through separate co-evolutionary processes 
in the cnidarian and bilaterian lineages that are the reason for the observed lack of 
inter-lineage interaction. This escalating process might have started from a mildly 
disadvantageous mutation in one of the proteins that reduced the AGO-GW182 
affinity and hence made a compensatory mutation in the partner protein 
advantageous684.  
Overall, the results presented in section 2.3 provide new insights into the 
evolution of the miRNA-mediated silencing mechanisms using a cnidarian species, 
Nematostella vectensis, separated by more than half a billion years from the vast 
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majority of Metazoa. The results show that the core component of the miRNA 
pathway GW182 is conserved in cnidarians and, analogously to bilaterians, is able 
to inhibit translation and stimulate mRNA decay by recruiting the CCR4-NOT 
deadenylation complex via W-motifs. An important task for the future is to test the 
functionality of nvGW182-mediated silencing in vivo and understand how the two 
mechanisms – slicing and translational regulation/mRNA deadenylation – interact 
with each other. 
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4. Materials 
4.1 Equipment and Consumables 
Name Company Description 
C100 Touch Thermal cycler Biorad  PCR machine 
S1000 Thermal cycler Biorad PCR machine 
CFX96 Real Time System Biorad qPCR machine 
Trans-Blot Turbo Biorad WB semi-dry transfer cassette  
ImageQuant LAS 4000 GE Healthcare Chemiluminescent detector 
Alpha Imager HP Proteinsimple UV light detector 
Berthold Centro XS3 LB960 DLReady Berthold Technologies Microplate reader (luminometer) 
5424 centrifuge Eppendorf Table top centrifuge 
5424 R centrifuge Eppendorf Table top centrifuge with cooling system 
5804 centrifuge Eppendorf Centrifuge 
5810 R centrifuge Eppendorf Centrifuge with cooling system 
Avanti J-26 XP Beckman Coulter High performance centrifuge 
Sorvall MTX 150 micro-ultracentrifuge ThermoFisher Scientific Micro-ultracentrifuge 
Binder CB incubator Binder CO2 incubator 
Incu-Line VWR  VWR Incubator 
Innova 42 incubator shaker Eppendorf Incubator shaker 
Thermomixer compact Eppendorf Thermomixer 
Biospectrometer basic Eppendorf Spectrometer 
Leica DMIL LED Leica Light microscope 
Dino-Lite digital microscope Dino-Lite Digital microscope 
LUNA automated cell counter Logos biosystems Cell counter 
Qubit fluorometer Life Technologies Fluorometer 
   
1.5 and 2.0 ml tubes Eppendorf  
15 and 50 ml falcon Lab supplier  
PCR tubes 0.2 ml LifeScience  
Low binding tubes Sigma Aldrich  
Amber tubes Kisker Biotech  
Cryotubes Simport  
Cuvettes Carl Roth  
Microseal 96-well skirted qPCR plates Biorad  
Optical adhesive covers Biorad  
Microplates Greiner  
Electronic pipettes VistaLab Technologies  
Manual pipettes Eppendorf  
Electronic multichannel pipettes Eppendorf  
Electronic multistep pipette Eppendorf  
Pipetboy tips Eppendorf  
Gel loading tips Lab supplier  
Combitips Eppendorf  
Filter tips Sarstedt  
Pipette buoy tips Lab supplier  
Glass homogenizer Wheaton USA  
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Name Company Description 
Magnetic rack Millipore  
Petri dishes Sarstedt  
CellStar greiner tissue culture dishes Lab supplier  
CellStart greiner tissue culture flasks Lab supplier  
PVDF roll Millipore  
4.2 Chemicals and Enzymes 
Reagent Catalogue number Company 
Acetic Acid technical grade A2083, 2500 Applichem 
40% Acrylamide/Bisacrylamide Solution 37.5:1 10688,03 Serva 
Agarose  2267,1 Carl Roth  
Agarose  A8963, 0500 Applichem 
Ammonium persulfate A3678-25G Sigma-Aldrich 
Ampicillin Sodium Salt K029.2 Carl-Roth 
ATP R0441 Thermo Scientific 
Attractene Transfection Reagent 301005 Qiagen 
Biorad Protein Assay 500-00006 Biorad 
Biotin  29129 Thermo Fisher 
BLasticidin Ant-bl-1 Invitrogen 
Boric acid B7901-500G Sigma-Aldrich 
Boric acid 15166,02 Serva 
Bromphenol blue 2830 OmniPur/Calbiochem 
Bovine Serum Albumin A9418-5g Sigma-Aldrich 
Albumin Fraction V A9418-50g Carl Roth  
Albumin Fraction V 8076,4 Carl Roth 
Calcium chloride dihydrate 208291 Calbiochem 
Chloramphenicol 3886,2 Carl Roth  
Chloroform C2432-500ml Sigma-Aldrich 
Coelenterazine 102171 PJK 
Coenzyme A  102211 PJK 
Complete Mini EDTA-free Protease Inhibitor tablets 4693159001 Roche 
Complete Mini Protease Inhibitor tablets 4693124001 Roche 
Copper (II) sulphate pentahydrate C8027-500G Sigma-Aldrich 
Coomassie Blue G250 (Serva Blue G) 35050-02 Serva 
p-Coumaric acid C9008-5G Sigma-Aldrich 
Deoxycholic Acid salt 6613-SOG Amrexo 
Diamidino-2-Phenylinarte-Dilactate 13130215-093M4106V Sigma-Aldrich 
Diethyl pyrocarbonate 159220-100g Sigma-Aldrich 
Dimethylsufoxid A994.1 Carl Roth 
Dimethylsulfoxid for cell culture P60-36700100 PAN 
Disodium-EDTA E5134-500G Sigma-Aldrich 
Dithiothreitol 3870 OmniPur 
DMEM (1x)-GlutaMAX 61965-026 Life Technologies 
DNA (Sodium salt) from salmon testes D1626-1g Sigma-Aldrich 
DNase I  A3778.0010 Applichem 
dNTP Mix 10mM each  R0193 Thermo FIsher 
DPBS P04-36500 PAN 
Doxycycline Hyclate Cay14422-5 Biomol 
DreamTaq DNA Polymerase EP0702 Thermo Scientific 
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Reagent Catalogue number Company 
Dynabeads protein G 100040 Life Technologies 
EGTA MB grade 324626 VWR 
EZ PCR Mycoplasma Test Kit 20-700-20 Biological Industries 
Ethanol 99% pure   MDC store 
Ethidium bromide   Carl Roth 
Ethylenediaminetetra-acetic acid EDS-500G Sigma-Aldrich 
EZ-Link Plus Activated Peroxidase 31487 Thermo Fisher 
Fast AP Thermosensitive Alkaline Phosphatase EF0651 Thermo Scientific 
Fetal Bovine Serum 10270 Life Technologies 
FBS heat inactivated F4135-500ML Sigma 
Ficoll PM 400 MB grade SA/F2637/000025 Th. Geyer 
Fungizione 15290026 Life Technologies 
Ganciclovir SYN-001B Linaris/Prospec 
Gel Code Blue Stain reagent  24592 Thermo Scientific 
GeneRuler 1kb ladder  SM0311 Thermo Scientific 
Geneticin sulphate solution M3118.0100 Genaxxon 
Gentamicin/Amphotericin  10R01 Life TEchnologies 
Gibson Assembly Master Mix E2611S NEB 
L-Glutathione reduced G4251-10g Sigma-Aldrich 
Glutathion Sepharose 4B 170756-01 GE Healthcare 
Glycerol G5516-500ml Sigma-Aldrich 
Glycine 23391,03 Serva 
GlycoBlue Blue Coprecipitant AM9516 Life TEchnologies 
Guanidine Hydrochloride G3272-100g Sigma-Aldrich 
Hepes H3375-500G Sigma 
Hydrochloric acid A0625.2500 Applichem 
Hydrogen Peroxide 30% 216763-500ml Sigma-Aldrich 
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid H3375-100G Sigma-Aldrich 
Hygromycin B sc-29067 Santa Cruz 
Igepal CA-630 18896-50ML Sigma-Aldrich 
Imidazole 26081,01 Serva 
Iso-Propanol (2-Propanol) 1.09634.1011 Merck 
jetPrime Transfection Reagent 114-01 Polyplus 
Kanamycin sulfate T832.2 Carl Roth  
LB-agar  X969.3 Carl Roth  
LB-medium X968.3 Carl Roth  
Lithium acetate dihydrate 62395-250G-F Sigma-Aldrich 
Lithium Chloride 4490410000 Acros Organics 
D-luciferin 500mg 102212 PJK 
Luminol A8511-5G Sigma-Aldrich 
Magnesium acetate tetrahydrate M5661-250G Sigma-Aldrich 
Magnesium chloride hexahydrate M2670-100G Sigma-Aldrich 
Magnesium sulfate heptahydrate S3264-500G Sigma-Aldrich 
Manganese (II) cloride tetrahydrate M3634-500g Sigma-Aldrich 
Maxima First Strand cDNA Synthesis Kit for RT-qPCR K1642 Thermo Scientific 
MEM Non-Essential Amino Acids Solution, 100X 11140035 Life Technologies 
MES free acid M8250 Sigma-Aldrich 
2-Mercaptoethanol M3148-100ml Sigma 
Methanol 4627,6 Carl Roth 
Micrococcal Nuclease EN0181 Thermo Scientific 
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Reagent Catalogue number Company 
MOPS, free acid 475922 Calbiochem 
Mung Bean Nuclease M0250S NEB 
Non-fat skimmed milk powder 54650,1 Biomol 
PageRuler Plus Prestained Protein Ladder 26620 Fermentas Life Sciences 
5x Passive Lysis Buffer E1941 Promega 
Pefabloc 50985,1 Biomol 
Polyethylenimine   Polysciences Inc. 
Penicillin 10KU/Streptomycin Solution 10 mg A2213 Biochrom 
Pfu DNA Polymerase EP0571 Thermo Scientific 
Phenol/Chloroform 25:24:1 KP31757 Calbiochem 
lambda-phosphatase sc-2003124 Santa Cruz 
Phosphatase Inhibitor Mix I 39050,02 Serva Electrophoresis  
Phusion DNA Polymerase F-530L Thermo Scientific 
Polyethylene glycol 33136,01 Serva Electrophoresis  
Ponceau S Sodium P3504-50g Sigma-Aldrich 
Potassium acetate 529543 Calbiochem 
Potassium chloride P9541-500G Sigma-Aldrich 
Potassium hydroxide 1.05012.1000 Merck 
Potassium phosphate monobasic P9791-500G Sigma-Aldrich 
Potassium phosphate tribasic P5629-25G Sigma-Aldrich 
Precision Plus Protein Standard Dual Color 161-0374 Biorad 
PreScission Protease 270843-0.5KU VWR 
propylgallate P3130-100g Sigma 
Proteinase K SAFSP4850 Sigma 
Puromycin dihydrochloride P9620-10 ml Sigma 
Restriction Endonucleases P10-020500 New England Biolabs 
RNase A K0489 Thermo Scientific 
RNase A K0509 Thermo Scientific 
RNAseOUT 10000000P40 Invitrogen 
RQ1 DNase Kit M610A Promega 
Rubidium Chloride 83980-50g Sigma 
SensiFast Sybr Green No-Rox Kit BIO-98002 Bioline 
SOB medium AE27.1 Carl Roth  
Sodium acetate trihydrate 71188-250G Sigma-Aldrich 
Sodium azide K305.1 Carl Roth  
Sodium chloride A2942,1000 Applichem 
Sodium dodecyl sulfate A2263,0100 AppliChem 
Sodium deoxycholate SAFS30970 VWR 
Sodium hydroxide 1064621000 Merck 
sodium phosphate monobasic A2901,1000 Applichem 
Sodium phosphate dibasic S3264-500G Sigma-Aldrich 
Sodium phosphate tribasic 342489-25g Sigma-Aldrich 
Spermidine 85558-1G Sigma-Aldrich 
Sucrose A2211,1000 Applichem 
Super Signal West Femto Maximum Sensitivity Substrate 34096 Pierce 
T4 DNA Ligase EL0011 Thermo Scientific 
T4 Polynucleotidkinase EK0031 Thermo Scientific 
N,N,N',N'-Tetramethyl-ethylenediamine T9281-25ML Sigma-Aldrich 
Topo TA cloning Kit 450641 Life Science 
TriFast FL PeqGold 30-2110 VWR 
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Reagent Catalogue number Company 
Trypsin P10-020500 PAN 
Tris(hydroxymethyl)aminomethane molecular biology grade 37186,03 Serva 
Triton X-100 A4975,1000 AppliChem 
Trizma base 93362-1KG Sigma-Aldrich 
Trypan Blue 15250-061 Life Technologies 
Tryptone/Peptone from Casein 8952,3 Carl Roth 
L-Tryptophan 6540-100GM Calbiochem 
Tween 20 P9416-100ML Sigma-Aldrich 
Urea 666122 Calbiochem 
Western Blocking Reagent 11921673001 Roche 
X-beta-Gal 2315,3 Carl Roth 
Xylene yanol FF X4126-10G Sigma-Aldrich 
YPD agar X971.1 Carl Roth  
YPD medium X970.1 Carl Roth  
Zeocin  ant-zn-1 InvivoGen 
 
4.3 Kits 
Kit Name Company Catalogue number Application 
Plasmid miniprep DNA kit Roboklon E3500-02 Plasmid isolation (mini) 
NucleobondXtra Macherey-Nagel 00740412/000050 Plasmid isolation (midi) 
GeneJET gel extraction kit Thermo Fisher K0692 DNA purification from gel 
GeneJET PCR purification kit Thermo Fisher K0702 DNA purification from PCR 
 
4.4 Buffers, solutions and Media 
4.4.1 Buffers and solutions 
Buffers Composition Application 
Lysis buffer 
50 mM Tris-HCl pH 7.4, 150 mM KCl, 0.5% (v/v) Triton X-100, 0.2 
mM Pefabloc (or 1 tablet Roche protease inhibitor cocktail in 10 ml 
buffer) 
Cell lysis and GST pull-
down, IP (*) 
Washing buffer 
50 mM Tris-HCl pH 7.4, 150 mM KCl, 0.1% (v/v) Triton X-100, 0.2 
mM Pefabloc (or 1 tablet Roche protease inhibitor cocktail in 10 ml 
buffer) 
GST pull-down, IP 
Elution buffer 50 mM GSH in washing buffer; pH ajusted to 7.5 with 1 M Tris GST pull-down 
Hypotonic buffer A 
0.1 M MES, pH 6.5 adjusted with NaOH, 0.2 mM EGTA, and 0.5 mM 
MgCl2 
CCVs isolation  (*) 
5x SDS loading buffer 
50%  (v/v) glycerol, 300 mM Tris-HCl pH 6.8, 5% (v/v) 14.3 M β2-
mercapto-ethanol, 0.1% (w/v) bromophenol blue, 10% (w/v) SDS 
SDS-PAGE 
Running buffer 25mM Tris-base, 191 mM glycine, 0.1% (w/v) SDS SDS-PAGE 
Transfer buffer 25mM Tris-base, 191 mM glycine, 20% (v/v) MetOH 
western blotting 
(transfer) 
PBS 0.137 mM NaCl, 2.6 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 Cell culture 
TBS 50 mM Tris-HCl pH 7.5, 150 mM NaCl 
western blotting 
(washing) 
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Buffers Composition Application 
PBS-T PBS and 0.1-0.2%  (v/v) Tween-20 
western blotting 
(washing) 
TBS-T TBS and 0.1% (v/v) Tween-20 
western blotting 
(washing) 
Blocking solution 
5% (w/v) milk or BSA in TBS-T or PBS-T (depending on antibody 
requirements) 
western blotting 
(blocking) 
ECL 
100 mM Tris-HCl pH 8.5, 1.25 mM luminol, 225 µM coumaric acid, 
0.01% H2O2 
western blotting 
(developing) 
Comassie staining 
solution 
50%  (v/v) H2O, 50%  (v/v) EtOH, 0.1% (w/v) Blue G powder Comassie staining 
Comassie destaining 
solution 
60%  (v/v) H2O, 30% (v/v) EtOH, 10%  (v/v) acetic acid Comassie destaining 
TBE 89 mM Tris-HCl pH 6.8, 89 mM boric acid, 2.5 mM EDTA DNA electrophoresis 
Fluc reagent 
75 mM Hepes pH 8.0, 0.1 mM EDTA, 4 mM MgSO4, 530 µM ATP, 
270 µM Coenzyme A, 470 µM DTT and 470 µM luciferin 
Luciferase assays 
Rluc reagent 
2.2 mM Na2EDTA, 220 mM K3PO4 pH 5.1, 0.44 mg/ml BSA, 1.1 M 
NaCl, 1.3 mM NaN3 and 0.6 µg/ml colenterazine 
Luciferase assays 
 
*Buffers for RNA work were prepared in DEPC-treated water 
4.4.2 Media 
Medium Composition Cell type 
DMEM DMEM-GlutaMAX high glucose (Gibco) with 10% (v/v) FBS (Gibco) Mammalian 
cells 
SILAC DMEM DMEM high glucose without L-Arg, L-Lys and L-Gln; with 10% (v/v) 
dialyzed FBS (Sigma-Aldrich), 100 U-ml penicillin-streptomycin 
(Invitrogen), 4 mM stable Gln, and 28 mg/L L-Arg and 48 mg/L L-Lys. Light 
medium (Arg0/Lys0, Sigma-Aldrich); medium heavy (Arg6/Lys4, Sigma-
Aldrich); heavy (Arg10/Lys8, Sigma-Aldrich) 
Mammalian 
cells 
LB (Lysogeny Broth) 25 g LB powder (Carl Roth) in 1 L Millipore water  E. coli 
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4.5 Bacterial strains and Cell lines 
4.5.1 Bacterial strains 
Strain Species Genotype 
XL1-blue E. coli endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F'[ ::Tn10 proAB+ lacIq 
Δ(lacZ)M15] hsdR17(rK- mK+) 
DH5α E. coli F– endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG purB20 φ80dlacZΔM15 
Δ(lacZYA-argF)U169, hsdR17(rK–mK+), λ– 
Mach1 E. coli ΔrecA1398 endA1 tonA Φ80ΔlacM15 ΔlacX74 hsdR(rK- mK+) 
dam-/dcm- (NEB; C2925) E. coli ara-14 leuB6 fhuA31 lacY1 tsx78 glnV44 galK2 galT22 mcrA dcm-6 hisG4 rfbD1 
R(zgb210::Tn10) TetS endA1 rspL136 (StrR) dam13::Tn9 (CamR) xylA-5 mtl-1 
thi-1 mcrB1 hsdR2 
 
4.5.2 Cell Lines 
Cell Line Species Source Description Use 
HEK 293 Homo 
sapiens 
Matthias Selbach 
Lab 
Human embryonic kidney cells with the 
morphology of epithelial cells 
Pull-down 
experiments and 
tethering assays 
HeLa-EM2-11ht 
(HeLa rtTA) 
Homo 
sapiens 
Kai Schoenig 
(Weidenfeld et al., 
2009, NAR)685 
HeLa line carrying reverse tetracycline 
transactivator for doxycycline (dox) inducible 
expression; and hygromycin/ganciclovir 
cassette flanked by FRT site (F&F3) for 
generation of arbitrary stable lines with dox-
inducible expression via RMCE (ganciclovir to 
be used for negative selection) 
miRNA reporter 
assays, rescue 
assays, CCV 
isolation 
HeLa-rtTA-1266 
clone 27 
(TNRC6A&B-
KD) 
Homo 
sapiens 
Marina 
Chekulaeva and 
Camilla Ciolli 
Mattioli (Mauri et 
al., 2016, NAR)668 
HeLa line with dox inducible KD of TNRC6A&B Rescue assays, 
CCV isolation 
HeLa-rtTA-755 
(hmga2 wt) 
Homo 
sapiens 
Julien Bethune 
(Bethune et al., 
2012, EMBO 
Rep)392 
HeLa line with dox inducible expression of 
FLuc/RLuc-hmga2 wt let-7 miRNA reporter 
miRNA reporter 
assays, CCV 
isolation 
HeLa-rtTA-756 
(hmga2 mut) 
Homo 
sapiens 
Julien Bethune 
(Bethune et al., 
2012, EMBO Rep) 
392 
HeLa line with dox inducible expression of 
FLuc/RLuc-mutated hmga2 let-7 miRNA 
reporter 
miRNA reporter 
assays, CCV 
isolation 
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4.6 Oligos 
4.6.1 Oligos for sequencing 
MCh Name Sequence (5’-3’) Purpose 
26 
Fluc upstream 
sequencing 
TTCATAGCCTTATGCAGTTGCTC 
Sequencing oligo for upstream region of 
Firefly luciferase 
814 pCiNeo-upstream CACAGGTGTCCACTCCCAGTTC 
Sequencing primers for pCiNeo plasmids 
815 pCiNeo-downstream ACTGCATTCTAGTTGTGGTTTGTCC 
816 pEBG-upstream (GST) ATAGCATGGCCTTTGCAGGG 
Sequencing primers for pEBG plasmids. 
817 pEBG-downstream ACAGGGATTTCTTGTCTCCCAC 
1002 
Rluc sequencing 
upstream 
TAGTTGATGAAGGAGTCCA Sequencing upstream of Renilla luciferase 
1042 GST upstream  CAAGGCCCTTAATTTTCCAATAACC Sequencing upstream of GST-Tag 
1125 CMV rev sequencing CACCGTACACGCCTAAAGC 
Sequencing primer binding the flanking region 
between CMV and Tet-O sites 
1268 
Rluc sequencing, 
downstream 
CTGAGGAGTTCGCTGCCTAC 
Sequencing primer binding in the 3' terminal 
region of Renilla luciferase  
2279 
pEBH upstream 
sequencing primer 
ATGGCTTACCCATACGATGTTC Upstream oligo to sequence pEBH  
 
4.6.2 Oligos for cloning 
MCh Name Sequence (5’-3’) Purpose 
658 
TNRC6A N-
terminus rev 
CACACCACCTCCTTTGTTTGTGTTA
AC 
Use oligos 658&1209 to amplify siRNA resistant 
N-terminus of TNRC6A isoform 2 (Q8NDV7-2) 
from p1218 
 
659 
TNRC6A-middle-
fw 
GTTAACACAAACAAAGGAGGTGGT
GTG 
Use oligos 659&660 to amplify C-terminus of 
TNRC6A with NotI site at the 3'end. Then mix two 
PCR products (from 1209&658 and 659&660 
PCRs) and amplify the full-length with 1209 and 
660. Digest with SbfI-NotI and clone into SbfI-NotI 
cut pCiNeo-HA and pCiNeo-NHA  
660 
NotI-Cterm-
reverse 
AGGGAAGCGGCCGCTTACATGGAC
TCTCCACCCC 
1183 SbfI-hAP2A2 fw 
AACCTGCAGGCATGCCGGCCGTGT
CCAAG   
Primers to amplify full length AP2A2. Use total 
human cDNA as template, digest with SbfI-NotI 
and clone into SbfI-NotI-cut p1238 1184 NotI-hAP2A2 rev 
aagcggccgcCTAAAACTGCGCTGAGA
GCA 
1185 
SbfI-hAP2A2 
appendage fw 
AACCTGCAGGCGCGCCTCTCGCTC
CTGG 
Fw primer to be used with MCh 1184 as rev to 
amplify AP2A2 appendage. Use total human 
cDNA as template, digest with SbfI-NotI and clone 
into SbfI-NotI-cut-p1238 
1186 
SbfI-hAP2B1 
hinge_appendage 
fw 
AACCTGCAGGCGAACAGCCTCAGG
TTATC 
Primers to amplify hinge and appendage region of 
AP2B1. Use total human cDNA as template, 
digest with SbfI-NotI and clone into SbfI-NotI-cut 
p1238 1187 
NotI-hAP2B1 
hinge_appendage
_rev 
aagcggccgcTTAGTTTTTCAAAATGCT
GTCG 
1188 SbfI-hAP2M fw AACCTGCAGGCatgattggaggcttattcat Primers to amplify full length AP2M. Use total 
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MCh Name Sequence (5’-3’) Purpose 
1189 NotI-hAP2M rev aagcggccgcctagcagcgagtttcataa 
human cDNA as template, digest with SbfI-NotI 
and clone into SbfI-NotI-cut p1238 
1209 
SbfI-TNRC6A-fw 
(full clone) 
tacgctcctgcaggcATGGATGCTGATTC
TGCCTCCAG 
To be used with mch658 (instead of 657) and 
p1218 as a template to amplify N-terminus of 
TNRC6A  
1648 CHC miR-1 
gcgatgctgttgacagtgagcgaAATCGCCC
ATCTGAAGGTCCTctgtgaagcca 
Oligos for cloning anti-CHC miR into BsaI-cut 
p1010 (Tet-inducible expression) based on the 
siMCh17 sequence deposited into the collection.  
PNK and anneal mch1648&1651 and 
mch1649&1650; ligate the two pairs; gel purify the 
shRNA, clone in dephosphorylated BsaI cut 
p1010 vector. miR seq: 
tgctgttgacagtgagcgaGCCTAATCTCCGTGCTCAA
ctgtgaagccacagatgggTTGAGCACGGAGATTAGG
Cctgcctactgcctcggacttcaaggg, GCGA and GCAG 
are compatible cohesive ends for BsaI site. 
1649 CHC miR-2 
cagatgggAGGACCTTCAGATGGGCG
ATTctgcctactgcctcggacttcaaggg 
1650 CHC miR-3 
gcagcccttgaagtccgaggcagtaggcagAAT
CGCCCATCTGAAGGTCCTccca 
1651 CHC miR-4 
tctgtggcttcacagAGGACCTTCAGATG
GGCGATTtcgctcactgtcaacagca 
1735 SbfI-nvGW182 fw 
aaatacctgcaggcATGCCTAAGGATGA
CAAGAAGGAATT 
Primers for cloning nvGW182 into SbfI-NotI cut 
pCiNEo-NHA and pCiNeo-HA for tethering and 
rescue 1736 NotI-nvGW182 rev 
AGGGAAGCGGCCGCCTTAGACACT
CTCACCACCGTTCAG 
1795 
NotI_Nterm-
nvGW182 rev 
AGGGAAGCGGCCGCtcaAGGGCTC
TGCTGAGTTATTCGC 
Primer to amplify the N-terminus of nvGW182. To 
be used with oligo 1735 as forward and p1429 as 
a template  
1796 
SbfI_Cterm-
nvGW182 fw 
aaatacctgcaggcATGGCCCCACAGTC
CAGGCTGAC 
Primer to amplify the C-terminus of nvGW182. To 
be used with oligo 1736 as reverse and p1429 as 
a template  
1855 
SbfI-nvGW182 
NED ΔDnaJ fw 
aaatacctgcaggcCACGACGGGATCAA
TGACAGCC 
Primer to amplify the N-terminus of nvGW182 
depleted of the DnaJ domain (aa 11-61). To be 
used with oligo 1795 as reverse and p1429 as a 
template  
1861 NotI_nvDnaJ rev 
AGGGAAGCGGCCGCCTGACGAGG
TACTCGAATGCTTTAG 
To be used with oligo 1735 as forward and p1429 
as template to amplify the DNAJ domain of 
NvGW182 between SbfI-NotI, to be cloned in 
pCiNeo and pEBG 
1889 SbfI-hAP2B fw 
aaatacctgcaggcATGACTGACTCCAA
GTATTTC 
Primer to amplify full-length hAP2B flanked by 
SbfI and NotI sites. 
1890 NotI-hAP2B rev 
AGGGAAGCGGCCGCCTTTAGTTTT
TCAAAATGCTGTCG 
 
1894 
SbfI-
hAP2Bappendage 
fw 
aaatacctgcaggcGGCATGGCACCTGG
TG 
To be used with 1187 as reverse to amplify 
hAP2B appendage w/o hinge 
1899 
TNRC6A 
NEDiso2-nvCED 
rev 
CCTGGACTGTGGGGCctgcgctaacaat
cgctgtaactg 
To be used with oligo 1209 as forward and p1377 
as template to amplify TNRC6Aiso2 NED (aa1-
1169) with 15 nt overlapping with nvGW182 CED. 
Final aim is to have a human-Nematostella 
GW182 chimera to be used in rescue and pull-
down assays. 
1900 
TNRC6A NED 
iso2-nvCED fw 
cgattgttagcgcagGCCCCACAGTCCAG
GCTG 
To be used with oligo 1736 as reverse and p1468 
and p1498 as templates to amplify nvGW182 
CED (aa1159-1698) wt or 11W11A mut with 15 nt 
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MCh Name Sequence (5’-3’) Purpose 
overlapping with TNRC6A NED. Final aim is to 
have a human-Nematostella GW182 chimera to 
be used in rescue and pull-down assays. 
1907 nv4W4A CED rev GACAGAGGGGGTATCGGGGA 
To be used with oligo 1796 as fw and p1498 as 
template to amplify a first fragment (fragment 1) of 
nvCED containing the first 4 W-motifs mutated. 
See below 
1908 nv4W4A CED fw TCCCCGATACCCCCTCTGTC 
To be used with oligo 1736 as rev and p1429 as 
template to amplify a second fragment of wt 
NvCED. Fragment 1 obtained with 1796&1895 
and fragment 2 (57bp overlap) obtained with 
1896&1736 will be then used as templates with 
oligos 1796&1736 to produce an nvCED with only 
the first 4 W-motifs mutated to test whether it is 
the position or number of mut W-motifs that affect 
repression. The final amplicon will be SbfI-NotI dig 
and cloned into SbfI-NotI digested pCiNeo-NHA 
and pEBG. 
1909 SbfI-nvAGO1 fw 
aaatacctgcaggcATGGCTTCTAATAAT
CCAGTGAAT 
Use to amplify nvAGO1, digest with SbfI and NotI 
and clone into p1238 and p1227 SbfI-NotI 
digested. Co-transfect with nvGW182 constructs 
and test it in pull-down  
1910 NotI-nvAGO1 rev 
AGGGAAGCGGCCGCCTTCAAGCAA
AGTACATTCCCTG 
1911 SbfI-nvAGO2 fw 
aaatacctgcaggcATGCCGAAGAAATC
GAAA 
Use to amplify nvAGO2, digest with SbfI and NotI 
and clone into p1238 and p1227 SbfI-NotI 
digested. Co-transfect with nvGW182 constructs 
and test it in pull-down  
1912 NotI-nvAGO2 rev 
AGGGAAGCGGCCGCCTTTAGGTAA
AGTACATGGATGCTTC 
2024 
SbfI-
CNOT6/CCR4 fw 
aaatacctgcaggcatgcccaaagaaaaatacg 
Primers to amplify CNOT6 and CNOT7 catalytic 
mutants and re-clone them into SbfI-NotI digested 
high copy and high expression vectors: pEBG-flag 
and pEBG-HA  
2026 
SbfI-CNOT7/CAF1 
fw 
aaatacctgcaggcatgccagcggcaactgta 
2027 
NotI-CNOT7/CAF1 
rev 
AGGGAAGCGGCCGCCTtcatgactgctt
gttggcttc 
2059 
NotI-
CNOT6/CCR4 rev 
AGGGAAGCGGCCGCCTCTACCTCC
TGCCAGGAAG 
2166 
SbfI-nvΔCED del 
mut1 fw 
aaatacctgcaggcGAGGATTGGGAGGA
GAACATCG 
Oligos to amplify deletion mutants of Nematostella 
ΔCED.To be used with oligo 1795 as reverse. 
2167 
SbfI-nvΔCED del 
mut2 fw 
aaatacctgcaggcAGTAACAGCAAAAA
CAGCAGTGAGAC 
2168 
SbfI-nvΔCED del 
mut3 fw 
aaatacctgcaggcGGCATGGGTACAGG
CGGAT 
2169 
SbfI-nvΔCED del 
mut4 fw 
aaatacctgcaggcGAGACTAGCGGGAC
TGAGACCA 
2237 
NotI-
NO_nvΔCEDmut1 
rev 
AGGGAAGCGGCCGCtcaGTTCTCAA
GGGAAGAATTGGGCT 
Use with oligo 2166 as fw and p1597 as template 
to amplify a non-overlapping (NO) deletion mutant 
of nvΔCED 
2238 
NotI-
NO_nvΔCEDmut2 
rev 
AGGGAAGCGGCCGCtcaAACCCAAT
TGACTCCCCCA 
Use with oligo 2167 as fw and p1597 as template 
to amplify a non-overlapping (NO) deletion mutant 
of nvΔCED 
2239 
NotI-
NO_nvΔCEDmut3 
AGGGAAGCGGCCGCtcaCACCCAG
GCGGAAGAAGAGTC 
Use with oligo 2168 as fw and p1597 as template 
to amplify a non-overlapping (NO) deletion mutant 
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MCh Name Sequence (5’-3’) Purpose 
rev of nvΔCED 
2240 
NotI-
NO_nvΔCEDmut 
N-term rev 
AGGGAAGCGGCCGCtcaGCTAGTC
CCTTCCCATCCAGA 
Use with oligo 1735 as fw and p1479 as template 
to amplify a non-overlapping (NO) deletion mutant 
of nvΔCED 
 
4.6.3 Oligos for site directed mutagenesis 
MCh Name Sequence (5’-3’) Purpose 
476 W1445A FW atcaaatcgacggcctcctctggccctacctcc 
Primers for site-
directed mutagenesis 
to introduce WA 
mutation in human 
TNRC6C CED 
domain.   
 
477 
W1445A 
REV 
GGCCAGAGGAGGCCGTCGATTTGATGTCTGACAG 
478 W1487A FW TCCACCGCCGGTGCCAGCCCCCTC 
479 
W1487A 
REV 
TGGCACCGGCGGTGGAGGAGGGCTTG 
480 W1494A FW CTCGGCGCCACCAGCTCCTACTCCTCG 
481 
W1494A 
REV 
AGCTGGTGGCGCCGAGGGGGCTG 
482 W1504A FW GTTCTGCCGCCAGCACCGACACCTCAGG 
483 
W1504A 
REV 
TCGGTGCTGGCGGCAGAACCCGAGGAG 
484 W1515A FW CCAGCAGCGCCCTCGTTCTTCGAAACC 
485 
W1515A 
REV 
AGAACGAGGGCGCTGCTGGTTCTTCCTG 
486 W1605A FW TCCAGCGCCCAGTCCAGCAGCGCG 
487 
W1605A 
REV 
TGGACTGGGCGCTGGAAGTGGGTGGC 
488 W1648A FW CTGCTGGCCGGCGGGGTGCCCC 
489 
W1648A 
REV 
CCGCCGGCCAGCAGCTCACTGCTCC 
490 W1659A FW AGCAGCCTGGCCGGCCCGCCCAGCGC 
491 
W1659A 
REV 
CGGGCCGGCCAGGCTGCTGGAGTACTGGG  
884 W1445Y FW atcaaatcgacgTATtcctctggccctacctcc 
Primers for site-
directed mutagenesis, 
to mutate WY in W-
motifs of TNRC6C 
CED 
 
885 
W1445Y 
REV 
GGCCAGAGGAataCGTCGATTTGATGTCTGACAG 
886 W1487Y FW TCCACCtacGGTGCCAGCCCCCTC 
887 
W1487Y 
REV 
TGGCACCgtaGGTGGAGGAGGGCTTG 
888 W1494Y FW CTCGGCtatACCAGCTCCTACTCCTCG 
889 
W1494Y 
REV 
AGCTGGTataGCCGAGGGGGCTG 
890 W1504Y FW GTTCTGCCtacAGCACCGACACCTCAGG 
891 
W1504Y 
REV 
TCGGTGCTgtaGGCAGAACCCGAGGAG 
896 W1659Y FW AGCAGCCTGtatGGCCCGCCCAGCGC 
897 
W1659Y 
REV 
CGGGCCataCAGGCTGCTGGAGTACTGGG 
908 W1648Y FW AGCTGCTGtacGGCGGGGTGCCCCAG 
909 W1648Y CCCCGCCgtaCAGCAGCTCACTGCTCCC 
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MCh Name Sequence (5’-3’) Purpose 
REV 
911 W1605Y FW cccacttccagctatcagtccagcagcgcgtccag 
912 
W1605Y 
REV 
 gctgctggactgatagctggaagtgggtggcagcg   
1196 
W1387,1397
Y FW 
TTCACTCtatGGGACCCCGCATTATTCCACAAGCCTGtacGGTCCCC
CAAGCAG 
Primers for site-
directed mutagenesis 
of W-motifs WY in 
TNRC6A CED. Use 
siRNA-insensitive 
TNRC6A clone as a 
template.  
1197 
W1387,1397
Y REV 
GGGACCgtaCAGGCTTGTGGAATAATGCGGGGTCCCataGAGTGAA
GTGCCGTG 
1198 W1340Y FW TCTCCCGGCtatCAGTCTCTCGGGTCCAGCCAG 
1199 
W1340Y 
REV 
ACCCGAGAGACTGataGCCGGGAGAAGGGGTCAG 
1200 W1239Y FW CAGGTTCCAGCtacGGTGAGAGCAGCTCAGG 
1201 
W1239Y 
REV 
GCTCTCACCgtaGCTGGAACCTGGGGTATATCTG 
1202 
W1226,1215
Y FW 
tctacgTATgataattctccccttcgtataggtggaggaTACggaaattctgacgc 
1203 
W1226,1215
Y REV 
atttccGTAtcctccacctatacgaaggggagaattatcATAcgtagaCAAGGGTG 
1204 W1171Y FW ccaaattgacaTATtctcctggttcagttacaaacacctc 
1205 
W1171Y 
REV 
tgtaactgaaccaggagaATAtgtcaatttggAATCACTA 
1206 W1141Y FW aactagtgccTATtcatccattcgtgcctccaac 
1207 
W1141Y 
REV 
cacgaatggatgaATAggcactagttGAAGGCAG 
1813 W1167 FW GCTGACCCAGgcgAAACAACCACTCCTC 
Primers for site 
directed mutagenesis 
of WA in nvGW182 
CED. Numbers refer 
to the W position 
according to the 
annotation of full-
length nvGW182 
1814 W1167 REV GTTGTTTcgcCTGGGTCAGCCTGGACTG 
1815 W1183 FW CGAAACAgcgGGCATGCCCAAGATTGAG 
1816 W1183 REV GCATGCCcgcTGTTTCGCCATGAGAGGT 
1817 W1227 FW CTCACGGgcgGGCGTTGACGCCTCTCTTAAG 
1818 W1227 REV CAACGCCcgcCCGTGAGCTCACGGGATC 
1819 W1309 FW GCAGTCCCgcgCAGAACACTGAACCCAC 
1820 W1309 REV GTGTTCTGcgcGGGACTGCTGGCTATAG 
1821 W1391 FW CAATTCCgcgAGTACCCAGGACGGGATG 
1822 W1391 REV GTACTcgcGGAATTGCCGCTGGCGGAG 
1823 W1453 FW CTCAAGTgcgTCCACCAACCAGCCAATTC 
1824 W1453 REV GGTGGAcgcACTTGAGATCCCTTCATCC 
1825 W1574 FW CCCGACgcgTCCAACAACCCAATGCCAC 
1826 W1574 REV GTTGGAcgcGTCGGGTGTCTGCTCAAAAAAC 
1827 W1589 FW GCAACCCTgcgTCCTTCGGAACAGTTGATC 
1828 W1589 REV CGAAGGAcgcAGGGTTGCCGAAGCTAG 
1829 W1627 FW GGCATGCAAgcgGGAAGTAGTTCTCAGCTCC 
1830 W1627 REV TACTTCCcgcTTGCATGCCCGGCGGAAC 
1831 W1638 FW CTCAACTCgcgGGCAACTCCCATCCTGG 
1832 W1638 REV GAGTTGCCcgcGAGTTGAGCGGGGAGC 
1833 W1657 FW ATCCATGgcgTCTTTCAGCGGAGGAGCC 
1834 W1657 REV CTGAAAGAcgcCATGGATGGCACCTGAGAC 
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4.6.4 Oligos for qRT-PCR 
MCh Name Sequence (5’-3’) Primer Bank ID/ source Amplicon size 
845 GAPDH fw CTGGGCTACACTGAGCACC 
378404907c3 101 
846 GAPDH rev AAGTGGTCGTTGAGGGCAATG 
1001 RLuc fw ATGGCTTCCAAGGTGTAC 
J. Bethune392  120 
1002 RLuc rev TAGTTGATGAAGGAGTCCA 
1043 FLuc fw GAGCACGGAAAGACGATGACGG 
J. Bethune392  165 
1044 FLuc rev GGCCTTTATGAGGATCTCTCTG 
1238 AP2A1 fw TGAAGCCGTCAAGACGCAC 
19913413c2 109 
1239 AP2A1 rev CCGGTCACACATGGCGTAG 
1240 AP2A2 fw TCTCTAGGCTAAGCAGAATCGT 
338827683c3 77 
1241 AP2A2 rev GGGAGCCGGGACAAAATAGTAA 
1242 AP1B1 fw GACCTCATCTCCGACTCTAACC 
260436859c1 75 
1243 AP1B1 rev GTGAGACTCGGCAATTTCTGA 
1244 AP1G1 fw TGCAATCCGGTCATCTTTTAGAG 
71772941c1 108 
1245 AP1G1 rev AACTGTCCAAAGTGAGCAGGG 
1246 AP2M1 fw ACGTTAAGCGGTCCAACATTT 
68798812c2 109 
1247 AP2M1 rev GCCATCACGTCACACATCTTAT 
1248 CLTC fw ACGGTTGCTCTTGTTACGGAT 
115527063c2 92 
1249 CLTC rev AGGCTAGAATGGCGATCAAAC 
1499 CNOT1 fw ACCCTGAAAAACGGGACATTC 
46275836c3 103 
1500 CNOT1 rev ACTTCTTGCATGAAATCAGCCA 
1501 CNOT7 fw AGGAACTTCAACTTGGCAGTTT 
85067506c2 195 
1502 CNOT7 rev GACAACCATTTGACCCCTTCA 
1529 CNOT9 fw CACTGGCACAAGTGGATAGAG 
4885578c1 99 
1530 CNOT9 rev GCTTCTTACTTAGCTCCAGCAAA 
 
4.7 siRNAs 
All siRNAs listed below are designed against human targets. siMCh7 can also 
function on mouse targets. 
siMCh Name Sequence (sense) Source 
1 AllStar Not provided Negative control from Qiagen 
5 TNRC6C  GCAUUAAGUGCUAAACAAAdTdT Chekulaeva et al. 2011275  
6 TNRC6A  GCCUAAUCUCCGUGCUCAAdTdT Huntzinger et al. 2010360  
7 TNRC6B  GGCCUUGUAUUGCCAGCAAdTdT Huntzinger et al. 2010360 
8 CNOT1  GGAACUUGUUUGAAGAAUAdTdT  
9 AP2A1 and AP2A2  CAACAACGCCATCAAGAATdTdT  
17 CLTC AAUCGCCCAUCUGAAGGUCCUdTdT  
33 CNOT9  GAUCUAUCAGUGGAUC AAUdTdT Ajiro et al. 2009686  
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4.8 Plasmids 
4.8.1 Backbones 
pMCh Vector Purpose Source 
805 pEBG 
High expression of GST-fusions in mammalian 
cells 
Addgene 22227 (Tanaka et al., 1995)687 gift from 
D. Baltimore 
1238 pEB-flag 
High expression of 3xflag-fusions in 
mammalian cells 
M. Chekulaeva 
1239 pEBH  
High expression of HA-fusions in mammalian 
cells 
M. Chekulaeva 
1124 
pCiNeo-
NHA  
Expression of NHA-fusions for tethering R. Pillai309  
1125 pCiNeo-HA  
Expression of HA-fusions for tethering 
(untethered controls) 
R. Pillai309  
1010 pBI-F3 Dox-inducible expression of shRNAs K. Schoenig688  
 
4.8.2 List of plasmids 
Plasmids listed in the table below were cloned by the author: 
pMCh Name Vector Insert Insert 
species 
Cloning strategy Purpose 
1299 pEBG-3xflag-
mAP1G1 
pEBG 
without 
GST-
tag 
3xflag tag-
mAP1G1iso2 
M. 
musculu
s 
Plasmid was generated by 
amplifying AP1G1 ORF with 
MCh 1068&1066 from 
p1243, digesting the insert 
with SbfI-NotI and cloning it 
into NotI-SbfI digested 
p1238  
Vector for high-level 
expression (EF1A 
promotor) of flag-
tagged adaptor 
proteins. Used for 
pulldown/OE 
experiments. 
 
1300 pEBG-3xflag-
hAP1B1 
pEBG 
without 
GST-
tag 
3xflag tag-
hAP1B1iso2 
H. 
sapiens 
Plasmid was generated by 
amplifying AP1B1 ORF with 
MCh 1071&1069 from 
p1244, digesting the insert 
with SbfI-NotI and cloning it 
into NotI-SbfI digested 
p1238 
1302 pEBG-3xflag-
mAP1G1 
appendage 
pEBG 
without 
GST-
tag 
3xflag tag-
mAP1G1iso2-
appendage 
M. 
musculu
s 
Plasmid was generated by 
amplifying AP1G1 
appendage region from 
p1251 with MCh 
1066&1067, digesting the 
insert with SbfI-NotI and 
cloning it into NotI-SbfI 
digested p1238 
1303 pEBG-3xflag-
hAP1B1 
appendage 
pEBG 
without 
GST-
3xflag tag-
hAP1B1iso2-
appendage 
H. 
sapiens 
Plasmid was generated by 
amplifying AP1B1 
appendage region from 
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pMCh Name Vector Insert Insert 
species 
Cloning strategy Purpose 
tag p1252 with MCh 
1072&1069, digesting the 
insert with SbfI-NotI and 
cloning it into NotI-SbfI 
digested p1238 
1304 pEBG-3xflag-
hAP1B1 N-
term+hinge 
region 
pEBG 
without 
GST-
tag 
3xflag tag-
hAP1B1iso2-
hinge region 
H. 
sapiens 
Plasmid was generated by 
amplifying AP1B1 hinge 
region from p1244 with MCh 
1071&1070, digesting the 
insert with SbfI-NotI and 
cloning it into NotI-SbfI 
digested p1238 
1316 pEBG-3xflag-
hAP2A 
appendage 
pEBG 
without 
GST-
tag 
3xflag tag-
hAP2A-
appendage 
H. 
sapiens 
Plasmid was generated by 
amplifying AP2A appendage 
region from HEK293 cDNA 
with 1185&1184, digesting 
the insert with SbfI-NotI and 
cloning it into NotI-SbfI 
digested p1238 
1318 pEBG-3xflag-
hAP2B 
appendage+hin
ge 
pEBG 
without 
GST-
tag 
3xflag tag-
hAP2B-
appendage+hing
e 
H. 
sapiens 
Plasmid was generated by 
amplifying AP2B 
appendage-hinge region 
from HEK293 cDNA with 
1186&1187, digesting the 
insert with SbfI-NotI and 
cloning it into NotI-SbfI 
digested p1238 
1377 pCiNeo-NHA-
TNRC6A 
pCiNeo NHA flTNRC6A 
siRNA 
insensitive 
H. 
sapiens 
flTNRC6A was amplified 
from 2 fragments: an N-
terminal fragment amplified 
using primers mch1209&658 
and pMCh1218 as a 
template. The C-terminal 
fragment was amplified 
using mch659&660 as 
primers and pMCh833 as 
template. A 1:1 mix of the 
resulting PCR fragments 
was used as template with 
primers mch1209&660 to 
amplify the full length 
TNRC6A. The resulting 
fragment was digested with 
Sbfi-NotI and cloned in SbfI-
NotI cut p1124 
Expression 
constructs for NHA 
flTNRC6A wt, 
8W8A mut and 
8W8W+PAM2 mut 
insensitive to siRNA 
targeting TNRC6A 
(siMCh6). Used in 
tethering and 
rescue experiments. 
1378 pCiNeo-NHA-
TNRC6A 8W8A 
pCiNeo NHA-fl TNRC6A 
8W8A, siRNA 
insensitive 
H. 
sapiens 
fl8W8A TNRC6A was 
amplified from 2 fragments: 
an N-terminal fragment 
amplified using primers 
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pMCh Name Vector Insert Insert 
species 
Cloning strategy Purpose 
mch1209&658 and 
pMCh1218 as a template. 
The C-terminal fragment 
was amplified using 
mch659&660 as primers and 
pMCh860 as template. A 1:1 
mix of the resulting PCR 
fragments was used as 
template with primers 
mch1209&660 to amplify the 
full ength TNRC6A. The 
resulting fragment was 
digested with Sbfi-NotI and 
cloned in SbfI-NotI cut 
p1124 
1379 pCiNeo-NHA-
TNRC6A 
8W8A/PAM2 
pCiNeo NHA-fl TNRC6A 
8W8A/PAM2MU
T, siRNA 
insensitive 
H. 
sapiens 
fl8W8A+PAM2 mut TNRC6A 
was amplified from 2 
fragments: an N-terminal 
fragment amplified using 
primers mch1209&658 and 
pMCh1218 as a template. 
The C-terminal fragment 
was amplified using 
mch659&660 as primers and 
pMCh863 as template. A 1:1 
mix of the resulting PCR 
fragments was used as 
template with primers 
mch1209&660 to amplify the 
ful length TNRC6A. The 
resulting fragment was 
digested with Sbfi-NotI and 
cloned in SbfI-NotI cut 
p1124 
1380 pCiNeo-HA-
TNRC6A 
pCiNeo HA-flTNRC6A 
siRNA 
insensitive 
H. 
sapiens 
flTNRC6A was amplified 
from 2 fragments: an N-
terminal fragment amplified 
using primers mch1209&658 
and pMCh1218 as a 
template. The C-terminal 
fragment was amplified 
using mch659&660 as 
primers and pMCh833 as 
template. A 1:1 mix of the 
resulting PCR fragments 
was used as template with 
primers mch1209&660 to 
amplify the full length 
TNRC6A. The resulting 
Expression 
constructs for HA 
flTNRC6A wt, 
8W8A mut and 
8W8W+PAM2 mut 
insensitive to siRNA 
targeting TNRC6A 
(siMCh6). Used in 
tethering as 
negative controls  
and in  rescue 
experiments. 
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pMCh Name Vector Insert Insert 
species 
Cloning strategy Purpose 
fragment was digested with 
Sbfi-NotI and cloned in SbfI-
NotI cut p1125 
1381 pCiNeo-HA-
TNRC6A 8W8A 
pCiNeo HA-fl TNRC6A 
8W8A, siRNA 
insensitive 
H. 
sapiens 
fl8W8A TNRC6A was 
amplified from 2 fragments: 
an N-terminal fragment 
amplified using primers 
mch1209&658 and 
pMCh1218 as a template. 
The C-terminal fragment 
was amplified using 
mch659&660 as primers and 
pMCh860 as template. A 1:1 
mix of the resulting PCR 
fragments was used as 
template with primers 
mch1209&660 to amplify the 
full ength TNRC6A. The 
resulting fragment was 
digested with Sbfi-NotI and 
cloned in SbfI-NotI cut 
p1125 
1382 pCiNeo-HA-
TNRC6A 
8W8A/PAM2 
pCiNeo HA-fl TNRC6A 
8W8A/PAM2MU
T, siRNA 
insensitive 
H. 
sapiens 
fl8W8A+PAM2 mut TNRC6A 
was amplified from 2 
fragments: an N-terminal 
fragment amplified using 
primers mch1209&658 and 
pMCh1218 as a template. 
The C-terminal fragment 
was amplified using 
mch659&660 as primers and 
pMCh863 as template. A 1:1 
mix of the resulting PCR 
fragments was used as 
template with primers 
mch1209&660 to amplify the 
ful length TNRC6A. The 
resulting fragment was 
digested with Sbfi-NotI and 
cloned in SbfI-NotI cut 
p1125 
1383 pCiNeo-NHA-
TNRC6A-
W1387,1397Y 
pCiNeo NHA-fl 
TNRC6A-2W2Y, 
siRNA 
insensitive 
H. 
sapiens 
Plasmid 1377 was used for 
site-directed mutagenesis 
with primers 1196&1197 to 
mutate W1387 and W1397 
to Y 
Expression 
constructs for NHA-
flTNRC6A bearing 
W-->Y mutations 
within W-motifs; the 
construct is 
insensitive to siRNA 
targeting TNRC6A 
1384 pCiNeo-NHA-
TNRC6A-
W1387,1397,13
pCiNeo NHA-fl 
TNRC6A-3W3Y, 
siRNA 
H. 
sapiens 
Plasmid 1383 was used for 
site-directed mutagenesis 
with primers 1198&1199 to 
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40Y insensitive mutate W1340 to Y (siMCh6). Used in 
tethering and 
rescue experiments. 
1385 pCiNeo-NHA-
TNRC6A-
W1387,1397,13
40, 1239Y 
pCiNeo NHA-fl 
TNRC6A-4W4Y, 
siRNA 
insensitive 
H. 
sapiens 
Plasmid 1384 was used for 
site-directed mutagenesis 
with primers 1200&1201 to 
mutate W1239 to Y 
1386 pCiNeo-NHA-
TNRC6A-
W1387,1397,13
40, 
1239,1226,121
5Y 
pCiNeo NHA-fl 
TNRC6A-6W6Y, 
siRNA 
insensitive 
H. 
sapiens 
Plasmid 1385 was used for 
site-directed mutagenesis 
with primers 1202&1203 to 
mutate W1226, 1215 to Y 
1387 pCiNeo-NHA-
TNRC6A-
W1387,1397,13
40,1239,1226,1
215,1171Y 
pCiNeo NHA-fl 
TNRC6A-7W7Y, 
siRNA 
insensitive 
H. 
sapiens 
Plasmid 1386 was used for 
site-directed mutagenesis 
with primers 1204&1205 to 
mutate W1171 to Y 
1388 pCiNeo-NHA-
TNRC6A-
W1387,1397,13
40, 
1239,1226,121
5,1171,1141Y 
pCiNeo NHA-fl 
TNRC6A-8W8Y, 
siRNA 
insensitive 
H. 
sapiens 
Plasmid 1387 was used for 
site-directed mutagenesis 
with primers 1206&1273 to 
mutate W1141 to Y 
1389 pCiNeo-HA-
TNRC6A-
W1387,1397,13
40, 
1239,1226,121
5,1171,1141Y 
pCiNeo HA-fl TNRC6A-
8W8Y, siRNA 
insensitive 
H. 
sapiens 
flTNRC6A-8Y was amplified 
with oligos 1209&660, 
digested with SbfI-NotI and 
inserted into sbfI-notI 
digested p1125 
1391 pCiNeo-NHA-
TNRC6A-
W1387,1397,13
40, 1239, 
1226Y 
pCiNeo NHA-fl 
TNRC6A-5W5Y, 
siRNA 
insensitive 
H. 
sapiens 
Plasmid 1385 was used for 
site-directed mutagenesis 
with primers 1202&1203 to 
mutate W1226, 1215Y, but 
only one mut was effective 
1392 pCiNeo-NHA-
TNRC6A-
W1387,1397,13
40, 1226, 
1215Y 
pCiNeo NHA-fl 
TNRC6A-5W5Y, 
siRNA 
insensitive 
H. 
sapiens 
Plasmid 1384 was used for 
site-directed mutagenesis 
with primers 1202&1203 to 
mutate W1226, 1215 to Y 
1427 pBIF3-CHC 
(siMCh17) 
miRNA-d1GFP 
p1010 tgctgttgacagtgag
cgaAATCGCCC
ATCTGAAGGT
CCTctgtgaagcca
cagatgggAGGA
CCTTCAGATG
GGCGATTctgcc
tactgcctcggacttc
aaggg 
synthetic miRNA sequence was 
generated by oligo 
anneling/ligation: PNK and 
anneal oligos 
mch1648&1651 and 
mch1649&1650, ligate the 
two pairs ON at RT, gel-
purify the shRNA, clone in 
dephosphorylated BsaI-cut 
pMCh1010. 
Plasmid expressing 
CHC-targeting 
siRNA (corresponds 
to siRNA from the 
lab collection 
siMCh17) under 
Tet-inducible 
promoter. Can be 
used to generate 
stable cell lines with 
conditional miRNA-
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mediated KD of 
clathrin heavy chain 
(CHC). 
1468 pCiNeo-HA-
nvGW182 
(Addgene 
82418) 
pCiNeo HA-nvGW182 N. 
vectensi
s 
nvGW182 was amplified 
using primers 
mch1735&1736 and 
pMCh1429 as a template. 
The resulting fragment was 
digested with SbfI-NotI and 
cloned in SbfI-NotI cut and 
dephosphorylated p1125 
(pCiNeo-HA) and p1124 
(pCiNeo-NHA) vectors. 
Expression 
constructs for HA-
nvGW182 and 
NHA-nvGW182. 
Used in tethering 
experiments. 
1469 pCiNeo-NHA-
nvGW182 
(Addgene 
82419) 
pCiNeo NHA-nvGW182 N. 
vectensi
s 
1474 pCiNeo-HA-
nvGW182-
ΔCED 
(Addgene 
82420) 
pCiNeo HA-nvGW182-
Nterminus (aa 1-
1158) 
N. 
vectensi
s 
NED of nvGW182 was 
amplified using primers 
mch1735&1795 and 
pMCh1429 as a template. 
CED using primers 
1736&1796 and p1429 as a 
template. The resulting 
fragments were digested 
with SbfI-NotI and cloned in 
SbfI-NotI cut and 
dephosphorylated p1125 
(pCiNeo-HA) and p1124 
(pCiNeo-NHA) vectors. 
Expression 
constructs for HA 
and NHA tagged N-
terminal and C-
terminal domain of 
nvGW182. Used in 
tethering 
experiments. 
1475 pCiNeo-HA-
nvGW182-CED 
(Addgene 
82421) 
pCiNeo HA-nvGW182-
Cterminus (aa 
1159-1698) 
N. 
vectensi
s 
1476 pCiNeo-NHA-
nvGW182- 
ΔCED 
(Addgene 
82422) 
pCiNeo NHA-nvGW182-
Nterminus (aa 1-
1158) 
N. 
vectensi
s 
1477 pCiNeo-NHA-
nvGW182-CED 
(Addgene 
82423) 
pCiNeo NHA-nvGW182-
Cterminus (aa 
1159-1698) 
N. 
vectensi
s 
1478 pEBG-
nvGW182 
(Addgene 
82424) 
pEBG Full length 
nvGW182 
N. 
vectensi
s 
fl-Nv-GW182 was amplified 
using primers 1735&1736 
and p1429 as a template; 
NED using primers 
mch1735&1795 and 
pMCh1429 as a template; 
CED using primers 
1736&1796 and p1429 as a 
template. The resulting 
fragments were digested 
with SbfI-NotI and cloned in 
SbfI-NotI cut and 
dephosphorylated p805 
(pEBG-GST). 
Plasmid for high-
yield expression of 
the GST-fused full 
length, NED or CED 
of nvGW182 in 
mammalian cells 
(for pull-downs and 
mass-spec) 
1479 pEBG-
nvGW182-
ΔCED 
(Addgene 
82425) 
pEBG nvGW182-
Nterminus  (aa 
1-1158) 
N. 
vectensi
s 
1480 pEBG-
nvGW182-CED 
(Addgene 
82426) 
pEBG nvGW182-
Cterminus (aa 
1159-1698) 
N. 
vectensi
s 
1488 pCiNeo-NHA-
nvGW182 
W1657A 
pCiNeo NHA-nvGW182-
1W1A 
N. 
vectensi
s 
Use oligos 1833&1834 and 
p1469 as template to mutate 
W1657A 
To generate a 
mutant nvGW182 
with 11 W-motifs 
within the CED 1489 pCiNeo-NHA-nv pCiNeo NHA-nvGW182- N. Use oligos 1831&1832 and 
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GW182 W1657, 
1638A 
2W2A vectensi
s 
p1488 as template to mutate 
W1638A 
mutated to Ala 
1490 pCiNeo-NHA-nv 
GW182 W1657, 
1638, 1627A 
pCiNeo NHA-nvGW182-
3W3A 
N. 
vectensi
s 
Use oligos 1829&1830 and 
p1489 as template to mutate 
W1627A 
1491 pCiNeo-NHA-nv 
GW182 W1657, 
1638, 1627, 
1589A 
pCiNeo NHA-nvGW182-
4W4A 
N. 
vectensi
s 
Use oligos 1827&1828 and 
p1490 as template to mutate 
W1589A 
1492 pCiNeo-NHA-nv 
GW182 W1657, 
1638, 1627, 
1589, 1574A 
pCiNeo NHA-nvGW182-
5W5A 
N. 
vectensi
s 
Use oligos 1825&1826 and 
p1491 as template to mutate 
W1574A 
1493 pCiNeo-NHA-nv 
GW182 W1657, 
1638, 1627, 
1589, 1574, 
1453A 
pCiNeo NHA-nvGW182-
6W6A 
N. 
vectensi
s 
Use oligos 1823&1824 and 
p1492 as template to mutate 
W1453A 
1494 pCiNeo-NHA-nv 
GW182 W1657, 
1638, 1627, 
1589, 1574, 
1453, 1391A 
pCiNeo NHA-nvGW182-
7W7A 
N. 
vectensi
s 
Use oligos 1821&1822 and 
p1493 as template to mutate 
W1391A 
1495 pCiNeo-NHA-nv 
GW182 W1657, 
1638, 1627, 
1589, 1574, 
1453, 1391, 
1309A 
pCiNeo NHA-nvGW182-
8W8A 
N. 
vectensi
s 
Use oligos 1819&1820 and 
p1494 as template to mutate 
W1309A 
1496 pCiNeo-NHA-nv 
GW182 W1657, 
1638, 1627, 
1589, 1574, 
1453, 1391, 
1309, 1227A 
pCiNeo NHA-nvGW182-
9W9A 
N. 
vectensi
s 
Use oligos 1817&1818 and 
p1495 as template to mutate 
W1227A 
1497 pCiNeo-NHA-nv 
GW182 W1657, 
1638, 1627, 
1589, 1574, 
1453, 1391, 
1309, 1227, 
1183A 
pCiNeo NHA-nvGW182-
10W10A 
N. 
vectensi
s 
Use oligos 1815&1816 and 
p1496 as template to mutate 
W1183A 
1498 pCiNeo-NHA-nv 
GW182 W1657, 
1638, 1627, 
1589, 1574, 
1453, 1391, 
1309, 1227, 
1183, 1167A 
pCiNeo NHA-nvGW182-
11W11A 
N. 
vectensi
s 
Use oligos 1813&1814 and 
p1497 as template to mutate 
W1167A 
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(Addgene 
82427) 
1510 pCiNeo-NHA-
Δdnaj-
nvGW182 
pCiNeo Δdnaj-nvGW182 N. 
vectensi
s 
Fragments were amplified 
using oligos 1855&1736 and 
1855&1795, SbfI-NotI 
digested and cloned into 
SbfI-NotI-cut p1124 
Constructs to tether 
Δdnaj-nvGW182 
and its NED to 
mRNAs. Used with 
p1468 and p1474, 
respectively as 
negative controls 
1511 pCiNeo-NHA-
Δdnaj-ΔCED 
nvGW182 
pCiNeo Δdnaj-ΔCED 
nvGW182 
N. 
vectensi
s 
1517 pEBG-Δdnaj-
nvGW182 
pEBG Δdnaj-nvGW182 N. 
vectensi
s 
Fragments were amplified 
using oligos 1855&1736 and 
1855&1795, SbfI-NotI 
digested and cloned into 
SbfI-NotI-cut p805 
Constructs 
encoding GST-
fusions of Δdnaj-
GW182 and  Δdnaj-
NED. Used in GST 
pull-down assays 
1518 pEBG- Δdnaj-
ΔCED 
nvGW182 
pEBG Δdnaj-ΔCED 
nvGW182 
N. 
vectensi
s 
1519 pEBG-nv-dnaj pEBG DNAJ domain nv 
GW182 
N. 
vectensi
s 
Fragments were amplified 
using oligos 1735&1861, 
SbfI-NotI digested and 
cloned into SbfI-NotI-cut 
p805 and p1124 
Construct for GST 
pulldowns 
1520 pCiNeo-NHA-
nv-dnaj 
pCiNeo DNAJ domain nv 
GW182 
N. 
vectensi
s 
Construct for 
tethering 
1522 pEBG-nv-
GW182-
CED_11W11A 
(W1657, 1638, 
1627, 1589, 
1574, 1453, 
1391, 1309, 
1227, 1183, 
1167A)  
(Addgene 
82428) 
pEBG nvGW182-
Cterminus (aa 
1159-1698) with 
11 W-motifs 
mutated to A 
N. 
vectensi
s 
Fragments were amplified 
using oligos 1796&1736, 
p1498, p1494, p1490 and 
p1488 were used as 
templates, respectively. 
Amplicons were SbfI-NotI 
digested and cloned into 
SbfI-NotI-cut p1124 
 
Construct for GST 
pulldowns 
1523 pCiNeo-NHA-
nv-GW182-
CED_1W1A 
(W1657A) 
pCiNeo nvGW182-
Cterminus (aa 
1159-1698) with 
1 W-motif 
mutated to A 
N. 
vectensi
s 
Constructs for 
tethering 
1524 pCiNeo-NHA-
nv-GW182-
CED_3W3A 
(W1657, 1638, 
1627A) 
pCiNeo nvGW182-
Cterminus (aa 
1159-1698) with 
3 W-motifs 
mutated to A 
N. 
vectensi
s 
1525 pCiNeo-NHA-
nv-GW182-
CED_7W7A 
(W1657, 1638, 
1627, 1589, 
1574, 1453, 
1391A) 
pCiNeo nvGW182-
Cterminus (aa 
1159-1698) with 
7 W-motifs 
mutated to A 
N. 
vectensi
s 
 125 
pMCh Name Vector Insert Insert 
species 
Cloning strategy Purpose 
1526 pCiNeo-NHA-
nv-GW182-
CED_11W11A 
(W1657, 1638, 
1627, 1589, 
1574, 1453, 
1391, 1309, 
1227, 1183, 
1167A)  
(Addgene 
82429) 
pCiNeo nvGW182-
Cterminus (aa 
1159-1698) with 
11 W-motifs 
mutated to A 
N. 
vectensi
s 
1527 pCiNeo-NHA-
nv-GW182-
CED_8W8A 
W1657, 1638, 
1627, 1589, 
1574, 1453, 
1391, 1309A 
pCiNeo nvGW182-
Cterminus (aa 
1159-1698) with 
8 W-motifs 
mutated to A 
N. 
vectensi
s 
Fragments were amplified 
using oligos 1796&1736, 
p1495, p1496 and p1497 
were used as templates, 
respectively. Amplicons 
were SbfI-NotI digested and 
cloned into SbfI-NotI-cut 
pCiNeo-NHA (p1124) 
 
1528 pCiNeo-NHA-
nv-GW182-
CED_9W9A 
W1657, 1638, 
1627, 1589, 
1574, 1453, 
1391, 1309, 
1227A 
pCiNeo nvGW182-
Cterminus (aa 
1159-1698) with 
9 W-motifs 
mutated to A 
N. 
vectensi
s 
1529 pCiNeo-NHA-
nv-GW182-
CED_10W10A 
W1657, 1638, 
1627, 1589, 
1574, 1453, 
1391, 1309, 
1227, 1183A 
pCiNeo nvGW182-
Cterminus (aa 
1159-1698) with 
10 W-motifs 
mutated to A 
N. 
vectensi
s 
1533 pEBG-3xflag-
hAP2B full 
length 
pEBG 
without 
GST-
tag 
3xflag tag-
hAP2B 
H. 
sapiens 
Plasmid was generated by 
amplifying AP2B from 
HEK293 cDNA with 
1889&1890, digesting it with 
SbfI-NotI and cloning it into 
p1238 NotI-SbfI digested  
Vector for high level 
expression (EF1A 
promotor) of flag-
taged proteins, 
used for 
pulldown/OE 
experiments. AP2B 
can be cut out with 
Sbfi-NotI. 
1534 pEBG-3xflag-
hAP2B 
appendage 
pEBG 
without 
GST-
tag 
3xflag tag-
hAP2B-
appendage 
H. 
sapiens 
Plasmid was generated by 
amplifying AP2B appendage 
region from plasmid p1318 
with oligos 1894&1187, 
digesting it with SbfI-NotI 
and cloning it into p1238 
Vector for high level 
expression (EF1A 
promotor) of flag-
taged proteins, 
used for 
pulldown/OE 
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NotI-SbfI digested  experiments. AP2B 
appendage can be 
cut out with Sbfi-
NotI. 
1535 pCiNeo-NHA-
nv-GW182-
CED_1st4W4A 
(W 1309, 1227, 
1183, 1167A) 
pCiNeo Nv GW182-
Cterminus (aa 
1159-1698) with 
the most N-
terminal 4 W-
motifs mutated 
to A 
N. 
vectensi
s 
Plasmid was generated by 
amplifying an N-terminus 
fragment of Nv CED with 
4W4A with oligos 
1796&1907 using p1498 as 
template and a C-terinal 
fragment with oligos 
1908&1736 and p1468 as 
template. The two 
overlapping fragments were 
amplified using oligos 
1796&1736. Final amplicon 
was SbfI-NotI digested and 
cloned into p1124 NotI-SbfI 
digested. 
Plasmid used in 
tethering assays to 
test whether these 4 
W-motifs are crucial 
for silencing 
1536 pEBG-nv-
GW182-
CED_1st4W4A 
(W 1309, 1227, 
1183, 1167A) 
pEBG Nv GW182-
Cterminus (aa 
1159-1698) with 
the most N-
terminal 4 W-
motifs mutated 
to A 
N. 
vectensi
s 
Plasmid was generated by 
amplifying an N-terminus 
fragment of Nv CED with 
4W4A with oligos 
1796&1907 using p1498 as 
template and a C-terinal 
fragment with oligos 
1908&1736 and p1468 as 
template. The two 
overlapping fragments were 
amplified using oligos 
1796&1736. Final amplicon 
was SbfI-NotI digested and 
cloned into p805 NotI-SbfI 
digested. 
Plasmid used in 
GST pull-down 
assays to test 
whether these 4 W-
motifs are crucial for 
CCR4-NOT binding 
1537 pCiNeo-NHA-
hybrid GW182 
(siR insensitive) 
(Addgene 
82430) 
pCiNeo Chimera GW182 
with N-terminus 
from human 
TNRC6A iso2 
and C-terminus 
of Nematostella 
GW182 
Homo 
sapiens
+ N. 
vectensi
s 
Plasmid was generated by 
amplifying an N-terminus 
fragment of hTNRC6A with 
oligos 1209&1899 using 
p1377 as template and a C-
terminal fragment of 
NvGW182 with oligos 
1900&1736 and p1468 (wt) 
or p1498 (mut) as template. 
The two overlapping 
fragments were amplified 
using oligos 1209&1736. 
Final amplicon was SbfI-NotI 
digested and cloned into 
p1124 NotI-SbfI digested. 
HA- and NHA- 
fusions used in 
rescue assays 
1538 pCiNeo-NHA-
hybrid GW182 
mut (siR 
insensitive) 
(Addgene 
82431) 
pCiNeo Chimera GW182 
with N-terminus 
from human 
TNRC6A iso2 
and mutant C-
terminus of 
Nematostella 
GW182 
Homo 
sapiens
+ N. 
vectensi
s 
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(11W11A) 
1539 pEBG-hybrid 
GW182 (siR 
insensitive) 
(Addgene 
82432) 
pEBG Chimera GW182 
with N-terminus 
from human 
TNRC6A iso2 
and C-terminus 
of Nematostella 
GW182 
Homo 
sapiens
+ N. 
vectensi
s 
Plasmid was generated by 
amplifying an N-terminus 
fragment of hTNRC6A with 
oligos 1209&1899 using 
p1377 as template and a C-
terminal fragment of 
NvGW182 with oligos 
1900&1736 and p1468 (wt) 
or p1498 (mut) as template. 
The two overlapping 
fragments were amplified 
using oligos 1209&1736. 
Final amplicon was SbfI-NotI 
digested and cloned into 
p805 NotI-SbfI digested. 
GST-fusions used 
in GST pull-down 
assays to test for 
AGO and CCR4-
NOT binding 
1540 pEBG-hybrid 
GW182 mut 
(siR insensitive) 
(Addgene 
82433) 
pEBG Chimera GW182 
with N-terminus 
from human 
TNRC6A iso2 
and mutant C-
terminus of 
Nematostella 
GW182 
(11W11A) 
Homo 
sapiens
+ N. 
vectensi
s 
1545 pEBG-3xflag-
nvAGO1 
pEBG 
without 
GST-
tag 
Nematostella 
Ago1 
N. 
vectensi
s 
Ago1 and Ago2 were 
amplified with oligos 
1909&1910 and p1541 and 
1542 as templates, 
respectively; digested with 
SbfI-NotI and cloned into 
SbfI-NotI digested p1238 
and p1239 
Plamsids co-
transfected with 
GST-nvGW182 and 
its domains to test 
interaction between 
nvGW182 and 
nvAgo1 and 2 in 
GST pull-down 
assays 
1546 pEBG-3xflag-
nvAGO2 
pEBG 
without 
GST-
tag 
Nematostella 
Ago2 
N. 
vectensi
s 
1547 pEBG-HA-
nvAGO1 
(Addgene 
82434) 
pEBG 
without 
GST-
tag 
Nematostella 
Ago1 
N. 
vectensi
s 
1548 pEBG-HA-
nvAGO2 
(Addgene 
82435) 
pEBG 
without 
GST-
tag 
Nematostella 
Ago2 
N. 
vectensi
s 
1552 pEBG-nv-
GW182-
CED_4W4A 
(W1657, 1638, 
1627, 1589A) 
pEBG nvGW182 CED 
(aa 1159-1698) 
with the last 4 
W-motifs 
mutated to A 
N. 
vectensi
s 
CED was amplified using 
oligos 1796&1736 and 
p1491 as templates. 
Amplicons were SbfI-NotI 
digested and cloned into 
SbfI-NotI-cut p805  
GST-fusion used in 
pull-down assays 
together with 1st 
4W4A mut o test 
whether the position 
of W-motifs is 
relevant for 
silencing and 
CNOT/AGO binding 
1553 pCiNeo-NHA-
nv-GW182-
CED_4W4A 
(W1657, 1638, 
1627, 1589A) 
pCiNeo nvGW182 CED 
(aa 1159-1698) 
with the last 4 
W-motifs 
mutated to A 
N. 
vectensi
s 
CED was amplified using 
oligos 1796&1736 and 
p1491 as templates. 
Amplicons were SbfI-NotI 
digested and cloned into 
SbfI-NotI-cut p1124  
NHA-fusion used in 
tethering assays 
together with 1st 
4W4A mut to test 
whether the position 
of mutated W-motifs 
is relevant for 
 128 
pMCh Name Vector Insert Insert 
species 
Cloning strategy Purpose 
silencing 
1554 pEBG-
nvGW182 
W1657, 1638, 
1627, 1589, 
1574, 1453, 
1391, 1309, 
1227, 1183, 
1167A 
pEBG nvGW182 
11W11A mut 
N. 
vectensi
s 
nvGW182 was amplified 
using oligos 1735&1736 and 
p1498 as templates. 
Amplicons were SbfI-NotI 
digested and cloned into 
SbfI-NotI-cut p805  
GST-fusion used in 
pull-down assays to 
test for CNOT/AGO 
binding 
1555 pEBG-TNRC6A 
siR resi 
pEBG TNRC6A H. 
sapiens 
TNRC6A was amplified 
using oligos 1209&660 and 
p1377 as templates. 
Amplicons were SbfI-NotI 
digested and cloned into 
SbfI-NotI-cut p805  
Used in pull-down 
assays as positive 
control for 
CNOT/AGO binding 
1556 pEBG-TNRC6A 
8W8A mut siR 
resi 
pEBG TNRC6A 8W8A 
mut 
H. 
sapiens 
TNRC6A 8W8A mut was 
amplified using oligos 
1209&660 and p1378 as 
templates. Amplicons were 
SbfI-NotI digested and 
cloned into SbfI-NotI-cut 
p805  
Used in pull-down 
assays as positive 
control for  AGO 
binding and 
negative control on 
CNOT binding 
1570 pEBG-3xflag-
Caf1 mut 
pEBG 
without 
GST-
tag 
CNOT7/CAF1 
D40A  
(Zheng 
et al., 
2008), 
Ann-Bin 
Shyu;  
Oligos 2026&2027 and 
2024&2059 were used to 
amplify CNOT7 and CNOT6 
cat mut from vectors 1530 
and 1531, respectively. 
Amplicons were SbfI-NotI 
digested and cloned into 
SbfI-NotI digested pEBG-
3xflag (p1545) 
High expression 
vectors for CCR4-
NOT catalytic 
mutants. Used in 
tethering 
experiment to test if 
silencing is truly 
mediated by the 
deadenylase activity 
of the CCR4-NOT 
complex 
1571 pEBG-3xflag-
Ccr4a mut 
pEBG 
without 
GST-
tag 
Ccr4a/CNOT6 
E240A 
(Chang 
et al., 
2004) -
Ann-Bin 
Shyu;  
1591 pCiNeo-NHA-
nv-GW182-
CED_1st1W1A 
(W1167A) 
pCiNeo Nv GW182-
Cterminus (aa 
1159-1698) with 
the most N-
terminal 1 W-
motifs mutated 
to A 
N. 
vectensi
s 
Plasmid was generated by 
site-directed mutagenesis of 
p1477 with oligos 
1813&1814. 
Used in tethering 
assays to 
discriminate 
whether is the 
number or the 
position (or both) of 
mutated W-motifs 
that mostly affects 
silencing 
1592 pCiNeo-NHA-
nv-GW182-
CED_1st2W2A 
(W1167, 
1183A) 
pCiNeo Nv GW182-
Cterminus (aa 
1159-1698) with 
the most N-
terminal24 W-
motifs mutated 
to A 
N. 
vectensi
s 
Plasmid was generated by 
site-directed mutagenesis of 
p1591 with oligos 
1815&1816. 
1593 pCiNeo-NHA-
nv-GW182-
pCiNeo Nv GW182-
Cterminus (aa 
N. 
vectensi
Plasmid was generated by 
site-directed mutagenesis of 
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pMCh Name Vector Insert Insert 
species 
Cloning strategy Purpose 
CED_1st3W3A 
(W1167, 1183, 
1227A) 
1159-1698) with 
the most N-
terminal 3 W-
motifs mutated 
to A 
s p1592 with oligos 
1817&1818. 
1594 pCiNeo-NHA-
nv-GW182-
CED_last2W2A 
(W1657, 
1638A) 
pCiNeo Nv GW182-
Cterminus (aa 
1159-1698) with 
the most C-
terminal 2 W-
motifs mutated 
to A 
N. 
vectensi
s 
Plasmid was generated by 
site-directed mutagenesis of 
p1523 with oligos 
1831&1832. 
1597 pEBG-nvΔCED 
mut 1 (aa 441-
1158) 
pEBG  nvNED N. 
vectensi
s 
Plasmids were generated by 
amplifying nvNED deletion 
mutants with 2166&1795,  
2167&1795,  2168&1795,  
2169&1795, respectively. 
Amplicons were then 
digested with SbfI-NotI and 
cloned into NotI-SbfI 
digested p805.  
Vectors for high 
level expression 
(EF1A promotor) of 
GST-tagged nvNED 
deletion mutants, 
used for 
pulldown/OE 
experiments to 
understand which 
GW-motifs are 
necessary for 
Nematostella Ago-
binding 
1598 pEBG-nvΔCED 
mut 2 (aa 497-
1158) 
pEBG  nvNED N. 
vectensi
s 
1599 pEBG-nvΔCED 
mut 3 (aa 565-
1158) 
pEBG  nvNED N. 
vectensi
s 
1600 pEBG-nvΔCED 
mut 4 (aa 643-
1158) 
pEBG  nvNED N. 
vectensi
s 
1607 pCiNeo-NHA-
nvAGO1 
pCiNeo Nematostella 
Ago1 
N. 
vectensi
s 
Ago1 and Ago2 were 
amplified with oligos 
1909&1910 and p1541 and 
1542 as templates, 
respectively; digested with 
SbfI-NotI and cloned into 
SbfI-NotI digested p1124 
(pCiNeo-NHA) and p1125 
(pCiNeo-HA) 
Constructs for 
tethering 1608 pCiNeo-NHA-
nvAGO2 
pCiNeo Nematostella 
Ago2 
N. 
vectensi
s 
1609 pCiNeo-HA-
nvAGO1 
pCiNeo Nematostella 
Ago1 
N. 
vectensi
s 
Negative controls 
for tethering. Used 
with the 
corresponding 
tethered nvAGOs 
encoded by p1607 
and p1608 
1610 pCiNeo-HA-
nvAGO2 
pCiNeo Nematostella 
Ago2 
N. 
vectensi
s 
1612 pCiNeo-HA-
hAgo2 
pCiNeo human Ago2 H. 
sapiens 
hAgo2 was amplified from 
p1189 with oligos 995&996; 
digested with SbfI-NotI and 
cloned into SbfI-NotI 
digested and 
dephosphorylated p1125 
Negative control for 
tethering. To be 
used with the 
corresponding 
tethered hAgo2 
encoded by p1192 
1620 pEBG-
NOnvΔCED 
mut 1 (aa 1-
440) 
pEBG  nvNED non 
overlapping del 
mut 
N. 
vectensi
s 
Non-overlapping fragments 
of nvNED were amplified 
with the following oligos and 
templates: mut1 1735&2240, 
mut2 2166&2237; mut3 
Vectors for high 
level expression of 
GST-tagged non-
overlapping nvNED 
deletion mutants. 1621 pEBG- pEBG  nvNED non N. 
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pMCh Name Vector Insert Insert 
species 
Cloning strategy Purpose 
NOnvΔCED 
mut 2 (aa 441-
496) 
overlapping del 
mut 
vectensi
s 
2167&2238; mut4 
2168&2239. p1429 was 
used as template. Amplicons 
were then digested with 
SbfI-NotI and cloned into 
NotI-SbfI digested p805. 
Used for 
pulldown/OE 
experiments to 
understand which 
GW-motifs are 
necessary for 
Nematostella Ago-
binding 
1622 pEBG-
NOnvΔCED 
mut 3 (aa 497-
564) 
pEBG  nvNED non 
overlapping del 
mut 
N. 
vectensi
s 
1623 pEBG-
NOnvΔCED 
mut 4 (aa 565-
642) 
pEBG  nvNED non 
overlapping del 
mut 
N. 
vectensi
s 
 
Colleagues or collaborators cloned plasmids listed below; the source is cited: 
pMCh Name Vector Insert Insert 
species 
Purpose Source 
124 pCiNeo-
NHA-
TNRC6C 
pCiNeo NHA-TNRC6C H. sapiens Tethering construct for 
expression of NHA-TNRC6C in 
mammalian cell 
J. Zipprich 
133 pCiNeo-
NHA-
TNRC6C 
CED 
pCiNeo NHA-TNRC6C-CED H. sapiens Tethering construct for 
expression of NHA-TNRC6C-
CED in mammalian cells 
J. Zipprich 
436 pCiNeo-
HA-
TNRC6B 
pCiNeo HA-TNRC6B H. sapiens Untethered control for TNRC6 
tethering experiments 
J. Zipprich 
437 pCiNeo-
HA-
TNRC6C 
pCiNeo HA-TNRC6C H. sapiens Untethered control for TNRC6 
tethering experiments 
J. Zipprich 
466 pEBG-CED pEBG TNRC6C CED H. sapiens High level expression of GST-
fused TNRC6C CED in 
mammalian cells (for pull-downs 
and mass-spec) 
H. Mathys 
607 pCiNeo-
NHA-CED 
7W7A 
pCiNeo TNRC6C-CED-
W1445,1487,1494,1
504,1605,1648,1659
A 
H. sapiens Tethering construct for CED 
with mutated W-motifs 
M. 
Chekulaeva 
633 pEBG-CED 
7W7A  
pEBG TNRC6C-CED-
W1445,1487,1494,1
504,1605,1648,1659
A 
H. sapiens High level expression of the 
GST-fused CED 7W7A in 
mammalian cells (for pull-downs 
and mass-spec) 
M. 
Chekulaeva 
729 pCiNeo-HA pCiNeo HA  Construct serving as negative 
control in tethering assay, can 
be used as filler DNA 
J. Zipprich 
730 pCiNeo-
NHA 
pCiNeo NHA Lambda 
phage 
Construct serving as negative 
control in tethering assay, can 
be used as filler DNA 
J. Zipprich 
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pMCh Name Vector Insert Insert 
species 
Purpose Source 
731 pCiNeo-
NHA-lacZ 
pCiNeo NHA-LacZ Lambda 
phage, E. 
coli 
Construct serving as negative 
control in tethering assay, can 
be used as filler DNA 
J. Zipprich 
1016 pCiNeo-
HA-CED 
pCiNeo HA-TNRC6C CED H. sapiens Untethered control for CED 
tethering experiments 
J. Zipprich 
1019 pCiNeo-
NHA-
TNRC6B 
pCiNeo NHA-TNRC6B H. sapiens Tethering construct for 
expression of NHA-TNRC6B in 
mammalian cell 
J. Zipprich 
1049 pEGFP-N1  enhanced GFP A. victoria Transfection control; can be 
used as filler DNA 
J. 
Schmoranze
r 
1070 pCiNeo-
NHA-CED 
7W7Y 
pCiNeo TNRC6C-CED-
W1445,1487,1494,1
504,1605,1648,1659
Y 
H. sapiens Tethering construct for CED 
with mutated W-motifs 
M. 
Chekulaeva 
1075 pEBG-CED 
7W7Y 
pEBG TNRC6C-CED-
W1445,1487,1494,1
504,1605,1648,1659
Y 
H. sapiens High level expression construct 
of GST-fused 7W7Y CED (for 
pull-downs and MS) 
M. 
Chekulaeva 
1192 pCiNeo-
NHA-
hsAGO2 
pCiNeo NHA-hsAGO2 H. sapiens Human AGO2 tethering 
construct 
M. 
Chekulaeva/ 
S.J 
Hermann 
1218 pCiNeo-
NHA-
TNRC6A-
siRNAresi 
pCiNeo TNRC6A iso2 
siRNA resistant 
H. sapiens To be used in rescue assays E. 
Izaurralde 
1238 pEBG-
3xflag-sic 
pEBG 
without 
GST-tag 
3xflag tag sic  High level expression of flag-
tagged sic peptide, to be used 
as filler DNA for pulldowns. 
M. 
Chekulaeva 
1243 GFP-
AP1Gamm
a 
pEGFP-
N1 
(Clontech
) 
GFP-AP 1 Gamma 
subunit 
M. 
musculus 
Expression of GFP tagged (C-
terminal) Adaptor Protein 
complex 1 gamma subunit 
(isoform 2) 
J. 
Bonifacino 
1244 GFP-
AP1Beta 
pEGFP-
N1 
(Clontech
) 
GFP-AP 1 Beta 
subunit 
H. sapiens Expression of GFP tagged (C-
terminal) Adaptor Protein 
complex 1 beta subunit (isoform 
2) 
J. 
Bonifacino 
1305 pEBG-
TNRC6CΔ
CED 
pEBG TNRC6CΔCED H. sapiens High level expression of GST-
fused TNRC6C delta CED (for 
pull-downs and MS) 
C.C. Mattioli 
1492 
nvGW182 pMA-RQ  
Humanized 
nvGW182 
N. 
vectensis 
 Y. Moran 
lab 
1530 pSR-HA-
Caf1 mut 
(CNOT7) pSRD5 CAF1 D40A  
H. sapiens  A. B. Shyu 
1531 pSR-HA-
Ccr4a mut pSRD5 E240A 
H. sapiens  A. B. Shyu 
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pMCh Name Vector Insert Insert 
species 
Purpose Source 
(CNOT6) 
1541 
nvAGO1 
pGEM-T 
easy 
Nematostella Ago1 
(cDNA) 
N. 
vectensis 
 Y. Moran 
lab 
1542 
nvAGO2 
pGEM-T 
easy 
Nematostella Ago2 
(cDNA) 
N. 
vectensis 
 Y. Moran 
lab 
 
Luciferase reporter plasmids are listed below: 
pMCh Name Description Source 
673 pRLuc-3Xb 
RLuc miRNA repoter with 3 artificial let-7 sites in 3'-UTR, for 
expression in mammalian cells 
R. Pillai412  
674 pRLuc-3Xb mut Negative control for p673 (with let-7 sites mutated) R. Pillai412 
755 
pSF3-
FLuc/RLuc-
hmga2-wt 
Dox-inducible miRNA RLuc reporter with hmga2 3'-UTR targeted 
by let-7 (FL serves as negative control) for expression in 
mammalian cells 
J. Bethune392  
756 
pSF3-
FLuc/RLuc-
hmga2-mut 
Dox-inducible negative control for p755 (with let-7 sites mutated) J. Bethune392  
1028 pRLuc-5boxB Tethering RLuc reporter for expression in mammalian cells R. Pillai309 
678 pFLuc Fluc transfection control for expression in mammalian cells R. Pillai309  
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4.9 Antibodies 
Name Host 
Raised 
against 
Working dilution 
Catalogue 
number 
Source 
anti-AGO2 
(11A9) 
rat human 
IP 1:130; IF 1:500; WB 
1:4000 
11A9 
Ascenion GmbH, Helmholtz 
Zentrum München, Elisabeth 
Kremmer 
anti-AGO2 
(M01) 
mouse human WB 1:2000 
H00027161-
M01 
Abnova 
anti-AP2α mouse mouse WB 1:2000 610502 
BD Transduction Laboratories 
(gift from M. Krauss, FMP) 
anti-AP2µ mouse human WB 1:500  
BD Transduction Laboratories 
(gift from M. Krauss, FMP) 
anti-CLTC mouse rat, human WB 1:5000; IF 1:250 610499 BD Biosciences 
anti-CNOT1 rabbit 
human, 
mouse, rat 
WB 1:500; IHC 1:25-
1:100 
14276-1-AP Proteintech 
anti-CNOT7 
(M01A) 
mouse human WB 1:2000 
H00029883-
M01A 
Abnova 
anti-CNOT9 
(RQCD1) 
rabbit human 
WB 1:5000; IHC 1:20-
1:200; IF 1:20-1:200 
22503-1-AP Proteintech 
anti-FLAG M2, 
Clone M2 
mouse  
WB 1:5000-1:10.000; 
IF 1:250 
F3165 Sigma-Aldrich 
anti-GAPDH 
(6C5) 
mouse rabbit 
WB 1:1000; IP: 1-2ug 
per 100-500ug of tot 
protein; IF 1:50-1:500 
sc-32233 Santa Cruz Biotechnology 
anti-GFP mouse  WB 1:1000; IP 1:150 11814460001 Roche 
anti-GST-HRP 
conjugate 
rabbit  WB 1:5000-1:10000  Abcam 
anti-GW182 
(TNRC6A) A329 
rabbit human WB 1:5000 A302-329A Bethyl Laboratories/biomol 
anti-GW182 
(TNRC6A) A330 
rabbit human IP 1:200 A302-330A Bethyl Laboratories/biomol 
anti-HA high 
affinity (3F10) 
rat  
WB 1:5000; IP 1:200-
1:400; ELISA 1:50-
1:200 
11867431001 Roche 
anti-αTubulin mouse 
sea urchin, 
reacts with 
human, fly 
WB 1:4000; IF 1:2000 T5168 Sigma-Aldrich 
Anti-mouse 
IgG(L)-HRP 
conjugate 
rat mouse WB 1:5000-1:100000 ab99632 Abcam 
Anti-rat-HRP 
conjugate 
goat rat WB 1:5000-1:200000 31470 Thermo Fisher 
Anti-rabbit-HRP 
conjugate 
mouse rabbit WB 1:5000-1:100000 ab99697 Abcam 
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4.10 Polyacrylamide gel compositions 
Sodium dodecyl sulfate polyacrylamide gels (SDS-PAG) consist of an upper layer 
of stacking gel and a lower layer of separating gel. Stacking gel contains a low 
percentage of acrylamide:methylenebisacrylamide (AA:MBA) and buffer conditions 
that allow proteins to migrate fast and concentrate into a narrow band before 
entering the separating gel where proteins are resolved according to their 
molecular weight. Separating gels can have different percentages of AA:MBA, 
depending on the size range of proteins to be analyzed. To solve big proteins 
(150-250 kDa) low percentages of AA:MBA are preferred, while for small proteins 
(10-30 kDa) high percentages are better. To solve a wide range of protein sizes a 
10% separating gel is recommended (20-200 kDa). 
5% stacking gel: 
Reagents Volumes 
H2O 2.2 ml 
Acrylamide:Bis 30% 37.5:1 0.5 ml 
1.5 M Tris pH 6.8 0.25 ml  
20% SDS 0.015 ml 
10% APS 0.03 ml 
TEMED 0.003 ml 
Final volume 3 ml 
Separating gels: 
Reagents 7.5% 10% 12.5% 15% 
H2O 2.9 ml 2.4 ml 1.9 ml 1.4 ml 
Acrylamide:Bis 30% 37.5:1 1.5 ml 2 ml 2.5 ml 3 ml 
1.5 M Tris pH 8.8 1.5 ml  1.5 ml  1.5 ml  1.5 ml  
20% SDS 0.03 ml 0.03 ml 0.03 ml 0.03 ml 
10% APS 0.06 ml 0.06 ml 0.06 ml 0.06 ml 
TEMED 0.005 ml 0.005 ml 0.005 ml 0.005 ml 
Final volume 6 ml 6 ml 6 ml 6 ml 
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4.11 Softwares 
Software name Provider Use 
Serial Cloner v2.6.1 Serialbasics.free.fr Molecular cloning  
Serial List v2.3 Serialbasics.free.fr List comparison 
SnapGene Viewer v3.1 GSL Biotech Chromatogram visualization 
Imagequant LAS 4000 GE Healthcare (Chicago, IL, USA)  WB 
ImageJ Imagej.nih.gov/ij Image processing 
AlphaView Proteinsimple (San Jose, CA, USA) DNA gel imaging 
Perseus Perseus-framework.org Proteomic data analysis 
MikroWin MikroTek, Germany Multiplate reader (luciferase assays) 
Adobe Photoshop CS6 Adobe Systems (San Jose, CA, USA) Photo editing 
Adobe Illustrator CS6 Adobe Systems (San Jose, CA, USA) Vector graphics editing (figure assembly) 
Prism v7 GraphPad Software Inc. (La Jolla, CA, USA) Graphing, statistics, data organization 
Edu PyMOL v1.7.4 Pymol.org Structure visualization 
DinoXcope v1.9.7 Dino-Lite Europe (The Netherlands) Inverted light microscope image 
acquisition 
Papers Papersapp.com Managing bibliographies  
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5. Methods 
5.1 Cell Culture 
Human embryonic kidney fibroblasts (HEK293) and Henrietta Lacks cervical 
cancer (HeLa) cells were grown in Dulbecco’s modified Eagle’s medium 
supplemented High glucose (4.5 g/L) with GlutaMAX™ (DMEM+GlutaMAX, 
GIBCO) and 10% (v/v) FBS (GIBCO), named complete medium. Cells were grown 
at 37°C in 5% CO2. Culture medium was replaced every 2-3 days depending on 
the growth rate of cells. To split cells the medium was removed, cells were washed 
once with 5 ml D-PBS without Ca2+ and Mg2+ (PAN Biotech) and detached by 
treatment with 1 ml Trypsin-EDTA (0.25%-0.02%; PAN Biotech) at 37°C for 2 to 5 
minutes. To inhibit trypsin cells were resuspended in fresh medium and split (1:2-
1:20) in a final volume of 9 ml per 10 cm dish.  For other formats, amounts were 
adjusted proportionally. Alternatively, after incubation with trypsin-EDTA cells were 
resuspended in fresh medium, transferred in a 15 ml falcon and centrifuged at 350 
g for 3 minutes. The supernatant was discarded and cells were resuspended in the 
desired volume of complete medium and distributed to new cell culture flasks or 
dishes.  Cells were cultured for a maximum of 30 passages and then discarded. In 
order to freeze cells for long term storage low passage cells were re-suspended in 
freezing medium (90% FBS or 90% complete DMEM, and 10% DMSO) after 
centrifugation; 1 ml of cell suspension was placed in cryovials; cryovials were 
stored overnight in a Nalgene freezing container filled with isopropanol at -80°C 
and transferred in liquid N2 the following day. Cells were routinely checked for 
mycoplasma contamination.  
For stable isotope labeling using amino acids in cell culture (SILAC) 
HEK293 cells were grown for at least five passages in SILAC media: Dulbecco’s 
modified eagle medium (DMEM) High glucose (4.5 g/L) depleted of L-arginine, L-
lysine and L-glutamine (PAA, custom preparation) supplemented with 10% (v/v) 
sterile-filtered dialyzed fetal bovine serum (dFBS, Sigma-Aldrich), 4mM stable 
glutamine (L-alanyl-L-glutamine, PAA), 100 U/ml penicillin-streptomycin 
(Invitrogen), and with 28 mg/L L-arginine and 48 mg/L L-lysine, either as the light 
version (L-arginine monohydrochloride, “Arg0” and L-lysine monohydrochloride, 
“Lys0” Sigma-Aldrich), the medium heavy version (13C6 14N4-L-arginine 
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monohydrochloride, “Arg6”; 4,4,5,5-D4-L-lysine monohydrochloride, “Lys4”; Sigma-
Aldrich) or the heavy version  (13C6 15N4-L-arginine monohydrochloride, “Arg10”; 
13C6 15N2-L-lysine monohydrochloride, “Lys8”; Sigma-Aldrich).  
5.2 DNA work 
5.2.1 DNA Extraction with Phenol-Chloroform 
DNA was extracted from clarified cell lysates by adding an equal volume of 
phenol:chloroform:isoamyl alcohol (25:24:1) equilibrated with Tris:HCl pH 8.0 to 
the DNA containing solution (1:1 ratio). Samples were centrifuged at 15000 g for 
15 min at 4°C. The aqueous phase (upper phase) was then transferred into a new 
tube and an equal volume of chloroform was added to the solution (1:1 ratio). 
Samples were vortexed and centrifuged at 15000 g for 15 min at 4°C. The upper 
layer was transferred in a new eppendorf and the DNA was precipitated by adding 
0.1 volumes of 3 M NaOAc pH 5.2 and 2.5 volumes of 100% ethanol. Samples 
were incubated at -80°C for 1 h to ON (overnight) and centrifuged at 15000 g for 1 
h at 4°C. Supernatants were discarded, 800 µl of 70% ethanol was added and 
samples were centrifuged at 15000 g for 15 min at 4°C. Pellets were air-dried and 
resuspended in sterile water. 
5.2.2 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to visualize and separate nucleic acids 
according to their size. Electrophoresis was carried out using a horizontal gel 
electrophoresis apparatus (Carl Roth) connected to a power supply (Biorad, 
Powerpac Basic). Tris-Borate-EDTA (TBE) buffer (90 mM Tris-Borate, 2mM 
EDTA) was used as a running buffer. In order to prepare 0.5-2% (w/v) agarose 
gels, the desired amount of agarose powder (Applichem) was mixed with TBE 
buffer and dissolved using a microwave. Upon cooling of the solution to ~60°C 0.5 
µg/ml of ethidium bromide (Carl Roth) was added and mixed well. The agarose 
solution was then transferred to a horizontal gel tray or alternatively stored at 60°C 
up to two weeks. Wells in the gel were formed with combs of the appropriate size. 
After jellification occurred, combs were removed and DNA or RNA samples were 
loaded. As a DNA size marker 6 µl of GeneRuler 1kb DNA ladder (ThermoFisher) 
were used. Samples (200 ng-5 µg) were resuspended in 10x DNA loading dye 
(ThermoFisher) and loaded. The electrophoretic run was carried out at 60-120 V. 
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DNA bands were visualized under ultraviolet (UV) light with an AlphaImager HP 
system (ProteinSimple) system using the AlphaView software (ProteinSimple). 
5.2.3 Cloning 
Plasmids produced in this study were cloned with PCR-based methods. 
Sequences of interest were PCR amplified from plasmids or cDNA/gDNA 
templates. Primers used for PCR reactions contained extra nucleotides in their 5’-
end for the addition of desired restriction sites to the ends of the PCR amplicon. 
PCR products were digested with the desired restriction enzymes and cloned into 
digested and dephosphorylated vectors with compatible DNA ends.   
In order to digest the vector two restriction enzymes producing non-
compatible ends were used. The restriction digest reaction was assembled as 
follows (amounts are given per one reaction):  
Reagents Amounts 
10x CutSmart buffer (NEB)/ 
compatible buffer 
5 µl 
Restriction enzyme I (20 U/µl) 0.5 µl 
Restriction enzyme I (20 U/µl) 0.5 µl  
Plasmid 5 µg 
H2O Add to 50 µl 
Final volume 50 µl 
As a negative control no restriction enzymes were added. Reactions were 
incubated at 37°C 4 h-ON. Digested samples and undigested controls were run on 
a 0.5-1% agarose gel (depending on the plasmid size) to determine whether 
digestion was successful. Digested fragments of interest were cut out from the gel 
and purified using the GeneJET Gel Extraction kit (ThermoFisher) according to the 
manufacturer instruction. Digested vectors were eluted in 30 µl elution buffer and 
dephosphorylated using thermosensitive alkaline phosphatase (FastAP, 
ThermoFisher) according to the following mixture (amounts are given per one 
reaction): 
Reagents Amounts 
10x FastAP buffer 3 µl 
FastAP (1 U/µl) 1 µl 
Digested vector  1-5 µg  
H2O Add to 30 µl 
Final volume 30 µl 
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Reactions were incubated 1-2 h at 37°C. Digested and dephosphorylated vectors 
were purified using the GeneJET PCR Purification kit (ThermoFisher) according to 
the manufacturer instruction and eluted in 50 µl elution buffer.  
Inserts were PCR amplified using the Phusion polymerase kit (ThermoFisher) 
according to the following mix (amounts are given per one reaction):  
Reagents Amounts 
5x DNA Polymerase buffer 10 µl 
10 mM dNTP mix 1 µl 
10 µM forward primer 2.5 µl  
10 µM reverse primer 2.5 µl 
2 U/µl Phusion DNA polymerase 0.5 µl 
Template DNA 25-50 ng plasmid DNA; ~250 ng cDNA/gDNA 
H2O Add to 50 µl 
Final volume 50 µl 
As a negative control a reaction mix without template was used. Enzymes were 
always kept on -20°C cold block.  
PCR program: 
Step Description Purpose 
1 3 min 98°C Denature 
2 10 sec 98°C Denature 
3 10 sec Ta Annealing  
4 30 sec per kb 
72°C 
Elongation 
5 Go to 2 30x Amplification  
6 5-10 min 72°C  
7 hold 8°C  
In order to calculate Tm and Ta of the oligos the web-based Tm calculator from 
ThermoFisher was used: Thermofisher Tm Calculator. PCR amplicons were run 
on a 1-2% agarose gel (depending on the size of the product) to determine 
whether amplification was successful. Fragments of interest were cut out from the 
gel and purified using the GeneJET Gel Extraction kit (ThermoFisher) according to 
the manufacturer instruction and eluted in 50 µl elution buffer. In order to digest 
the amplicons the two restriction enzymes recognizing the restriction sites 
introduced via PCR were used. The restriction digest reaction was assembled as 
follows (amounts are given per one reaction): 
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Reagents Amounts 
10x CutSmart buffer (NEB)/ 
compatible buffer 
5 µl 
Restriction enzyme I (20 U/µl) 0.5 µl 
Restriction enzyme I (20 U/µl) 0.5 µl  
PCR amplicon 44 µl 
Final volume 50 µl 
Reactions were incubated at 37°C ON. Digested fragments were purified using the 
GeneJET PCR Purification kit (ThermoFisher) according to the manufacturer 
instruction. Digested inserts were eluted in 30 µl elution buffer. Ligation of 
processed inserts and vectors was performed using the T4 DNA Ligation kit 
(ThermoFisher). Reactions were assembled as follows (amounts are given per 
one reaction): 
Reagents Amounts 
10x T4 Ligase buffer 1 µl 
Vector (~100 ng) 2 µl 
Insert (3x molar excess than 
vector) 
6 µl  
T4 DNA ligase 1 µl 
Final volume 10 µl 
As a negative control on vector re-ligation a reaction mix without insert was used. 
Ligation reactions were incubated at room temperature (RT) 1 h-ON. 5 µl of 
ligation product were transformed into chemically competent Xl1b or Mach1 E. coli 
cells. Briefly, competent E. coli cells (competency above 107-108) were thaw on 
ice. 5µl of ligation mix were added to 50 µl of competent cells and cells were kept 
on ice for 10 min. Cells were then heat shocked for 1 min at 42°C and transferred 
back on ice for 2 additional min. 200µl of LB medium were added to each vial and 
cells were grown at 37°C with shaking for 45 min. Cultures were then spread on 
LB agars plates containing the corresponding selective antibiotic (resistance 
encoded from the vector). On the next day, bacteria colonies were counted. If a 
good ratio of colonies between the positive and negative control was observed, 2-
4 colonies from the positive samples were grown in mini cultures of 5 ml LB and 
antibiotic ON at 37°C shaking at 180 rpm. Plasmid isolation was carried out using 
the Plasmid Miniprep DNA kit (Roboklon) according to the manufacturer 
instructions. The success of the cloning was confirmed by screening PCR or 
restriction digest and DNA sequencing (LGC Genomics). Screening PCRs were 
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performed using the DreamTaq PCR kit (ThermoFisher). PCR reactions were 
assembled as follows (amounts are given per one reaction): 
Reagents Amounts 
10x DreamTaq Polymerase buffer 2 µl 
10 mM dNTP mix 0.4 µl 
10 µM forward primer 0.6 µl  
10 µM reverse primer 0.6 µl 
5 U/µl DreamTaq DNA polymerase 0.08 µl 
Template plasmid DNA 10-50 ng  
H2O Add to 20 µl 
Final volume 20 µl 
Enzymes were always kept on -20°C cold block.  
PCR program: 
Step Description Purpose 
1 3 min 95°C Polymerase activation 
2 30 sec 95°C Denature 
3 45 sec Ta Annealing  
4 1 min per kb 72°C Elongation 
5 Go to 2 30-35x Amplification  
6 5-10 min 72°C  
7 hold 8°C  
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5.2.4 Mutagenesis 
Site directed mutagenesis was performed according to Zheng et al., 2004689. In 
short, primers used to introduce the mutation were designed according to the 
following four requirements: (I) minimum 4 nt from the change at the 5'-end, 
minimum 6 nt from the change at the 3'-end, 8 nt non-overlapping at the 3'-end of 
each primer; (II) up to 7 nt change for a 40 nt primer; (III) C or G at the primer 3'-
end; (IV) primers Tm above 74°C, ΔTm between primers below 2°C. The PCR 
reaction was performed according to the following mix using the Phusion 
polymerase kit (ThermoFisher); amounts are given per one reaction: 
Reagents Amounts 
5x DNA Polymerase buffer 4 µl 
10 mM dNTP mix 0.4 µl 
10 µM forward primer 1 µl  
10 µM reverse primer 1 µl 
2 U/µl Phusion DNA 
polymerase 
0.2 µl 
Template plasmid DNA 25-50 ng 
H2O Add to 20 µl 
Final volume 20 µl 
As a negative control a reaction mix without primers was used. Enzymes were 
always kept on -20°C cold block.  
PCR program: 
Step Description Purpose 
1 30 sec 98°C Polymerase activation 
2 10 sec 98°C Denature 
3 10 sec 72°C Annealing 
4 30 sec per kb 72°C Elongation 
5 Go to 2 25x Amplification of mutated plasmid 
6 hold 8°C  
To eliminate the wild type template plasmid, each PCR reaction was incubated 
with 0.5 µl of the restriction enzyme DpnI (20 U/µl) at 37°C for 30 min (up to 
overnight, ON). The negative control is used to assess the background given by 
the undigested template. 5 µl were then used to transform 50 µl of chemically 
competent Xl1b or Mach1 E. coli cells as described in the previous cloning 
chapter. Bacteria cultures were spread on LB agar plates containing the antibiotic 
whose resistance gene is present in the template plasmid. On the next day, 
bacteria colonies were counted. If a good ratio of colonies between the positive 
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and negative control was observed, 2-4 colonies from the positive samples were 
grown in mini cultures of 5 ml liquid LB and antibiotic ON at 37°C shaking at 180 
rpm. Plasmid isolation was carried out using the Plasmid Miniprep DNA kit 
(Roboklon) according to the manufacturer instructions. The success of the 
mutagenesis was confirmed by DNA sequencing (LGC Genomics).   
5.3 RNA work 
All experimental procedures dealing with RNA were done using nuclease-free 
water, filter tips and nuclease-free tubes. Reactions were always assembled on ice 
and enzymes were kept on a -20°C block. Unless otherwise indicated RNA work 
was performed in an RNA-dedicated hood to minimize the risk of cross 
contamination with DNA and nucleases.  
5.3.1 RNA isolation 
Cells were lysed with cytoplasmic RNA lysis buffer (50 mM Tris-HCl pH 7.4, 150 
mM KCl, 0.5% Triton X-100, 0.2 mM Pefabloc prepared in DEPC-treated water), 
clarified and split for luciferase, western blotting and qRT-PCR assay. To isolate 
RNA, 250 µl of clarified lysates were mixed with 750 µl of TriFast FL (Peqlab) by 
pipetting the mix up and down several times. After 5 min incubation at RT, 200 µl 
of chloroform were added, samples were mixed by inversion for 15-20 times and 
incubated 5 min at RT. Tubes were centrifuged at 12000 g for 15 min at 4°C. The 
upper aqueous phase (~550 µl) was transferred into new tubes and if the expected 
RNA yield was low (<10 µg) 1 µl of 15 mg/ml GlycoBlue (Ambion) was added as a 
carrier for precipitation. To precipitate the RNA 500 µl of isopropanol were added, 
samples were vortexed and incubated 10 min at RT. All steps described above 
were performed in a laminar flow hood. After incubation, tubes were centrifuged at 
12000 g for 10 min at 4°C. Samples were then transferred on ice, the supernatant 
was discarded and pellets were washed by adding 1 ml 70% EtOH, vortexing and 
centrifuging at 12000 g for 5 min at 4°C. Supernatants were discarded and RNA 
pellets were briefly air dried and then resuspended in DEPC-treated H2O. RNA 
concentration and absorbance was estimated using an Eppendorf 
Biospectrometer or Qubit 2.0 fluorometer (Life Technologies). Only samples with 
OD260/280 between 1.6-2.0 were used for downstream analysis.  
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5.3.2 cDNA synthesis 
1 pg-5 µg of pure RNA (not degraded and with no traces of phenol) was 
resuspended in 8 µL DEPC-treated H2O. Within a single experiment the same 
amount of RNA per each sample was used (i.e. 1 µg). To remove genomic DNA 
contaminant RNA samples were first treated with RQ1 RNase-free DNase 
(Promega) according to the following mixture (amounts are given per sample): 
Reagents Amounts 
RQ1 DNase 10x buffer 1 µl 
RQ1 DNase (1 U/µl) 1 U/µg 
RNA 1 pg-5µg  
Final volume 10 µl 
Samples were incubated at 37°C for 30 min; 1 µL of DNase stop solution 
(Promega) was then added to the mix to inhibit DNase digestion and samples 
were incubated at 65°C for 10 min. DNase-treated RNA was immediately used for 
first strand cDNA synthesis performed with a mixture of random hexamers and 
oligo-dT primers. Components of the Maxima first strand cDNA synthesis kit 
(Thermo Fisher) were assembled according to the following formulation (amounts 
are given per sample): 
Reagents Amounts 
5x Reaction mix 4 µl 
Enzyme mix 2 µl 
RNA  1 pg-4µg  
H2O  To 20 µl 
Final volume 20 µl 
 
For each reaction a corresponding “NO RT control” without enzyme and 5x 
reaction mix was used.  
PCR program: 
Step Description 
1 10 min 25°C 
2 15 min 50°C 
3 5 min 85°C 
4 Hold 4°C 
 
cDNA samples were stored at -20°C. 
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5.3.3 qRT-PCR 
To estimate relative RNA expression levels of a set of transcripts across samples 
quantitative real time PCR (qRT-PCR) was performed using the sensiFAST 
SYBR® No ROX kit (Bioline) and primers listed in section 4.6.4. First, the 
amplification efficiency (E) of each primer pair used was estimated using a series 
of 10 fold cDNA dilutions and the following formula:  
𝐸𝐸 = 10/ 
Only primer pairs with good amplification efficiency (E-1=0.9-1.1; 90%-110%) 1.9≤ 
E ≤2.1 were used. Technical and biological duplicates for each sample and for the 
respective NO RT controls were run in a CFX96™ real time machine (Biorad). No 
template controls were added for each primer pair tested.  
qRT-PCR mixes were assembled according to the following formulation (amounts 
are given per sample): 
Reagents Amounts 
2x sensiFAST SYBR No ROX 
mix 
5 µl 
10 µM forward primer 0.4 µl  
10 µM reverse primer 0.4 µl 
Template plasmid DNA 5 ng 
H2O Add to 10 µl 
Final volume 10 µl 
 
The following PCR program was used: 
Step Description Purpose 
1 2 min 95°C Polymerase activation 
2 5 sec 95°C Denature 
3 10 sec 60°C Annealing 
4 15 sec 72°C Elongation 
5 Read fluorescence Quantification 
6 Go to 2 40x Amplification  
7 Melting curve 1°C intervals Check specificity of amplification 
8 Hold 8°C  
 Lid 105°C  
At the end of the PCR reaction the amplification curves of all samples were 
visualized on the Biorad CFX Manager software in a graph plotting cycle numbers 
(y axis) against the log2 function of the fluorescence intensity derived from the 
intercalating SYBR green dye (x axis). A cycle threshold (Ct), intersecting the 
linear regions of all curves, was arbitrarily placed and Ct values were exported. 
Before proceeding to the analysis, Ct values for NO RT and NO template samples 
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were checked and a minimal difference of 6 Ct values between negative controls 
and test samples was accepted. Melting curves were also checked to detect the 
eventual presence of multiple peaks indicating aspecific amplification products. If 
specificity was achieved, RNA expression levels were calculated using the ΔΔCt 
method and normalized to reference GAPDH or FLuc mRNA. Briefly, the mean Ct 
values obtained from technical replicates and another mean between biological 
replicates were calculated. The biological mean Ct value of reference mRNA was 
subtracted from the biological mean Ct value of target mRNA for both the test 
samples and the control samples according to the following formula: 
∆𝐶𝐶𝐶𝐶 = 𝐶𝐶𝐶𝐶 − 𝐶𝐶𝐶𝐶 
The standard deviation (SD) of ΔCt was calculated as follows: 
𝑆𝑆𝑆𝑆 = 𝑠𝑠 + 𝑠𝑠 
Where s is the standard deviation of either target or reference Ct values 
Subsequently a ΔΔCt was calculated according to the following formula: 
∆∆𝐶𝐶𝐶𝐶 = ∆𝐶𝐶𝐶𝐶  − ∆𝐶𝐶𝐶𝐶 
Where SD of ΔΔCt corresponds to SD of ΔCt of the test sample. Lastly, the fold 
difference was calculated as shown below  
2∆∆ 
And the standard deviation was incorporated in the fold difference as follows: 
2(∆∆) and 2(∆∆) 
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5.4 Protein work 
5.4.1 Protein Extraction 
For protein extraction cells were placed on ice, rinsed with ice-cold PBS and lysed 
in the following lysis buffer: 
Lysis buffer 
50 mM Tris-HCl pH 7.5 
150 mM KCl 
0.2 mM Pefabloc or 1 tablet 
EDTA-free Roche protease 
inhibitor cocktail  
0.5% (v/) Triton X-100 
Cells were mechanically scraped in 1 ml lysis buffer per 10 cm dish. For other 
formats the amount of lysis buffer was adjusted proportionally. Lysates were 
placed on ice for 5 min, incubated 10 min at 4°C on a rotating wheel and clarified 
by centrifugation at 1000 g for 5 min at 4°C. 
5.4.2 Determination of protein concentration 
The colorimetric Bradford assay was used to estimate protein concentration. The 
assay relies on a shift in the color, and consequently the absorbance, of the 
Comassie Brilliant Blue G-250 dye caused by binding to various concentrations of 
proteins. The absorbance of the protein bound form of the dye peaks at a 
wavelength of 595 nm. In order to estimate protein concentrations of cell lysates a 
series of bovine serum albumin (BSA) dilutions to final concentrations of 100, 250, 
500, 750, 1000 and 1500 µg/ml were used as protein standards. As blank sample, 
5 µl of lysis buffer were diluted 1:4 in H2O in a total volume of 20 µl. 5 µl of lysates 
from test samples (lysed in 1ml) were also diluted 1:4 in H2O in a total volume of 
20 µl.  20 µl of blank, BSA standards and test samples were transferred in 1.5 ml 
cuvettes; 1 ml of 1x Biorad protein assay (Biorad) containing the G-250 dye was 
added to each cuvette and mixed by pipetting. A spectrophotometer was adjusted 
to a wavelength of 595 nm; the absorbance of the blank sample was measured 
and used as a baseline; standards were then measured. The eppendorf 
spectrophotometer automatically plots the absorbance of the standards (y axis) 
against their concentration (x axis) to derive a standard curve. Linear regression of 
the data point is calculated. Regression coefficient (R2) values close to 1 (0.9-1) 
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had to be obtained in order to proceed with the measurements of test samples. 
OD595 of test samples was then measured and their concentration (C) was 
automatically derived according to the Beer-Lambert law: 
𝐶𝐶 =
𝑂𝑂𝑂𝑂
𝜀𝜀𝜀𝜀
∗ 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 
Where ε is the slope of the standard curve and L is the length of the cuvette. 
Concentrations were reliable with OD595 values between 0.1-1. If absorbance 
exceeded this range samples were further diluted. 
5.4.3 GST pull-down 
HEK293 cells were seeded to 10 cm dishes to reach 70% confluency on the next 
day. The following day, 0.2-10 µg of plasmids encoding GST fusions (or GST 
alone) were transfected into HEK293 cells using the transfection reagent 
polyethylenimine (PEI; Polysciences Inc.) in a 1:5 w/w ratio (DNA:PEI). Within 
each experiment the same amount of DNA per sample was transfected. In order to 
obtain comparable expression levels of GST-fusions of considerably different sizes 
different amounts of GST-fusions were transfected and filler DNA (encoding for the 
yeast peptide sic) was used to top up to same final amounts (Figures 20B, 22A, 
23B, S3). Transfection mixtures were assembled by adding first the DNA, 
secondly 500 µl DMEM without FBS, and lastly PEI (amounts are given per 
sample). Mix were vortexed, briefly spinned down and incubated 10 min at RT to 
allow complex formation. Transfection mixes were then added dropwise to the 
cells.  
In order to perform GST pull-down of GST fusions upon knockdown of 
CCR4-NOT and CCV components (Figure 15) 2.5x105 HEK293 cells were seeded 
per 10 cm dish. One day after seeding, cells were transfected with siRNAs to a 
final concentration of 20 nM using jetPRIME (Polyplus transfection). siRNAs were 
resuspended in 500 µl of jetPRIME, 20 µl of jetPRIME transfection reagent were 
added and mixes were vortexed. After 10 min of incubation at RT, mixes were 
added dropwise to the cells. 48 h post siRNA transfection a second siRNA 
transfection round was performed using siRNA to a final concentration of 30 nM. 
Transfection was performed with jetPRIME as described above. 24 h after the 
second round of siRNA tranfection cells were transfected with 5 µg GST-fusions 
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using PEI in a 1:5 ratio (5 µg DNA: 30 µg PEI). Cells were lysed on the next day 
as described below. 
24 h post-transfection of GST-fusions cells were placed on ice, media was 
removed and cells were rinsed in ice-cold PBS.  PBS was removed and cells kept 
on ice were scraped with 1 ml of lysis buffer [50 mM Tris-HCl pH 7.5, 150 mM KCl, 
0.2 mM Pefabloc, 0.5% (v/v) Triton X-100] per dish. In case of co-expression of 
GST-fusions and HA-fusions (Figure 22A, 23B) the percentage of Triton-X-100 in 
the lysis buffer was lowered to 0.25%. Lysates were incubated 15 min at 4°C on a 
rotating wheel and clarified by centrifugation at 1000 g for 5 min at 4°C. To 
exclude the identification of protein interactions mediated by nucleic acids clarified 
lysates (1.5 mg/ml) were treated with one of the following nucleases: (I) 10 ng/µl 
S7 micrococcal nuclease (Roche) and 1 mM CaCl2 shaking for 30 min at RT 
(Figures 8-10, 12, S3) (II) 300 U/ml micrococcal nuclease (ThermoFisher) and 1 
mM CaCl2 shaking for 30 min at RT (Figures 20B, 20C, 23B) (III) 10 U/µl RNase 
T1 (ThermoFisher) shaking for 10 min at 37°C (Figure 19, 20A, 22A, 23B). During 
lysates nuclease treatment, 20 µl of glutathione (GSH)-Sepharose beads (GE 
Healthcare) per sample were equilibrated 2x in 1 ml washing buffer [50 mM Tris-
HCl, pH 7.5, 150 mM KCl, 0.2 mM Pefabloc, 0.1% (v/v) Triton X-100] and 1x in 1 
ml lysis buffer. Between each wash beads were spinned down at 1000 g for 5 min 
at 4°C and the supernatants were discarded. Protein concentration of each lysate 
was assessed by Bradford assays; lysates concentrations were equalized and 
then incubated with 20 µl of equilibrated beads for 2-4 h at 4 °C on a rotating 
wheel. Beads were washed three times with washing buffer. Next, washed beads 
were incubated for 1 h at 4°C on a rotating wheel with 60 µl elution buffer (50 mM 
GSH in washing buffer, pH adjusted to 7.5 with Tris). Per each experiment, heavy, 
medium heavy and light SILAC labeled GST-fusions were pooled together and 
eluted in 8 M guanidinium hydrochloride. Eluates to be used for mass 
spectrometry were precipitated ON by adding 1 µl of 15 mg/ml GlycoBlue 
(Ambion) and 10 volumes of 100% EtOH. Samples destined to SDS-PAGE and 
western blotting were boiled 5 min at 95°C upon addition of 0.2 volumes of 
5xSDS-loading buffer [50% glycerol, 300 mM Tris-HCl pH 6.8, 5% 14.3 M β2-
mercapto-ethanol, 0.1% (w/v) bromophenol blue, 10% (w/v) SDS]. 
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5.4.4 TNRC6A IP 
Per each IP a confluent 10 cm dish of HeLa rtTA cells was used. Cells were lysed 
in 1 ml lysis buffer [50 mM Tris-HCl pH 7.5, 150 mM KCl, 0.5% (v/v) Triton X-100, 
1 tablet of Roche protease inhibitor cocktail complete EDTA free in 10 ml buffer] 
per 10 cm dish. Lysates were clarified and nuclease treated as described for GST 
pull-down in section 5.4.3. Protein G Dynabeads slurry (Invitrogen) was mixed by 
inversion and 50 µl magnetic beads per IP were transferred in an eppendorf tube. 
Beads were washed three times in PBS-T [PBS with 0.1% (v/v) Tween-20], 
resuspended in 250 µl PBS-T and 10 µg of TNRC6A A330 antibody (Bethyl) were 
added. Beads were incubated 3 h to ON on a rotating wheel at 4°C to permit 
antibody binding. With the help of a magnetic rack the unbound antibody was 
removed and beads were resuspended in 900 µl cell lysate (~1 mg proteins). 
TNRC6A IP was performed by incubating samples for 2-4 h on a rotating wheel at 
4°C. Beads were then washed three times with washing buffer [50 mM Tris-HCl 
pH 7.5, 150 mM KCl, 0.1% (v/v) Triton X-100, 1 tablet of Roche protease inhibitor 
cocktail complete EDTA free in 10 ml buffer], resuspended in 60 µl 1x SDS loading 
buffer [50% glycerol, 300 mM Tris-HCl pH 6.8, 5% 14.3 M β2-mercapto-ethanol, 
0.1% (w/v) bromophenol blue, 10% (w/v) SDS] and boiled 5 min at 95°C. Magnetic 
beads were removed with the help of a magnetic rack and samples were then 
analyzed by western blotting. 
5.4.5 Nematostella AGO1 and CNOT9 IP 
For Nematostella AGO1-IP a custom antibody raised against the synthetic peptide 
CMMDRDKEAGNDNSS derived from nvAGO1 was generated in rabbit 
(GenScript, USA). 10 µg of αnvAGO1 (GenScript) or αCNOT9 (OriGene) 
antibodies were coupled with protein A magnetic beads (Bio-Rad). Nematostella 
embryos were lyzed in lysis buffer [25 mM Tris-HCl pH 7.5, 150 mM KCl, 25 mM 
EDTA, 0.5 % NP-40, 1 mM DTT, complete Ultra (Roche) and 2 Set III (Merck) 
protease inhibitor cocktails] 48 h post-fertilization and 500 µg of lysate were used 
per each IP. After IP the beads were washed with the wash buffer [50 mM Tris-HCl 
pH 7.5, 300 mM NaCl, 5 mM MgCl2, 0.05 % NP-40, complete Ultra (Roche) and 
Set III (Merck) protease inhibitor cocktails], and bound proteins were eluted with 
SDS-PAGE sample buffer. Inputs and IPs were analyzed by westrn blotting using 
the following antibodies: a custom αnvGW182 antibody raised against a 
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recombinant fragment spanning amino acid positions 1301-1698 of nvGW182 in 
guinea pig (GenScript, USA) 1:1000; αCNOT9 (OriGene) 1:1000; αnvAGO1 
(GenScript, described above) 1:1000. In vivo Nematostella IPs were performed by 
Dr. Yehu Moran Lab. 
5.4.6 SILAC and Mass Spectrometry  
For SILAC and mass spectrometry described in chapter 2.1, labeled HEK293 cells 
were expanded to one 70% confluent 15 cm dish per affinity purification. Heavy, 
medium heavy and light labelled cells were transiently transfected with 10-15 µg of 
the following GST-fusions: TNRC6C CED wt, 7W7A mutant and a GST control on 
background binders. Alternatively cells were transfected with: CED wt, 7W7A 
mutant and 7W7Y mutant. Transfections were performed using polyethylenimine 
transfection reagent (PEI; Polysciences Inc.) in a 1:2 ratio DNA: PEI. Each 
experiment consisted of a forward replicate and a reverse replicate, in which the 
labels were swapped to exclude eventual biases introduced by the labelling 
procedure.  
For mass spectrometry experiments described in chapter 2.3, HEK293 cells were 
expanded to one 70% confluent 10 cm dish per affinity purification. Cells were 
transiently transfected with 4 µg of the indicated GST-fusions (GST control, 
nvGW182, nvDNAJ, nvΔCED, nvCED, nvCED11W11A) using PEI in a 1:5 ratio.  
In both setups, 24 h post-transfection cells were lysed and nuclease-treated 
lysates were used in GST pull-downs as described in section 5.4.3. GST pull-
downs were eluted in 2 ml eppendorfs and precipitated by adding up to 2 ml 100% 
EtOH (~20 volumes). Protein precipitates were resuspended in denaturation buffer 
[6 M urea/2 M thiourea in 10 mM HEPES pH 8.0] then reduced for 30 min at RT in 
10 mM dithiothreitol solution, followed by alkylation by 55 mM iodacetamide for 20 
min in the dark at RT. The endoproteinase LysC (Wako, Japan) was added 
following a protein:enzyme ratio of 50:1 and incubated for 4 h at RT. After dilution 
of the sample with 4x digestion buffer [50 mM ammonium bi-carbonate in water, 
pH 8.0], sequence grade modified trypsin (Promega) was added (same 
protein:enzyme ratio as for LysC) and digested overnight. Finally, trypsin and Lys-
C activity were quenched by acidification of the reaction mixtures with TFA to 
pH~2. Afterwards, peptides were extracted and desalted using StageTips690. 
Peptide mixtures were separated by reversed phase chromatography using the 
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EASY-nLC system (Thermo Scientific) on in-house manufactured 20 cm fritless 
silica microcolumns with an inner diameter of 75 µm. Columns were packed with 
ReproSil-Pur C18-AQ 3 µm resin (Dr. Maisch GmbH). Peptides were separated on 
a 8-60% acetonitrile gradient (224 min) with 0.5% formic acid at a nanoflow rate of 
250 nl/min. Eluting peptides were directly ionized by electrospray ionization and 
transferred into a Q Exactive mass spectrometer (Thermo Scientific). Mass 
spectrometry was performed in the data dependent positive mode with one full 
scan (m/z range = 300-1700; R = 70000; target value: 5 x 106; maximum injection 
time = 120 ms). The ten most intense ions with a charge state greater than one 
were selected (R = 35000, target value = 5 x 105; isolation window = 4 m/z; 
maximum injection time = 120 ms). Dynamic exclusion for selected precursor ions 
was set to 30 s.  
MS/MS data were analyzed by MaxQuant691 software v1.3 (for data shown 
in chapter 2.1) and v1.5.1.2 (for data shown in chapter 2.3). The internal 
Andromeda search engine692 was used to search MS/MS spectra against a decoy 
human UniProt database (HUMAN.2012 for data in chapter 2.1 and HUMAN.2014-
10 for data in chapter 2.3) containing forward and reverse sequences 
supplemented with the bait sequences. The search included variable modifications 
of methionine oxidation and N-terminal acetylation, and fixed modification of 
carbamidomethyl cysteine. Minimal peptide length was set to six amino acids, 
trypsin was set as the selected protease and a maximum of two missed cleavages 
was allowed. The FDR was set to 0.01 for peptide and protein identifications. 
In SILAC-MS/MS (data in chapter 2.1) corresponding forward and reverse 
experiments were analyzed together. Subsequent analysis was done using 
Perseus v1.5.6.0 (MaxQuant environment). First, the data from five experiments 
(each with forward and reverse; n=9 since one forward experiment had to be 
excluded due to protein precipitation) were combined using their Uniprot identifier. 
The mean log2 fold change (avg log2FC) of the transformed normalized ratios 
given by MaxQuant was calculated for each of the following comparisons (both 
forward and reverse): wt/mut (either 7W7A or 7W7Y), wt/7W7A mut, wt/7W7Y 
mut, 7W7A/7W7Y. Each mean is representative of 2-5 independent experiments. 
Proteins were considered enriched interactors if the mean log2FC of both forward 
and reverse experiments was above 0.4 (1.3 fold enrichment). Threshold was set 
to 0.4 to avoid missing low affinity interactions. The 80 W-motif specific interactors 
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were identified using a one-sample t-test plotting the mean log2FC wt/mut against 
the t-test p-value (mean log2 wt/mut≥ 0.4; p-value< 0.05). Only interactors that 
were also enriched in comparison to the GST control (mean log2FC wt/GST≥ 0.4) 
were considered. 
Label-free quantification (LFQ) (data in chapter 2.3) was performed in MaxQuant 
as described693. Unique and razor peptides were considered for quantification with 
a minimum ratio count of 1. Retention times were recalibrated based on the built-in 
nonlinear time-rescaling algorithm. MS/MS identifications were transferred 
between LC-MS/MS runs with the “Match between runs” option, in which the 
maximal retention time window was set to 2 min. Subsequent analysis was done 
using Perseus v1.5.6.0 (MaxQuant environment). LFQ intensity values were 
logarithmized and missing values were imputed with random numbers from a 
normal distribution whose mean and standard deviation were chosen to best 
simulate low abundance values below the noise level (width = 0.3; shift= 1.8). 
nvGW182 GST-fusions pull-downs and GST control were defined as groups of 2 
biological replicates and 3 technical replicates; significantly enriched proteins were 
determined by a volcano plot-based strategy, combining standard two-sample t-
test p-values with ratio information. Significance corresponding to an FDR of 0.05 
was determined by a permutation-based method694. A total of 2275 proteins were 
identified; to exclude background (GST control) binders from further analysis, only 
proteins enriched with nvGW182 as compared to GST (log2 ratio nvGW182/GST> 
0; 1337 proteins) were used as inputs of t-tests comparing nvGW182 domains to 
GST. MS runs and MaxQuant analysis were performed by Dr. Marieluise Kirchner 
(Selbach Lab). 
5.4.7 Western blotting 
Proteins were separated by SDS-PAGE according to their size using linear 
polyacrylamide gels listed in section 4.10. Electrophoresis was performed in a 
Biorad minitank filled with running buffer [25 mM Tris-base, 191 mM glycine, 0.1% 
SDS] and ran first at 80 V while samples crossed the stacking gel and at 110 V in 
the separating gel for ~2.5 h. In order to transfer proteins from a polyacrylamide 
gel to a PVDF membrane (Millipore) two types of transfer were used: a wet 
transfer, preferentially for big proteins (above 100 kDa) and lowly expressed 
proteins or a semi-dry transfer, for proteins between 10-200 kDa and for routine 
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checks.  Once an SDS-PAGE run was over, polyacrilammide gels were removed 
from their glass support, the stacking gel was cut and the separating gel was wet 
in transfer buffer [25 mM Tris-base, 191 mM glycine, 20% (v/v) MetOH] for 2 min. 
PVDF membranes (Millipore) of the same size of the gel were activated for 30 sec 
in MetOH. For a wet transfer a transfer cassette was assemble by placing the 
following items in this order: 1 filter pad and 3 filter papers wet in transfer buffer, 
the gel, an activated PVDF membrane, 2 additional filter papers and a filter pad 
wet in transfer buffer. The cassette was closed, placed in the transfer module with 
the membrane side facing the anode, the module was then transferred in a Biorad 
mini-tank filled with transfer buffer and 0.025-0.1% SDS (for efficient transfer of 
proteins between 200-250 kDa). Transfer was performed ON at 4°C at 30 V or 1 h 
at 4°C at 100 V. 
For a semi-dry transfer, 7 pieces of filter pads (Biorad) wet in transfer buffer 
were placed on the bottom (anode) of the transfer cassette (Biorad). The activated 
membrane was then placed on top, followed by the gel and other 7 wet filter pads. 
The cassette was closed and transfer was performed for 30 min at 25 V. 
After transfer, membranes were blocked in blocking solution [5% (w/v) milk 
(or BSA) in PBS-T (or TBS-T), PBS with 0.1% (v/v) Tween-20] for 1 h at RT and 
incubated ON at 4°C in blocking buffer containing the specified primary antibody 
amongst the ones listed in section 4.9 at the stated working dilution. After primary 
staining, membranes were washed 3 times for 10 min at RT in PBS-T (or TBS-T); 
incubated for 1 h at RT with the corresponding HRP-conjugated secondary 
antibody listed in section 4.9 at the dilution specified and washed 3 times for 10 
min at RT in PBS-T (or TBS-T). In order to detect the chemiluminescent signal 
membrane was incubated with constant shaking in 10 ml ECL reagent [10 ml 100 
mM Tris-HCl pH 8.5, 25 µl 90 mM coumaric acid, 50 µl 250 mM luminol and 3 µl 
30% (w/w) H2O2] for 30 sec and exposed in an ImageQuant LAS 4000 (GE 
Healthcare) chemiluminescent analyzer. In case the chemiluminescent signal was 
low the 10x more sensitive Femto kit (Thermo Fisher) was used instead of 
homemade ECL. Images were acquired and later processed with Photoshop 
(Adobe). Only minimal adjustments, such as contrast increase, were performed. 
When explicitly stated signals were quantified using ImageJ64 software. 
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5.5 CCVs Isolation from HeLa cells 
CCV-enriched fractions were prepared as described in664, with the omission of the 
RNase A treatment and subsequent pelleting of partially digested ribosomes. 
Briefly, per each condition tested four confluent 15 cm dishes of HeLa cells were 
rinsed in ice-cold D-PBS without Ca2+ and Mg2+ (PAN Biotech) and scraped into 
800 µl/dish hypotonic buffer A (0.1 M MES, pH 6.5 adjusted with NaOH, 0.2 mM 
EGTA, and 0.5 mM MgCl2), resulting in ~4 ml cell suspension per condition. Cells 
were homogenized with a motorized glass homogenizer with the power head set 
at 1500 rpm (20 strokes) and the homogenates were clarified by centrifugation at 
4100 g for 30 min at 4°C. Membranes were pelleted by centrifugation at 55000 
rpm (209900 g RCFmax) for 40 min in a S110-AT rotor (Thermo Scientific) at 4°C. 
Pellets were resuspended in 300 µl buffer A with a 1 ml Dounce homogenizer, 
mixed with an equal volume of FS buffer (12.5% (w/v) ficoll and 12.5% (w/v) 
sucrose in buffer A) and centrifuged at 20000 rpm (21700 g RCFmax) for 35 min in 
a S55-A2 rotor (Thermo Scientific) at 4°C. The following centrifugation steps were 
performed in an S110-AT rotor (Thermo Scientific). Supernatants were diluted with 
four volumes of buffer A and centrifuged at 20000 rpm (21700 g RCFmax) for 15 
min at 4°C. Supernatants were centrifuged at 35000 rpm (66500 g RCFmax) for 30 
min at 4°C to obtain the CCV-enriched fraction (pellet). Pellets were resuspended 
in 100 µl buffer A with a micro-tube sample pestle and used for downstream 
analysis (yield: 0.3-0.5%). Fractions were snap-frozen in liquid N2 and stored at -
80°C. All steps described above were performed at 4°C and all reagents used 
were prepared with diethylpyrocarbonate (DEPC)-treated water. HeLa cells stably 
integrating dox-inducible wt and mut let-7 reporters (HeLa rtTA-755 and HeLa 
rtTA-756) were induced ON with 1 µg/ml doxycycline prior to CCVs isolation 
(Figure 13).    
5.6 Tethering assays 
On the first day, 7x103 HEK293 cells were seeded per well of a 96-well plate. The 
following day cells were transfected with 2 ng RLuc-5BoxB and 30 ng FLuc 
(transfection control), and 10 ng HA- or NHA-fusion constructs per well of a 96-
well plate. Transfections were performed using polyethylenimine (PEI) in a 1:5 
ratio DNA:PEI, as described in section 5.4.3. In tethering experiments shown in 
Figure 21, increasing amounts of plasmids encoding CNOT6cat and CNOT7cat (50, 
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100, and 200 ng) were co-transfected. Transfections containing less than 200 ng 
of CNOTcat plasmids were topped up to 200 ng with LacZ-encoding plasmid. For 
other formats, the amounts of plasmids were adjusted proportionally. The media 
was removed 24 h post transfection, cells were lysed and lysates were used for 
downstream applications, such as luciferase assays, western blotting and qRT-
PCR.  
5.7 miRNA reporter assays 
HeLa cells stably expressing Tet-On machinery (HeLa rtTA) were used in miRNA 
reporter assays685. In experiments shown in Figure 14A (left), 4x104 HeLa rtTA 
cells were seeded per well of a 96-well plate. Shortly after seeding, cells were co-
transfected with 10 ng of dox-inducible wt or mut Fluc/RLuc-hmga2 reporters, 190 
ng of filler DNA (pCiNeo-NHA) per well of a 96-well plate and the indicated siRNAs 
to a final concentration of 10 nM.  Transfections were performed using 0.75 µl/well 
attractene reagent (Qiagen) according to the manufacturer instructions. 6-24 h 
post transfection medium was replaced to minimize the toxic effects of attractene. 
48 h post transfection the expression of the reporters was induced with 0.2 µg/ml 
doxycycline. 4 h after induction, the media was aspirated and cells were lysed in 
1x Passive lysis buffer (Promega) for luciferase assays. In experiments shown in 
Figure 14A (right), 4x103 HeLa rtTA cells stably integrating wt or mut dox-
inducible Fluc/RLuc-hmga2 reporters392 were seeded per well of a 96-well plate. 
The day after, cells were transfected with the indicated siRNAs to a final 
concentration of 10 nM using 0.6 µl/well of jetPRIME transfection reagent 
(Polyplus Transfection) according to the manufacturer instructions. 48 h post 
transfection, the expression of the reporters was induced with 1 µg/ml doxycycline. 
4 h after induction, cells were lysed as described above. In experiments shown in 
Figure S5, 4x103 HeLa rtTA cells were seeded per well of a 96-well plate. The day 
after, cells were co-transfected with 30 ng Fluc, 1 ng Rluc-3xb artificial let-7 
reporter412, and 19 ng of filler DNA (pCiNeo-NHA) per well of a 96-well plate and 
the indicated siRNAs to a final concentration of 40 nM. Co-transfection was 
performed using 0.6 µl/well of jetPRIME transfection reagent (Polyplus 
Transfection) according to the manufacturer instructions. 48 h post transfection, 
cells were lysed as described above. 
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5.8 TNRC6 rescue assays 
On the first day, 3x103 HeLa rtTA (“no knockdown” control) and Hela rtTA-TNRC6-
KD cells were seeded per well of a 96-well plate. shRNA-mediated TNRC6A&B 
knockdown was induced for 2 days with doxycycline (1 µg/ml). On day 2, 
doxycycline was removed and cells were transfected with 0.5 ng/well of 
FLuc/RLuc-hmga2-wt or FLuc/RLuc-hmga2-mut dox-inducible let7 reporters275,392, 
and increasing amounts (50, 100 and 200 ng/well) of the indicated rescue 
constructs. The same vector backbone encoding LacZ was used as a filler, to top 
up each transfection to the same total amount of DNA. Transfections were 
performed using polyethylenimine (PEI) in a 1:5 ratio DNA:PEI, as described in 
section 5.4.3. On day 3, expression of the reporters was induced with doxycycline 
(1 µg/ml) for 4 h prior media removal and cell lysis in 1x Passive lysis buffer 
(Promega). RLuc and FLuc expression was measured via luciferase assays. 
5.9 Luciferase assays 
Cells transfected with Renilla and Firefly luciferase reporters were lysed 24 h after 
transfection or 4 h after induction when experiments were done using inducible 
reporters. Media was aspirated and 40 µl of 1x Passive lysis buffer (Promega) 
were added per well of a 96-well plate. Cells were lysed for 15 min at RT on an 
orbital shaker. 5 µl lysate per sample were then transferred in a Greiner white 
microplate and luciferase activities were measured with a homemade luciferase 
reporter assay system. 45 µl of FLuc reagent (75 mM Hepes pH 8.0, 0.1 mM 
EDTA, 4 mM MgSO4, 530 µM ATP, 270 µM Coenzyme A, 470 µM DTT and 470 
µM luciferin) per sample were used to measure firefly luciferase activity. After 
firefly quantification, the reaction was quenched and Renilla activity measured by 
adding 45 µl of RLuc reagent (2.2 mM Na2EDTA, 220 mM K3PO4 pH 5.1, 0.44 
mg/ml BSA, 1.1 M NaCl, 1.3 mM NaN3 and 0.6 µg/ml colenterazine) to the same 
sample. RLuc values were then normalized to the corresponding FLuc values and 
expressed as percentage of the experimental negative control: samples 
expressing untethered fusions for tethering assay, and samples expressing mut 
miRNA reporter without depletion for miRNA reporter assays and rescue assays. 
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5.10 Transferrin uptake assays 
HeLa cells seeded in a 6-well plate were transfected with siRNAs (final 
concentration: 100 nM) targeting TNRC6A/B, or a non-targeting scrambled control 
siRNA 48 h before conducting the uptake assay. 24 h before the assay siRNA-
treated cells were seeded on Matrigel-coated coverslips. Cells were starved in 
serum-free DMEM for 1 h and then incubated with 25 µg/ml Transferrin-Alexa647 
(Life Technologies; spun down at 15000 g for 3 min to remove ligand precipitates; 
diluted in serum-free DMEM) for 10 min at 37°C. Cells were washed twice with ice-
cold PBS containing MgCl2 (10 mM) and a 1min acid wash on ice (0.2 M NaCl, 0.1 
M NaOAc pH 5.3) was used to remove surface bound transferrin from the cells 
followed by two times washing with ice-cold PBS-MgCl2 and fixation with ice-cold 
PFA (4% PFA, 4% sucrose) for 45 min at room temperature. For the surface 
labeling, cells were serum-starved for 1 h and then incubated at 4°C with 25 µg/ml 
Transferrin-Alexa647 for 45min. Cells were washed two times with ice-cold PBS-
MgCl2 followed by fixation with ice-cold PFA (4% PFA, 4% sucrose) for 45 min at 
room temperature. After fixation, PFA was quenched with 50 mM NH4C in PBS 
and coverslips were mounted with immomount (with Dapi, 50 µg/ml) and 
Transferrin uptake and surface labeling was analyzed by epifluorescent 
microscopy. Per conditions, 15-20 images with a total number of 200-400cells 
were analyzed. After background subtraction the total fluorescence intensities per 
cells were calculated and values were normalized to scrambled control cells 
(Figure S6A). The ratio of internalized Tfn to surface-bound Tfn was used to 
distinguish between uptake and recycling defects. Tfn uptake assays were 
performed by Dr. Caroline Bruns (Haucke Lab). 
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5.11 GO and KEGG pathways enrichment analysis 
Gene ontology (GO) and KEGG pathway enrichment analysis was performed for 
the W-motif-specific interactome (80 proteins) using the whole proteome detected 
by Mass Spectrometry (2609 proteins) as background. Overrepresentation of GO 
terms and KEGG pathways was identified using a Fisher Exact test via the online 
tool DAVID v6.7662,663, requiring at least 3 protein hits per term/pathway and 
adjusted p-values< 0.01 (Figure 8C).  
5.12 Motif analysis 
The MEME motif finder tool available online at http://meme-suite.org/ was used to 
identify consensus motifs across stretches of amino acids. As inputs eleven 
(Figure S2) and thirteen (Figure S9) amino acid long regions of the indicated 
proteins were used. Only sequences surrounding tryptophan residues were 
chosen and tryptophan was always placed centrally. MEME was asked to find a 
maximum of three motifs with a minimal length of 6 amino acids. The motif with the 
top score is displayed. 
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6. Appendix 
6.1 Supplementary Figures 
 
Figure S 1. Human TNRC6C amino acid sequence Amino acid sequence of Homo 
sapiens TNRC6C isoform 1 (Uniprot identifier: Q9HCJ10-1). The C-terminal effector 
domain (CED) used in this study corresponds to the region between residues 1369-1690 
and is highlighted in blue. The two structured domains Ubiquitin Associated Domain 
(UBA) and RNA Recognition Motif (RRM) are shown in purple and red, respectively. The 
PABP Associated Motif (PAM2) is shown in cyan and seven CED W-motifs are highlighted 
in green. Exactly these seven tryptophan residues were mutated to either tyrosine or 
alanine in the 7W7Y and 7W7A mutants, respectively. Amino acid positions of the 
domains and motifs are annotated below the sequence.  
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Figure S 2. Consensus human W-motif and the corresponding count matrix Motif 
was derived using MEME Suite (Bailey and Elkan, 1994)661 with a set of experimentally 
validated W-motifs from TNRC6A (Q8NDV7-1) and TNRC6C (Q9HCJ0-1) proteins. 
Sequences used as inputs are provided below the count matrix. The number after W 
refers to the amino acid position of the tryptophan (W) residue in the corresponding full-
length protein. 
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Figure S 3. TNRC6C CED interacts with AP1 proteins via W-motifs (A) Illustration 
representing an eukaryotic animal cell with budding clathrin-coated vesicles (CCVs) 
associated to different type of adaptor proteins: AP1 (green), AP2 (red) and AP3 (blue).  
AP1 mediate internal trafficking between the transgolgi network (TGN) and endosomes, 
AP2 mediate trafficking from the plasma membrane to endosomes and AP3 additionally 
mediate endo-lysosomal trafficking. (B) HEK293 cells were co-transfected with plasmids 
encoding GST-fusions of TNRC6C CED and plasmids encoding flag-tagged AP21G or 
AP1B subunits (or filler DNA encoding flag-sic peptide). Nuclease-treated cell lysates 
were used in GST pull-down, and inputs (6%) and GST pull-downs were analyzed by 
western blotting with the indicated antibodies. Cells transfected with only flag-AP1G were 
used as negative control on unspecific precipitation.  
 163 
 
Figure S 4. Ratio of wt to mut RLuc-hmga2 reporter does not vary between input-
isolated and CCV-isolated RNA (A) FLuc (top) and RLuc (bottom) mRNA levels were 
expressed as fold-change (FC) relative to Input wt (always set to 1). (B) RLuc mRNA 
levels were normalized to that of Fluc and expressed as fold-change relative to Input wt 
(set to 1). Not normalized and normalized RLuc-hmga2 wt is shown in blue, mutant in red. 
Values represent means ± SD from 3 technical replicates. 
 164 
 
 
Figure S 5. Knockdown of AP2A proteins does not enhance miRNA repression 
when using RLuc-3xb artificial miRNA reporters (A) Schematic representation of 
RLuc-3xb reporters expressing RLuc fused to an artificial 3’UTR sensitive to let-7 miRNA 
(wt, green) or its mutant version with disrupted let-7 sites (mut, grey).  FLuc insensitive to 
let-7 miRNA is used as a control. Reporters were previously described in412 (B) siRNAs 
against the indicated genes were co-transfected with plasmids encoding wt or mut RLuc-
3xb let-7 reporters and FLuc control as illustrated in (A) (means ± SEM, n=4). RLuc 
activity was normalized to that of FLuc and expressed as a percentage of RLuc activity 
produced by 3xb-mut reporter in samples co-transfected with scramble siRNA (set to 
100%).  Knockdown of RLuc was used as a proxy for knockdown efficiency (~5-fold).  
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Figure S 6. Knockdown of TNRC6 proteins does not significantly affect CCV-
mediated endocytosis (A) HeLa cells transfected with siRNAs targeting TNRC6A and B 
or with a non-targeting siRNA (scramble) were stained using an Alexa Fluor 647-
conjugated transferrin (Tfn) (ligand of Tfn receptors). The fluorescence signals coming 
from the internalized receptor (Tfn uptake, histogram on the left) and from the ligand-
bound surface receptor were quantified (Tfn surface; central histogram). Tfn uptake 
normalized to Tfn on the cell surface is shown on the right histogram (means ± SEM; n=6, 
biological replicates). Values are expressed as fold change of Tfn fluorescence in samples 
transfected with siRNA targeting TNRC6 proteins as compared to samples transfected 
with scramble siRNA (set to 1). None of the differences observed is significant (two-
samples t-test). (B) TNRC6 KD is efficient and does not affect CLTC expression levels. 
Lysates of samples used in (A) were analyzed by western blotting with the indicated 
antibodies. Numbers 1 to 6 correspond to the different biological replicates. 
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Figure S 7. Nematostella GW182 (nvGW182) amino acid sequence Amino acid 
sequence of full-length Nematostella vectensis GW182. Starting from the N-terminus, 
DNAJ domain characteristic of nvGW182 is shown in yellow, Ubiquitin Associated Domain 
(UBA) is shown in purple. The C-terminal effector domain (nvCED) used in this study 
corresponds to the region between residues 1159-1698 and is highlighted in blue. Within 
nvCED the structured RNA Recognition Motif (RRM) is shown in red and the PABP 
Associated Motif (PAM2) in cyan. Eleven W-motifs are highlighted in green. Exactly these 
eleven tryptophan residues were mutated to alanine in the 11W11A mutant. Amino acid 
positions of the domains and motifs are annotated below the sequence. 
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Figure S 8. Tethering of nv∆CED does not affect mRNA repression (A) Schematic 
representation of nvGW182 and the C-terminal deletion mutants used in (B). DNAJ 
domain (yellow); N-GW: GW-repeat–rich region (grey); UBA: ubiquitin associated domain 
(green); PAM2: PABP associated motif 2 (light blue); RRM: RNA-recognition motif (red). 
The C-terminal effector domain (CED) is formed by RRM, PAM2 and the unstructured 
flanking regions with tryptophan-containing motifs, or W-motifs (W). Numbers correspond 
to the amino acid positions. (B) Expression of RLuc-boxB mRNA is not affected by 
tethering NHA-nvGW182 C-terminal and DNAJ deletion mutants. Human HEK293 cells 
were co-transfected with plasmids encoding RLuc-boxB, FLuc, and the indicated NHA-
nvGW182 deletion mutants. As negative control, a plasmid encoding untethered HA-
fusion was used. RLuc activity was normalized to that of FLuc and presented as a 
percentage of RLuc produced in the presence of the untethered HA-fusion (means ± SD; 
n=3-8). 
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Figure S 9. Consensus W-motif and the corresponding count matrix Consensus W-
motif and the corresponding count matrix, derived using MEME Suite (Bailey and 
Elkan,1994)661 with a set of validated W-motifs from human TNRC6A (Q8NDV7-1) and 
TNRC6C (Q9HCJ0-1), Drosophila GW182 (Q8SY33-1) and Nematostella GW182 
proteins. Sequences of validated W-motifs used as input in MEME motif prediction are 
provided below the count matrix. The numbers after W refer to the amino acid position of 
the corresponding tryptophan (W) in the indicated TNRC6/GW182 proteins. 
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Figure S 10. Sequence alignment of human and Nematostella DDX6 Sequence 
alignment of hsDDX6 and nvDDX6 was performed with Clustal Omega (EBI) and 
visualized with Jalview. Percentage of identity (ID) is shown below the alignment. 
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Figure S 11. Proteins other than TNRC6 containing W-motifs W-motif-containing 
proteins across species. Amino acid sequences of proteins containing W-motifs are 
shown; the central tryptophan residue of W-motifs is highlighted in red. Uniprot identifiers 
of the sequence used are provided.  
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Figure S 12. Coexpression of nvGW182 and nvAGOs cannot rescue TNRC6 
depletion in mammalian cells HeLa cell line carrying stably integrated inducible shRNAs 
construct against endogenous TNRC6A and B was used for TNRC6 knockdown 
experiments (open bars); HeLa cells not expressing TNRC6-directed shRNAs was used 
as a control (filled bars). Expression of shRNAs was induced for 2 days prior to 
transfection of miRNA reporters and rescue constructs. Cells were transfected with RLuc-
hmga2 reporter containing let-7 sites (RLuc-hmga2 wt) or its mutant version (RLuc-hmga2 
mut), and increasing amounts (50 ng and 100 ng) of plasmids expressing nvGW182 wt or 
its 11W11A mutant cotransfected with 100 ng of a filler plasmid encoding LacZ or 100 ng 
nvAGOs (50 ng nvAGO1 and 50 ng nvAGO2). TNRC6A was used as a positive control. 
Values represent percentages of RLuc activity produced by hmga2-mut reporter without 
TNRC6 depletion (means ± SD; n=3).
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Figure S 13. Affinity purification of endogenous TNRC6A shows abundant 
interactions with CCR4-NOT and less abundant interactions with CLTC Nuclease-
treated HeLa cell lysate was used to pull-down endogenous TNRC6A, and input (6%), 
flow through (FT, 7%) and TNRC6A IP were analyzed by western blotting with the 
indicated antibodies.  
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6.2 Supplementary Tables 
Table S1. W-motif enriched interactors identified by SILAC followed by AP-MS/MS   
80 W-motif specific interactors identified by SILAC-AP-MS/MS, their mean log2 ratio 
wt/mut and the corresponding t-test p-values are shown. Proteins that resulted specific wt 
CED binders (enriched over GST by at least 1.3 fold) and were significantly enriched (p-
value< 0.05) with wt TNRC6 CED as compared to either 7W7Y and 7W7A CED mutants 
by at least 1.3 fold (log2=0.4) are listed (one sample t-test; p-value< 0.05; n= 9, biological 
replicates, 4 forward and 5 reverse). 
Gene name Mean log2 wt CED/mut -log10 p-value 
CNOT3 2.43 7.53 
CNOT9 2.27 5.24 
PYCRL 2.13 4.79 
CNOT1 2.00 5.92 
CNOT2 1.92 8.34 
CNOT10 1.89 5.81 
TIMM13 1.75 5.03 
AP2A1 1.72 5.33 
AP2S1 1.67 2.19 
CNOT7 1.60 3.80 
CNOT8 1.59 4.84 
AP2B1 1.53 5.02 
PHGDH 1.50 6.54 
CLTC 1.36 4.52 
TIMM8A 1.25 2.69 
TUBB4B 1.20 1.85 
AP2M1 1.19 2.42 
CAD 1.17 3.19 
TIMM8B 1.14 3.15 
SSBP1 1.13 2.38 
CLTA 1.12 4.02 
CNOT6 1.11 2.32 
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Gene name Mean log2 wt CED/mut -log10 p-value 
SLC25A11 1.05 2.22 
SLC25A5 0.99 2.64 
PABPC1 0.99 3.19 
DCAF7 0.97 5.10 
GIGYF2 0.95 4.40 
CPNE1 0.92 1.93 
CCZ1 0.90 1.57 
AP2A2 0.89 2.36 
PPP2R1A 0.88 3.46 
PABPC4 0.87 2.53 
TUBB4 0.84 2.46 
ATP12A 0.83 1.93 
CNOT6L 0.83 1.90 
PRKDC 0.82 2.07 
DNAJA1 0.79 4.17 
TIPRL 0.78 2.49 
PPP2CA 0.78 2.27 
OGT 0.78 2.88 
TUBB 0.76 2.47 
SLC25A6 0.74 2.60 
DNAJA2 0.71 2.82 
CTPS 0.69 1.38 
FXR1 0.69 1.85 
ABCF2 0.68 1.75 
TUBB3 0.68 2.17 
RPL36 0.67 1.39 
USP9X 0.66 2.13 
CDK4 0.66 2.94 
RPN1 0.62 2.38 
MLLT1 0.62 1.77 
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Gene name Mean log2 wt CED/mut -log10 p-value 
HSPB1 0.60 2.14 
FAM98A 0.59 1.42 
ATAD3A 0.59 1.70 
RPS27A 0.58 1.79 
SLC25A3 0.57 2.22 
XPO1 0.57 1.44 
RPL18 0.55 1.90 
DKC1 0.55 1.82 
PCBP1 0.54 1.68 
DDX46 0.52 1.48 
YWHAB 0.51 1.30 
C14orf166 0.51 1.85 
DDX20 0.50 1.55 
FMR1 0.49 1.35 
NUP93 0.48 1.48 
SF3B3 0.47 1.33 
EIF4E2 0.46 1.60 
TUBB2A 0.46 1.64 
KHSRP 0.46 2.74 
TPM1 0.45 1.38 
RPS4X 0.44 1.49 
NUP205 0.44 1.79 
DYNLL1 0.42 2.49 
LARP4 0.42 1.69 
HSPD1 0.42 1.93 
CLINT1 0.41 1.69 
RPL29 0.41 2.14 
PDHB 0.41 1.62 
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Table S2.  nvGW182 MS results Quantitative mass spectrometric analysis of proteins 
associated with nvGW182. Table listing the 43 proteins that are significantly enriched with 
nvGW182 full-length as compared to the negative control GST (two sample t-test; FDR≤ 
0.05; S0= 0.1; n= 2, biological replicates). The logarithmic ratios of protein intensities, and 
the corresponding t-test p-values are shown.  
Gene name Mean log2 nvGW182/GST -log10 p-value 
SNAPC4 8.28 4.01 
MRPS22 6.09 5.01 
NOP2 5.80 5.30 
SND1 5.68 3.64 
CNOT1 5.61 4.79 
NONO 5.01 3.37 
HNRNPR 4.87 3.25 
STAU1 4.63 3.21 
TOP1 4.48 3.96 
SLC25A10 4.27 6.05 
FAU 4.27 3.54 
HADHA 4.23 3.37 
MAPRE2 4.18 2.88 
ILF3 4.13 2.83 
PABPC4 3.91 2.98 
DNAJB6 3.90 4.14 
ABCD3 3.84 4.04 
SRRT 3.78 2.87 
RMDN3 3.74 3.05 
HP1BP3 3.62 3.69 
PRC1 3.60 3.54 
TFAM 3.42 4.46 
IGF2BP3 3.34 2.98 
MRPS28 3.32 2.91 
POLR2H 3.25 3.86 
DAP3 3.09 3.45 
DIMT1 3.06 3.01 
CNOT9 3.04 4.38 
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Gene name Mean log2 nvGW182/GST -log10 p-value 
MYO1B 3.04 4.35 
EDC3 2.98 3.02 
SART3 2.86 3.03 
WDR75 2.80 3.86 
MAP7D3 2.79 3.38 
MRPS21 2.41 7.17 
PCBP2 2.15 3.99 
ACTB 2.14 3.56 
RPL13A 2.04 4.28 
MYO1C 1.93 4.53 
RPL10 1.69 4.50 
RPL28 1.55 3.98 
RPL10A 1.42 5.16 
RPLP2 1.25 4.22 
RPL38 0.97 4.27 
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Table S3. nvΔCED MS results Quantitative mass spectrometric analysis of proteins 
associated with nvΔCED. Table listing the 174 proteins that are significantly enriched with 
nvΔCED as compared to the negative control GST (two sample t-test; FDR ≤ 0.05; S0= 
0.1; n= 2, individual experiments). The logarithmic ratios of protein intensities and the 
corresponding t-test p-values are shown. As input for the t-test only proteins that showed 
logarithmic ratios nvGW182/GST above 0 were considered in order to filter out 
background interactors. 
Gene name Mean log2 nv∆CED/GST -log10 p-value 
SNAPC4 9.48 7.12 
NONO 6.52 4.15 
SND1 6.49 5.07 
MRPS22 6.15 4.91 
NOP2 6.09 5.99 
YTHDF2 5.90 8.47 
POLR1C 5.83 7.48 
ZNF768 5.66 2.29 
PYCRL 5.49 4.64 
ZC3H7A 5.33 5.47 
STAU1 5.23 3.42 
MRPS27 4.81 5.79 
CKAP4 4.79 3.47 
HNRNPR 4.77 3.38 
HADHA 4.70 3.71 
SPG7 4.67 2.01 
RPL10 4.65 1.98 
IGF2BP3 4.55 4.54 
PTPLAD1 4.53 4.09 
USP7 4.47 5.38 
GNL3 4.44 3.23 
NKRF 4.31 2.21 
MRPS31 4.27 6.23 
EIF3C 4.20 3.43 
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Gene name Mean log2 nv∆CED/GST -log10 p-value 
PRPS1 4.19 3.78 
RFC2 4.15 4.34 
EIF3B 4.15 4.08 
IRS4 4.15 2.84 
ASCC3 4.10 4.70 
ANKRD17 4.09 2.95 
RPS11 4.06 1.99 
SLC25A10 4.03 5.79 
FAU 4.00 2.10 
GNL2 3.99 2.00 
LARP4B 3.98 2.83 
ILF3 3.98 1.93 
MRPS34 3.93 2.29 
KPNA1 3.92 3.06 
NOP14 3.88 3.59 
COPG1 3.83 3.24 
MAPRE2 3.81 2.83 
MRPS18B 3.73 3.01 
DNAJB6 3.72 4.01 
DIMT1 3.71 3.90 
MRPS26 3.67 6.64 
HADHB 3.66 2.74 
SRRM1 3.66 2.00 
SF3B1 3.65 2.77 
SFPQ 3.64 2.54 
POLR2H 3.64 5.58 
PPAN 3.54 2.81 
PPP2CA; PPP2CB 3.49 4.05 
LTV1 3.46 3.18 
EIF2S3; EIF2S3L 3.43 2.72 
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Gene name Mean log2 nv∆CED/GST -log10 p-value 
EIF3F 3.37 2.57 
TMPO 3.36 2.01 
PTCD3 3.36 4.92 
MRPL24 3.34 3.72 
C11orf48 3.34 3.36 
CTNND1 3.32 3.59 
EIF3E 3.31 2.94 
SLC25A13 3.28 3.89 
NOC4L 3.28 2.62 
EIF3D 3.22 2.32 
ABCD3 3.20 3.72 
MYO1B 3.19 4.04 
MYO1C 3.16 5.86 
PCBP2 3.13 5.30 
MRPS28 3.12 3.04 
MRPS6 3.11 2.77 
RPS5 3.11 3.50 
PES1 3.11 2.82 
FARSA 3.08 4.20 
NOP16 3.08 2.77 
IGF2BP2 3.07 2.06 
MRPL23 2.98 2.50 
MRPS9 2.96 2.96 
EXOSC2 2.96 3.52 
DDX20 2.91 2.43 
CNOT1 2.91 2.00 
HNRNPH2 2.91 2.47 
RPS3A 2.90 2.05 
IPO7 2.89 2.69 
MRPS35 2.89 2.66 
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Gene name Mean log2 nv∆CED/GST -log10 p-value 
BLM 2.83 2.76 
SRP72 2.83 2.29 
MRPS14 2.82 1.96 
DDX39A; DDX39 2.79 1.99 
NDUFA10 2.78 2.72 
MRPL3 2.77 2.48 
IMPDH1 2.76 2.03 
RPL19 2.75 2.29 
HBS1L 2.73 2.08 
RFC3 2.72 2.94 
RPS8 2.66 2.99 
MSH6 2.66 2.10 
FAF2 2.65 3.79 
GNB2L1 2.64 2.91 
DPM1 2.62 2.86 
RRP12 2.57 2.79 
RPL36 2.57 2.22 
PELO 2.56 3.10 
PPP2R1A 2.53 2.16 
AHCYL1 2.53 2.12 
HIGD1A 2.52 3.21 
AIMP2 2.51 2.34 
TSR1 2.51 2.11 
SF3B2 2.50 3.17 
IPO5 2.49 4.45 
RPS6 2.47 2.38 
MKI67IP 2.46 2.06 
MTCH2 2.43 2.59 
RPS15 2.42 2.52 
DAP3 2.41 3.17 
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Gene name Mean log2 nv∆CED/GST -log10 p-value 
PRPF4 2.40 2.35 
WDR75 2.35 2.46 
RPS2 2.34 2.70 
LUC7L 2.34 2.21 
RPL13A 2.34 6.05 
IGF2BP1 2.33 3.36 
UBAP2 2.28 2.22 
EIF2AK2 2.27 2.56 
ESF1 2.26 3.75 
USP9X 2.14 2.40 
MRPS21 2.10 6.19 
RPL18A 2.09 4.60 
CNOT10 2.08 2.28 
RPL24 2.07 2.49 
RPL35A 2.05 2.07 
RPS26 2.04 2.36 
RPL10A 2.02 3.75 
UTP14A; UTP14C 2.01 2.52 
GCDH 2.00 2.08 
MRPL41 1.98 2.09 
RPL27A 1.93 3.31 
RPL28 1.92 4.68 
RPL26; KRBA2 1.91 4.01 
RPL13 1.90 2.86 
RBM39 1.90 3.50 
RPL8 1.89 3.72 
RPS27 1.85 2.36 
RPS24 1.83 2.70 
RPL18 1.83 4.43 
RPL32 1.83 5.79 
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Gene name Mean log2 nv∆CED/GST -log10 p-value 
RPS3 1.82 2.58 
HNRNPC 1.74 2.68 
RPL10; RPL10L 1.73 4.04 
RPL29 1.72 4.53 
SLC25A6 1.68 6.41 
RPLP2 1.67 3.01 
RPS13 1.67 3.30 
ACTB 1.65 2.39 
LSM14B 1.65 2.37 
RPL6 1.61 4.49 
RPL4 1.57 2.80 
RPL23A 1.54 2.32 
NOP58 1.53 2.20 
POLR2B 1.52 2.52 
RPL3 1.47 4.64 
RPL21 1.44 3.81 
SMC2 1.39 3.77 
RPS25 1.37 2.36 
RPL27 1.36 4.25 
RPL7 1.34 2.69 
RPL7A 1.34 4.83 
SRSF7 1.31 2.72 
SURF4 1.29 2.36 
RPS19 1.24 3.56 
PGAM5 1.24 3.12 
RPL15 1.18 2.78 
RPL34 1.14 3.33 
C22orf28 1.10 2.61 
RPS16 1.01 2.87 
HNRNPM 0.83 2.90 
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Table S4. nvDNAJ MS results Quantitative mass spectrometric analysis of proteins 
associated with nvDNAJ domain. Table listing the 375 proteins that are significantly 
enriched with nvDNAJ as compared to the negative control GST (two sample t-test; FDR≤ 
0.05; S0= 0.1; n= 2, biological replicates). The logarithmic ratios of protein intensities and 
the corresponding t-test p-values are shown. As input for the t-test only proteins that 
showed logarithmic ratios nvGW182/GST above 0 were considered in order to filter out 
background interactors.  
Gene name Mean log2 nvDNAJ/GST -log10 p-value 
PTPLAD1 7.82 7.80 
ECM29; KIAA0368 7.64 7.93 
ATP2A2 7.34 7.65 
PPP2R2A 7.32 4.52 
USP9X 7.25 7.63 
STT3A 7.16 8.15 
NUP205 7.14 7.10 
TMEM33 7.11 8.11 
LRPPRC 6.94 3.65 
IMMT 6.84 4.89 
SLC25A10 6.82 8.08 
QKI 6.78 7.29 
MSH2 6.56 4.41 
SLC25A1 6.55 5.46 
HADHA 6.53 4.76 
SLC1A5 6.53 9.11 
HEATR2 6.51 5.70 
KDM1A 6.39 4.78 
PSMC6 6.36 4.21 
SLC25A3 6.34 2.96 
PRKDC 6.32 3.54 
MTCH2 6.31 6.70 
PRC1 6.29 7.56 
SFXN1 6.23 4.76 
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Gene name Mean log2 nvDNAJ/GST -log10 p-value 
PDS5A 6.21 7.27 
IPO7 6.06 4.07 
CAND1 6.06 3.58 
MTHFD2 6.04 5.37 
PPP2R1A 5.95 5.33 
NCLN 5.94 5.09 
GNB1; GNB2 5.93 10.40 
MAPRE2 5.88 5.23 
SLC25A11 5.83 4.69 
NCAPD2 5.81 5.25 
TBRG4 5.72 5.43 
TRIP13 5.71 3.99 
G6PD 5.69 8.21 
COMT 5.69 6.19 
SLC25A13 5.68 6.58 
EMD 5.66 4.33 
NUP93 5.65 4.45 
SMC3 5.65 2.95 
PSMD14 5.64 4.30 
FAF2 5.63 8.11 
CUL1 5.62 4.78 
SEC63 5.62 4.27 
EARS2 5.61 5.39 
AFG3L2 5.61 6.36 
PRPS1 5.54 4.77 
CAD 5.51 2.48 
TUBB4A 5.49 6.23 
DHCR24 5.39 8.19 
NCDN 5.39 4.71 
PSMC3 5.37 3.59 
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Gene name Mean log2 nvDNAJ/GST -log10 p-value 
COPG1 5.35 3.07 
SMC4 5.35 2.48 
ABCD3 5.34 5.38 
IPO5 5.33 6.25 
NDUFA9 5.31 5.49 
UQCRC2 5.30 3.12 
PYCRL 5.23 4.34 
NUP107 5.21 5.57 
BAG2 5.19 6.42 
CCT2 5.19 1.95 
KPNA2 5.18 3.05 
MTCH1 5.18 5.89 
RCOR1 5.17 6.14 
UCK2 5.17 4.27 
SMC2 5.16 5.25 
XPO7 5.16 6.61 
MCM7 5.15 2.75 
NDUFS2 5.15 3.60 
CHCHD3 5.12 5.05 
GCDH 5.09 6.38 
PPP2R5B 5.07 5.33 
MMS19 5.05 2.73 
ARL1 5.02 5.94 
TIMM23; TIMM23B 5.01 5.15 
POLR1C 5.01 2.22 
MAPK14 4.95 3.73 
THOC3 4.95 3.33 
PELO 4.95 7.28 
PSMC4 4.93 3.81 
SKP1 4.91 3.07 
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Gene name Mean log2 nvDNAJ/GST -log10 p-value 
NDUFA4 4.89 2.80 
PPP2CA; PPP2CB 4.89 3.72 
NDUFS8 4.88 5.00 
CCT3 4.88 1.86 
SCD 4.86 6.61 
CCT6A 4.85 1.88 
POLR2B 4.85 4.51 
SLC16A1 4.83 2.68 
AIFM1 4.83 4.30 
MSH6 4.82 4.24 
CCT5 4.78 2.01 
PPM1G 4.77 2.48 
LBR 4.77 3.18 
TIMMDC1 4.76 4.86 
PHGDH 4.76 2.22 
DPM1 4.74 6.20 
DNAJA1 4.71 3.58 
NDUFA13; YJEFN3 4.71 4.75 
PSMD6 4.70 2.12 
NSF 4.69 1.58 
COPB2 4.69 3.37 
RPN1 4.69 2.77 
PDXDC1 4.68 1.91 
TBC1D9B 4.67 1.71 
OPA1 4.67 3.96 
DCXR 4.62 4.84 
TELO2 4.59 2.94 
VPS16 4.51 8.52 
AGK 4.50 3.69 
PGRMC1 4.46 2.69 
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Gene name Mean log2 nvDNAJ/GST -log10 p-value 
DNAJA2 4.44 2.86 
CANX 4.44 2.69 
TUBA1C 4.44 3.02 
RFC2 4.42 5.99 
CTPS1 4.41 2.34 
HSP90AB2P 4.37 3.18 
FARSA 4.35 2.71 
TOMM22 4.33 4.35 
TNPO3 4.33 2.96 
DNAJB6 4.31 4.24 
EIF2S3; EIF2S3L 4.31 3.10 
DDX39A; DDX39 4.30 3.10 
PFKM 4.28 1.67 
CDIPT 4.26 4.70 
DDX20 4.25 2.87 
RFC5 4.24 5.02 
AKAP1 4.24 2.57 
EIF3F 4.22 4.11 
IRS4 4.18 2.22 
TCP1 4.17 1.77 
MST4 4.17 2.79 
STUB1 4.14 2.00 
UBXN1 4.13 3.31 
TECR 4.13 2.14 
YTHDF2 4.12 4.33 
MARCKSL1 4.12 1.64 
HSPBP1 4.11 4.60 
NPEPPS 4.11 1.59 
ADCK3 4.09 3.82 
NSDHL 4.08 2.73 
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Gene name Mean log2 nvDNAJ/GST -log10 p-value 
FARSB 4.05 3.18 
GEMIN5 4.04 2.62 
CUL4B 4.04 3.85 
SMN1 4.02 3.58 
SCRIB 4.01 7.37 
HMOX2 3.99 2.22 
SURF4 3.98 2.61 
DNAJA3 3.97 3.68 
VPS33A 3.97 5.05 
CKAP4 3.93 5.18 
CNP 3.93 2.86 
PUM1 3.93 2.06 
MRFAP1 3.92 3.79 
HSD17B10 3.91 3.52 
TUBGCP2 3.91 5.15 
COPG2 3.90 2.69 
TMPO 3.90 2.37 
AAAS 3.89 4.08 
GNPAT 3.89 1.61 
TXNDC5 3.88 3.49 
SPTLC1 3.86 6.89 
AHCYL1 3.85 7.20 
RUVBL2 3.84 1.80 
ACADM 3.84 1.48 
TRAP1 3.84 3.87 
TAGLN2 3.84 1.58 
PCBP2 3.83 6.15 
CTBP1 3.83 4.40 
EIF2B2 3.83 3.70 
VDAC1 3.82 1.84 
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Gene name Mean log2 nvDNAJ/GST -log10 p-value 
QIL1 3.81 4.56 
STAT1 3.81 1.77 
MRPS6 3.81 4.54 
HAUS8 3.80 2.68 
PA2G4 3.80 1.52 
SRPRB 3.80 4.46 
POLR2H 3.79 5.46 
CECR5 3.78 2.34 
TIMM50 3.77 4.09 
FDFT1 3.76 6.43 
USP7 3.76 4.59 
ATAD3A 3.75 1.63 
HDAC1 3.75 1.89 
FKBP8 3.75 1.74 
SLC25A24 3.75 1.83 
CTNND1 3.74 2.86 
MCM3 3.73 1.94 
PCID2 3.71 2.23 
ABCF2 3.70 1.86 
HELLS 3.69 2.08 
RBBP7 3.68 1.53 
CCT4 3.67 3.27 
RUVBL1 3.67 1.72 
DLD 3.66 1.73 
NCKAP1 3.65 1.74 
FRYL 3.63 3.61 
YME1L1 3.63 2.16 
POLD3 3.63 1.84 
AUP1 3.61 3.43 
POLD2 3.59 2.69 
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Gene name Mean log2 nvDNAJ/GST -log10 p-value 
MTHFD1L 3.58 1.77 
RBFOX2; RBM9; RBFOX1 3.56 2.16 
QARS 3.56 1.72 
CDK1 3.55 1.54 
MTA2 3.52 2.27 
AIMP2 3.49 3.69 
EIF2B5 3.49 2.05 
KCTD12 3.48 1.72 
RRP1 3.48 3.60 
TRMT10C 3.46 1.56 
MAGT1 3.43 3.26 
IMPDH1 3.43 2.70 
TARS2 3.42 2.32 
ATP5J2; PTCD1 3.42 5.26 
EIF3M 3.37 4.40 
CPSF2 3.36 3.98 
TCEB1 3.36 2.50 
IRAK1 3.35 2.58 
SLC7A1 3.35 4.31 
TBL2 3.34 2.13 
SRM 3.33 1.75 
SLC39A7 3.33 2.71 
SNRNP70 3.32 5.60 
MRPL37 3.32 1.81 
SCO2 3.32 2.56 
HSDL1 3.31 3.32 
CSRP2 3.31 1.92 
EIF3E 3.31 2.81 
C12orf45 3.27 5.27 
HSPA9 3.27 2.16 
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Gene name Mean log2 nvDNAJ/GST -log10 p-value 
UBAC2 3.27 6.30 
ATP5O 3.26 3.44 
AAR2 3.25 4.30 
GCAT 3.23 2.98 
BYSL 3.22 1.77 
CYC1 3.21 1.99 
PMPCB 3.21 3.63 
EIF2B4 3.19 4.19 
SLC25A5 3.18 4.23 
EEF1E1; hCG_2043275 3.17 2.05 
ALDH9A1 3.16 1.53 
ADAR 3.14 1.56 
ARFGAP1 3.13 2.81 
TTK 3.13 6.63 
DERL1 3.13 4.21 
RCL1 3.12 2.53 
VDAC2 3.12 4.07 
GMPPA 3.10 1.89 
TPP1 3.10 3.79 
KPNA1 3.10 2.51 
SCAMP1 3.09 3.58 
RFC3 3.08 2.18 
PRDX3 3.07 2.12 
MRPS22 3.07 1.72 
GCFC2 3.07 2.50 
WDR70 3.05 1.66 
ELOVL1 3.04 2.98 
MYL6 3.04 2.28 
SEH1L 3.03 1.73 
UBE2G2 3.03 2.42 
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Gene name Mean log2 nvDNAJ/GST -log10 p-value 
NDUFA10 3.03 2.90 
TCEB2 3.03 1.59 
CDC45 3.01 4.56 
RBBP4 3.00 2.05 
FPGS 2.99 4.85 
NUP160 2.96 3.13 
RANGAP1 2.95 1.78 
DSG2 2.95 1.52 
PGRMC2 2.94 2.44 
FAR1 2.93 3.24 
FAM115A 2.93 1.65 
UQCRQ 2.93 2.24 
EIF3K 2.92 2.52 
RMDN3 2.90 1.83 
TSG101 2.85 2.98 
UBA5 2.85 1.82 
FAM96B 2.84 4.35 
UBR4 2.82 1.73 
PFN2 2.81 2.77 
USP11 2.81 1.93 
SNRPD2 2.81 1.71 
NCAPG2 2.81 1.79 
BCR 2.81 1.51 
GTF3C4 2.79 3.04 
HBS1L 2.77 1.91 
PRIM1 2.77 2.27 
HLTF 2.77 5.22 
NOC4L 2.73 3.83 
MAGED1 2.73 1.63 
NTPCR 2.73 1.87 
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Gene name Mean log2 nvDNAJ/GST -log10 p-value 
RHOT2 2.72 2.61 
SKIV2L2 2.72 4.25 
MRPL11 2.72 1.71 
AAGAB 2.71 3.26 
HSP90AB1 2.70 1.70 
HNRNPAB 2.69 1.81 
AKAP8L 2.69 4.07 
PTGES2 2.67 2.60 
ERAL1 2.65 2.22 
POLE 2.61 2.37 
NDUFB10 2.59 1.53 
GTF3C5 2.57 1.86 
TMEM165 2.56 3.43 
STEAP3 2.55 1.80 
EXOSC9 2.55 4.19 
KIF2A 2.55 1.95 
CUL3 2.55 3.53 
ECD 2.54 4.27 
PYCR2 2.51 2.12 
LRRC41 2.50 2.45 
AP3D1 2.50 1.97 
ZNF207 2.48 1.83 
GEMIN4 2.48 1.97 
HIGD1A 2.48 2.38 
ELAC2 2.47 1.78 
TFB2M 2.46 2.30 
EIF2B3 2.45 2.08 
CMSS1 2.41 2.74 
PSME4 2.40 2.16 
SF3B5 2.39 1.56 
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Gene name Mean log2 nvDNAJ/GST -log10 p-value 
EXOSC7 2.37 2.61 
UBXN4 2.36 2.17 
SMARCAD1 2.36 2.30 
LIN7C; LIN7A 2.35 2.51 
WDR3 2.34 2.22 
ERGIC1 2.33 1.92 
NUP43 2.31 1.84 
SDAD1 2.31 2.20 
MYO1C 2.31 4.34 
C5orf51 2.27 1.88 
TARBP1 2.26 3.45 
DARS2 2.20 1.73 
MRPS27 2.20 3.17 
DNAJB11 2.19 2.27 
SRPR 2.19 2.03 
SRP72 2.14 1.65 
PPFIA1 2.12 2.17 
ASCC3 2.10 2.33 
ZC3H11A 2.08 2.20 
CDC20 2.03 2.18 
TMEM109 2.01 3.01 
ATXN2 2.00 1.86 
HSD17B4 1.99 1.88 
RFC4 1.98 2.49 
ARAF; BRAF 1.94 1.88 
MCU 1.91 1.63 
DHX36 1.89 2.16 
XRN2 1.88 2.23 
SLC25A6 1.86 2.16 
PDIA6 1.82 2.03 
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Gene name Mean log2 nvDNAJ/GST -log10 p-value 
LAMTOR5 1.81 2.04 
SUPT4H1 1.81 1.91 
TMPO 1.79 1.99 
GTPBP1 1.77 2.35 
GOLGA2 1.74 1.88 
DIMT1 1.70 1.76 
PET112 1.69 1.65 
EXOSC4 1.65 1.81 
WDR6 1.64 2.45 
FAM213A 1.57 2.15 
EIF4A1 1.54 1.81 
PRKCI 1.50 2.31 
HCCS 1.49 2.12 
WDR82 1.46 2.00 
ERP44 1.44 2.60 
CDKAL1 1.42 2.02 
MYBBP1A 1.31 2.75 
CCNB1 1.26 1.75 
GNG12 1.23 1.90 
UBR5 1.20 1.83 
NMNAT1 0.90 1.97 
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Table S5. nvCED MS results Quantitative mass spectrometric analysis of proteins 
associated with nvCED domain. Table listing the 214 proteins that are significantly 
enriched with nvCED as compared to the negative control GST (two sample t-test; FDR≤ 
0.05; S0= 0.1; n= 2, biological replicates). The logarithmic ratios of protein intensities and 
the corresponding t-test p-values are shown. As input for the t-test only proteins that 
showed logarithmic ratios nvGW182/GST above 0 were considered in order to filter out 
background interactors. 
Gene name 
Mean log2 nvCED/GST -log10 p-value 
CNOT1 10.96 8.81 
MAPRE2 8.85 7.85 
SLC25A1 8.55 6.28 
SLC25A13 8.42 8.18 
SLC25A11 8.17 5.66 
SLC25A10 7.98 8.47 
PABPC4 7.95 4.79 
CNOT3 7.89 7.72 
SFXN1 7.65 5.36 
MTCH2 7.65 7.70 
CNOT2 7.48 8.93 
STT3A 7.27 6.39 
FAF2 7.17 8.13 
SLC25A3 7.17 3.21 
NUP205 6.95 5.04 
UQCRC2 6.91 3.99 
CAD 6.90 3.20 
NSDHL 6.85 3.79 
PTPLAD1 6.85 6.08 
SLC1A5 6.83 10.17 
PFKM 6.74 4.27 
GCDH 6.69 6.77 
MTCH1 6.65 7.51 
BAG2 6.62 6.34 
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Gene name 
Mean log2 nvCED/GST -log10 p-value 
RBFOX2; RBM9; RBFOX1 6.60 4.76 
CNOT9 6.60 7.27 
POLR2H 6.56 7.77 
SLC16A1 6.50 3.97 
EARS2 6.45 6.41 
TIMMDC1 6.43 6.26 
ATP2A2 6.42 4.89 
CNOT10 6.39 5.93 
MSH2 6.38 2.75 
MCM7 6.37 2.89 
TIMM23; TIMM23B 6.34 7.08 
ATP5A1 6.28 2.19 
CECR5 6.27 3.39 
SMC3 6.26 3.13 
HSPA9 6.12 4.09 
FARSA 6.06 4.20 
DPM1 6.05 7.05 
YTHDF2 6.05 6.17 
NUP93 6.04 4.51 
TMEM33 5.94 6.70 
DHCR24 5.86 6.43 
PRKDC 5.77 3.16 
EMD 5.74 4.61 
NDUFA13; YJEFN3 5.72 4.98 
TUBB2B 5.70 5.06 
NONO 5.61 1.98 
IMMT 5.52 2.24 
SCD 5.49 6.07 
DNAJA3 5.49 4.86 
TUBGCP2 5.42 5.16 
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Gene name 
Mean log2 nvCED/GST -log10 p-value 
PHGDH 5.40 2.37 
NDUFA12 5.32 3.52 
YARS 5.30 1.69 
HIGD1A 5.23 4.64 
TUBA1C 5.23 3.60 
PELO 5.23 4.28 
SPTLC1 5.21 6.74 
PABPC1 5.21 4.19 
ABCD3 5.19 5.59 
LBR 5.17 2.62 
TUBB4A 5.16 6.38 
PUM1 5.14 1.88 
TCP1 5.13 2.26 
TOMM22 5.10 4.92 
QIL1 5.07 7.14 
SPCS2 5.07 1.69 
FAR1 5.04 4.86 
NDUFA9 5.02 3.44 
TECR 4.99 2.36 
PDHB 4.95 1.95 
NDUFA10 4.93 4.76 
TIMM50 4.91 5.07 
NDUFS2 4.87 3.02 
HADHA 4.85 2.31 
RPN1 4.85 2.55 
UCK2 4.81 3.75 
ARL1 4.81 6.04 
ABCF2 4.77 2.43 
NDUFS8 4.77 2.49 
AIFM1 4.74 3.05 
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Gene name 
Mean log2 nvCED/GST -log10 p-value 
CAND1 4.72 2.36 
TBRG4 4.71 2.56 
RBM14 4.71 2.06 
MSH6 4.71 3.18 
DNAJA1 4.70 3.54 
KPNA2 4.70 2.50 
MAGED1 4.66 2.97 
DNAJA4 4.62 4.60 
CNOT8 4.61 1.94 
ABCB7 4.61 4.59 
RFC5 4.58 5.22 
TPP1 4.58 2.83 
TARS2 4.57 1.79 
PCBP2 4.53 5.23 
DNAJA2 4.50 2.90 
MPC2 4.49 4.74 
TELO2 4.49 3.96 
LARP4B 4.46 2.52 
HNRNPA0 4.45 2.40 
ATP5J2; PTCD1 4.44 3.77 
CNOT7 4.39 2.14 
SRM 4.39 1.88 
QARS 4.38 1.78 
DDX39A; DDX39 4.36 2.77 
AGK 4.35 3.52 
COQ5 4.34 4.50 
SFXN3 4.33 2.75 
ELOVL1 4.30 3.60 
ECM29; KIAA0368 4.30 1.88 
PRPS1 4.26 2.54 
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Gene name 
Mean log2 nvCED/GST -log10 p-value 
NDUFA4 4.26 2.01 
BYSL 4.18 1.75 
POLR1D 4.15 2.30 
POLR2B 4.15 1.81 
ERAL1 4.13 3.46 
CTPS1 4.09 1.72 
GNB1; GNB2 4.09 2.40 
DNAJB6 4.08 2.42 
AUP1 4.06 4.25 
VDAC1 4.05 3.10 
IPO5 4.05 6.65 
MCM3 4.03 2.20 
PPP2R1A 4.03 2.75 
SLC25A5 4.00 5.74 
HNRNPH2 3.99 3.12 
ADCK3 3.99 4.42 
IRS4 3.94 2.11 
HEATR2 3.92 3.76 
AKAP8L 3.90 4.16 
SLC25A6 3.87 4.21 
AIMP2 3.86 4.09 
EIF2S3; EIF2S3L 3.84 1.93 
PSMD10 3.83 1.87 
IPO7 3.82 3.51 
PGRMC1 3.82 2.23 
CYFIP1 3.79 2.48 
CNOT6 3.77 4.05 
COMT 3.72 2.03 
MLF2 3.71 2.30 
EEF1E1; hCG_2043275 3.71 2.47 
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Gene name 
Mean log2 nvCED/GST -log10 p-value 
CNOT11 3.68 1.77 
ATP5C1 3.67 1.91 
PLK1 3.66 4.54 
TMEM165 3.59 3.51 
MARCKSL1 3.57 2.13 
AAAS 3.56 2.24 
UBE2G2 3.56 3.82 
TMCO1 3.47 1.97 
PYCRL 3.45 1.78 
NCAPD2 3.45 3.02 
UBAP2L 3.43 2.91 
CDIPT 3.40 2.38 
VMP1; TMEM49 3.39 2.34 
ATAD3B 3.38 2.80 
USP9X 3.34 1.94 
VPS33A 3.33 3.19 
MMS19 3.33 3.49 
LARP4 3.32 2.48 
HSP90AB2P 3.29 1.96 
TRAP1 3.29 1.83 
PMPCB 3.27 1.85 
ATXN2 3.25 2.08 
XPO7 3.21 1.79 
RFC2 3.18 1.89 
MRPL11 3.13 2.36 
FPGS 3.10 2.64 
FDFT1 3.09 3.87 
PSME4 3.09 1.85 
SURF4 3.09 4.45 
CCT4 3.09 2.01 
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Gene name 
Mean log2 nvCED/GST -log10 p-value 
SRRT 3.07 2.32 
SRPR 3.06 3.55 
MPC1; BRP44L 3.02 1.90 
ZNF703 2.97 2.43 
HSD17B11 2.93 2.67 
ECSIT 2.87 1.94 
MCU 2.83 2.23 
UBE2E1; UBE2E2 2.82 2.19 
QKI 2.79 1.79 
EIF2B5 2.78 1.93 
CDC45 2.77 1.98 
MRPL37 2.74 1.99 
DERL1 2.74 2.58 
RCL1 2.71 2.01 
NSUN4 2.66 2.42 
SMARCAD1 2.66 2.36 
UBAC2 2.62 2.29 
HSD17B4 2.61 2.23 
TTK 2.57 3.55 
EIF4E2 2.53 2.99 
AASS 2.47 1.84 
VDAC2 2.47 2.01 
IMPDH1 2.42 1.91 
UTP20 2.35 2.12 
EIF2S1 2.29 1.85 
DHX36 2.22 2.57 
SLC7A1 2.20 2.22 
GNE 2.18 2.64 
SF3B5 2.14 1.86 
HNRNPH1 2.14 2.89 
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Gene name 
Mean log2 nvCED/GST -log10 p-value 
ARFGAP1 2.13 2.12 
EIF4A1 2.10 4.06 
FAM213A 2.06 2.74 
SCRIB 2.01 2.24 
TXNDC5 1.95 2.40 
RBM39 1.66 2.68 
MRPS6 1.53 2.22 
CPSF2 1.43 2.19 
ECD 1.39 2.33 
ASCC3 1.36 2.95 
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Table S6. W-motif enriched interactors detected in b-isoxazol precipitates 21 
TNRC6C W-motif-specific interactors, as well as TNRC6 proteins, were identified by Kato 
and colleagues and Han and colleagues as components of b-isoxazol precipitates from 
the indicated cell lysates676,677. Comparison of RNase treated and untreated U-2 OS b-
isox precipitates revealed whether the presence of these proteins is RNA independent (--), 
RNA insensitive (-) or RNA dependent (+).  
Gene Name B-isoxazole precipitates RNA dependency 
KHSRP U-2 OS, NIH-3T3, mESC cells, mouse brain, mouse testis - - 
SLC25A5 U-2 OS cells - - 
TUBB U-2 OS cells, NIH-3T3, mESC cells, mouse brain, mouse testis - - 
CLTC U-2 OS cells - 
FAM98A U-2 OS cells, NIH-3T3, mESC cells, mouse brain, mouse testis - 
HSPB1 U-2 OS cells - 
PABPC1 U-2 OS cells, NIH-3T3, mESC cells, mouse brain, mouse testis - 
PABPC4 U-2 OS cells, NIH-3T3, mESC cells, mouse brain, mouse testis - 
PCBP1 U-2 OS cells, NIH-3T3, mESC cells, mouse brain, mouse testis - 
C14orf166 U-2 OS cells + 
FXR1 U-2 OS cells, NIH-3T3, mESC cells, mouse brain, mouse testis + 
RPL18 U-2 OS cells, S2 cells + 
RPL36 U-2 OS cells, S2 cells + 
RPLP0 U-2 OS cells, S2 cells + 
RPS4X U-2 OS cells + 
AP2A2 NIH-3T3, mESC cells, mouse brain, mouse testis not tested 
AP2B1 NIH-3T3, mESC cells, mouse brain, mouse testis not tested 
FMR1 S2 cells not tested 
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7. Abbreviations 
AGO Argonaute eIF6 Eukaryotic translation initiation factor 6 
AP Adaptor protein EMCV Encephalomyocarditis virus 
CAF1 CCR4-associated factor 1 ER Endoplasmatic reticulum 
CCR4 Carbon catabolite repressor 
protein 4 homolog 
ES 
cells 
Embryonic stem cells 
CCV Clathrin-coated vesicle ESCRT complex Endosomal sorting complex 
required for transport complex 
cDNA Complementary 
deoxyribonucleic acid 
EtOH Ethanol 
CDS Coding Sequence FC Fold change 
CED C-terminal effector domain FLuc Firefly luciferase 
CNOT CCR4-NOT transcription 
complex subunit 
GO Gene ontology 
CrPV Cricket paralysis virus GST Glutathione S-transferase 
CVD Cardiovascular Disease GTP Guanosine triphosphate 
DAZL Deleted in azoospermia-like HA Hemagglutinin 
DCP1 mRNA-decapping enzyme 1 HCV Hepatitis C virus 
Dgcr8 DiGeorge syndrome critical 
region gene 8 
HRP Horseradish peroxidase 
Dhh1 DEAD box helicase homolog 1 hs Homo sapiens 
DNA Deoxyribonucleic acid HSL Histone stem-loop 
DNase Deoxyribonuclease i.e. that is 
Dnd1 Dead-end 1 IP Immunoprecipitation 
EDC3 Enhancer of mRNA-decapping 
protein 3 
IRES Internal ribosomal entry site 
EDD E3 ubiquitin-protein ligase 
UBR5 
ITAFs Internal ribosome-entry site (IRES) trans-
acting factors 
eIF3 Eukaryotic translation initiation 
factor 3 
KEGG Kyoto encyclopedia of genes and genomes 
eIF4A Eukaryotic translation initiation 
factor 4A 
LC Liquid Chromatography 
eIF4E Eukaryotic translation initiation 
factor 4E 
LFQ Label Free Quantification 
eIF4G Eukaryotic translation initiation 
factor 4G 
m7G 7-methyl-guanylate cap 
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miR MicroRNA           RBP RNA binding proteins         
miRNA MicroRNA           RISC RNA-induced silencing complex         
MNase Microccocal nuclease RLuc Renilla luciferase          
mRNA Messenger ribonucleic acid         RNA Ribonucleic acid          
MS Mass spectrometry          RNAi RNA interference          
mut Mutant RRM RNA recognition motif         
MVBs Multivesicular bodies          RT Room temperature or Reverse 
Transcriptase, can be  inferred from 
context 
MW Molecular Weight          SD standard deviation           
NED N-terminal effector domain         SDS-
PAGE 
Sodium dodecyl sulfate polyacrylamide 
gel electrophoresis      
nv Nematostella vectensis SEM Standard error of the mean       
ORF Open reading frame         shRNA short hairpin RNA 
PABP Polyadenylate-binding protein          SILAC Stable isotope labelling with amino acids 
in cell culture 
PAM2 PABP-interacting motif 2         siRNA  Small interfering RNA 
PAN2 PABP-dependent poly(A)-
specific ribonuclease subunit 2       
TNRC6A Trinucleotide repeat containing gene 6A 
protein      
PAN3 PABP-dependent poly(A)-
specific ribonuclease subunit 3       
TNRC6B Trinucleotide repeat containing gene 6B 
protein      
PAZ domain Piwi-Argonaute-Zwille 
domain         
TNRC6C Trinucleotide repeat containing gene 6C 
protein      
PBS Phosphate Buffered Saline TRBP TAR RNA-binding protein         
PCR Polymerase Chain Reaction         tRNA Transfer ribonucleic acid         
pH Potential of Hydrogen UTR Untranslated region          
PIC Pre-Initiation Complex          W tryptophan 
piRNA Piwi-interacting RNA          wt Wild type 
qRT-
PCR 
Quantitative real time PCR        XRN1 5’-3’ exoribonuclease 1         
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8. Symbols and Units 
% Percentage            
%v/v Percentage volume/ volume   
%w/v Percentage weight/ volume  
°C Degree Celsius  
bp Base pairs  
g Gram      
g  Acceleration of gravity (see RCF) 
h Hour           
kb Kilobase           
kDa Kilodalton           
L Liter 
mg Milligram           
min Minute           
µl Microliter           
ml Milliliter           
µM Micromolar           
mM Millimolar           
ng Nanogram           
nt Nucleotide           
rcf (g) Relative centrifugal force  
rpm Revolutions per minute  
µg Microgram           
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